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ABSTRACT 
 
Flora C. Luk: Role of Post Translational Modifications:  Glycosylation and Palmitoylation in 
Toxoplasma gondii 
(Under the direction of Con Beckers) 
 
Many eukaryotic proteins are post-translationally modified to regulate protein-protein 
interactions, protein stability, folding, localization, and proteolysis.  Modified proteins play 
essential roles in cellular processes such as protein-protein interactions, signal transduction, 
and membrane association. Given the prevalence and importance of these modifications, post 
translational modifications such as protein palmitoylation and glycosylation have not been 
explored in Toxoplasma.  At the time of our study, protein glycosylation was known to 
modify two proteins: GAP50 and gp23.  And protein palmitoylation has only been 
experimentally confirmed for a few parasite specific proteins although many have been 
predicted to have cysteine residues that are modified. This body of work explored the 
contributions of two key post-translational modifications, glycosylation and protein 
palmitoylation, to Toxoplasma biology.   
Toxoplasma gondii is an obligate intracellular parasite that infects more than 60 
million people in the U.S.  Infection can cause congenital neurological defects, and severe 
disease in immuno-compromised individuals.  Toxoplasma survival is dependent on parasite 
motility, which governs essential processes: invasion, egress, and dissemination throughout 
the host.   We described the analysis of protein glycosylation in Toxoplasma.  We began with
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the detection of N-glycosylation of myosin XIV motor complex anchor, GAP50, and 
proceeded to characterize the structure and immune-reactivity of Toxoplasma N-linked 
glycans.  Subsequently, to identify palmitoyl proteins in Toxoplasma, we took advantage of 
recently developed biochemical and proteomic approaches allowing us to decrease the length 
of time of analysis and increase the number of proteins analyzed.  The palmitoyl proteome of 
Toxoplasma included cytoplasmic and transmembrane proteins that also had additional 
acylation sites.  The two analysis presented below would help us identify how post-
translational modifications – glycosylation and palmitoylation – regulate parasite proteins to 
mediate important cellular processes essential to survival.    
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Introduction 
Parasites are organisms that co-op their host cells‟ nutrients and resources for 
survival.  This intimate parasite/host relationship usually occurs at the expense of the host, 
solely benefiting the parasite.  Three classes of parasites that cause human disease include:  
protozoa, helminths, and ectoparasites. Protozoa are microscopic, unicellular organisms such 
as Plasmodium, Giardia, and Toxoplasma, which multiply within their human hosts for 
survival [10].   Plasmodium is the causative agent of malaria. Giardia infections cause 
diarrheal illness. Toxoplasma infections can cause flu-like symptoms as well as more severe 
disease such as congenital encephalitis. Helminths are large, multicellular worms that can 
reside in the gastrointestinal tract, blood, lymphatic system, and subcutaneous tissues of their 
hosts [10]. Ectoparasites include arthropods such as ticks, fleas, mites, and lice, which not 
only cause diseases themselves but also transmit pathogens that cause disease [10].  In 
addition to human infections, parasites can also infect livestock and contaminate water; thus 
causing an agriculture concern in which transmission occurs via fecal/oral routes.   
Parasitic infections are of medical and agricultural concern, outbreaks of which place 
tremendous public health and economic burdens on endemic areas including both developing 
and developed areas.  Malaria results in 1 million deaths per year, mostly in young children 
in sub-Saharan Africa [10].  Cryptosporidium causes diarrheal illness, and an estimated 
300,000 infections occur annually in the U.S. from contaminated water.  The CDC has 
estimated 1.5 million new Toxoplasma infections in the U.S. each year, as well as 400-4,000 
cases of congenital Toxoplasmosis and 1.26 million individuals with ocular disease due to 
infection [10].   
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Given the devastating disease caused by parasitic infection, it is obvious that parasites 
serve as an important area of research for the development of therapeutic agents.  However, 
the prevalence of parasitic infections suggests that parasites have developed sophisticated 
means to invade their hosts, evade host immune defenses, and acquired appropriate nutrients 
to thrive within the host.  We have yet to completely understand the molecular basis of these 
important cellular processes; thus the complexities of parasite cell biology serve not only as a 
necessary and important area of research, but also an interesting organism for study.  Our 
contribution to this research begins with the apicomplexan parasite, Toxoplasma gondii. 
 
Apicomplexa 
The phylum apicomplexa encompasses over 4,000 species, which comprises 
protozoan parasites that infect vertebrate and invertebrate hosts [11].  Apicomplexan 
parasites of medical and veterinary significance includes:  Plasmodium falciparum the 
causative agent of malaria in humans; Theileria spp., and Neospora spp. infects cattle, 
resulting lymphoproliferative diseases [12] and abortion in pregnant cows respectively [13]; 
Toxoplasma gondii, Cryptosporidium spp., and Eimeria spp. have the ability to infect both 
humans and cattle in addition to other mammals.      
Apicomplexa along with the ciliates and the dinoflagellates comprise a higher order 
group of organisms known as alveolates. A common structure of alveolates is the membrane 
system surrounding the parasite, known as the pellicle.  The pellicle consists of the outer 
most plasmalema, and a series of underlying cisternae called inner membrane complex or 
alveoli [14].  In addition to common eukaryotic organelles (mitochondria, nucleus, 
endoplasmic reticulum, and golgi), apicomplexa also have defining structures characteristic 
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of this phylum such as the apical complex and the apicoplasts. The apical complex defines 
the apical end of the parasite, and includes cytoskeletal and secretory organelles important 
for parasite invasion and parasitophorous vacuole formation.  The apicoplast is a chloroplast-
like organelle that consists of 35kb circular DNA, and has been intensely studied as a 
potential target for drug development [15].  
The life cycles of apicomplexa are extremely complex involving both sexual and 
asexual reproduction in one or most hosts.  Apicomplexans are haploid for most of their life 
cycles.  However, haploid parasites have the ability to differentiate into gametes that can fuse 
to form diploid zygotes.  Thereafter, zygotes undergo meiosis to reestablish haploid parasites.  
The life cycle of Toxoplasma gondii would be explored in detail in section below. 
 
Life cycle of Toxoplasma gondii 
Toxoplasma gondii is a unique member of apicomplexa that has the ability to infect 
nucleated cells from many different species of mammals [16].  The molecular basis of the 
specificity to different hosts remains unknown.  The life cycle of Toxoplasma is separated 
into feline and non-feline infections, which corresponds to sexual and asexual reproduction 
respectively (Figure 1-1) [17].   The two cycles of reproduction culminates in the production 
of three infectious stages: oocyst, tachyzoites, and bradyzoites [18].  Production of oocysts 
occurs soley by sexual reproduction, and is the only stage of Toxoplasma that survives 
outside of the host.  Tachyzoites represent the fast growing stage, in which parasites undergo 
repeated rounds of host cell invasion, replication, and egress.  Lastly, bradyzoites are slow 
growing parasites that forms tissue cysts.   
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The sexual cycle of reproduction occurs exclusively in the intestines of felines after 
the ingestion of infectious oocysts or tissues infected with bradyzoite cysts [17].   Within the 
intestines, parasites differentiate into male and female gametes, which fuse to produce 
oocysts that are shed in the feces [17]. Oocysts can survive in the external environment for 
months to years, and become highly infectious to any mammal that ingests these oocysts; 
thus becoming the intermediate host for asexual cycle of reproduction [17].  Although sexual 
reproduction is limited to the intestines of feline hosts, asexual reproduction can also occur in 
other tissues of the infected feline.   
The asexual cycle of reproduction occurs in non-feline hosts as parasites are released 
from oocysts to infect the intestinal epithelium.  Parasites differentiate into the rapidly 
replicating tachyzoites, which disseminates throughout the body of the host defining the 
acute phase of infection [17].  Assult from host immune defenses triggers subsequent 
differentiation into slow growing bradyzoites, which reside as cysts within the tissues of the 
host; thus establishing a chronic infection for the lifetime of the host [17].  Ingestion of 
bradyzoite tissue cysts by intermediate hosts results in repetition of asexual reproduction.  
However, ingestion by felines, the definitive host, triggers the sexual reproduction cycle of 
Toxoplasma.  The research presented utilizes Toxoplasma gondii that reproduces asexually in 
human foreskin fibroblasts cultured in-vitro.  
 
Toxoplasmosis 
Toxoplasma gondii infection in humans is common and widespread [18].  The CDC 
estimates 1.5 million new Toxoplasma infections occur annually in the United States alone 
[10]. Additionally, Toxoplasma gondii infection in livestock is a serious concern affecting the 
public health of most endemic areas [10].   Toxoplasma infection in humans occurs most 
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commonly through the consumption of bradyzoites in infected meat and/or contact with 
oocyts in water, soil, or cat feces [18].  Another route of transmission occurs congenitally, in 
which parasite can infect the fetus of pregnant women [18].   
The clinical presentation of acute and chronic Toxoplasma infections differs between 
immunocompetent and immunocompromised individuals.  Acute infection occurs when 
repeated cycles of tachyzoite invasion, replication, and egress cause tissue damage and 
lesions at site of infection. Upon activation of the host immune response, tachyzoites 
differentiate into the slow growing bradyzoite, which form tissue cysts that persist 
asymptomatically for the lifetime of the host. Regardless of immuno-state of the host, 
Toxoplasma establishes a chronic infection for the lifetime of the host [17].   
Acute Toxoplasma infection in immunocompetent hosts is usually self-limiting with 
presentations that range from asymptomatic to flu-like symptioms, and in more severe cases, 
ocular disease [18].  Chronic infection results in tissue cysts that reside in the musculature 
and/or in the eye of the host, and rupture of cysts reactivates acute infection. Repeated 
reactivation of chronic infection can cause serious tissue damage and lesions especially in the 
eye, and eventually lead to blindness [18].  Toxoplasma can infect the fetus of pregnant 
women, and the severity of congenital Toxoplasmosis is dependent on stage of pregnancy 
[17].  Infection before the second trimester results in the most serious symptoms, such as 
blindness, encephalitis, intracranial calcification, and retinochoroiditis [17].  Infections that 
occur during the third trimester are asymptomatic at birth, but may develop into 
retinochoroiditis later in life.   
Immunocompromised individuals, such as HIV positive patients, infected with 
Toxoplasma develop severe neurological disease such as encephalitis and present with 
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symptoms such as altered mental states, seizures, and abnormalities of speech [17].  
Encephalitis can cause death in these patients if left untreated.   
Diagnosis of Toxoplasma infection involves the detection of IgM and IgG antibodies 
that are present during acute and chronic infection, respectively [18].  The standard treatment 
for Toxoplasmosis is a combination of two drugs, pyrimethamine and sulfonamide, both of 
which treat only the rapidly replicating tachyzoites that are responsible for acute infection 
[18]. The drugs force tachyzoites to differentiate into the slow-growing bradyzoite cysts that 
persist in latent, asymptomatic form.  At this time, there are no drugs available to eliminate 
bradyzoites and the drugs available have toxic side effects.   
 
Toxoplasma gondii – the “model” apicomplexa parasite 
Toxoplasma gondii is considered a „model” organism for the study of apicomplexa as 
it is the most readily amendable to genetic and biochemical manipulation.  Genetic protocols 
such as transient transfections are highly efficient in Toxoplasma allowing for the expression 
of heterologous and epitope tagged proteins.  The tachyzoite stage of Toxoplasma is easily 
propagated in mammalian cells, and grown in our laboratory for key studies.  Genome 
sequences for other apicomplexans are at various stages of completion, but the Toxoplasma 
genome has been completely sequenced.  Additionally, reagents such as antibodies have been 
generated and available for biochemical studies.  Thus far the tools mentioned above are 
most readily available for Toxoplasma gondii, placing this organism at an experimental 
advantage over other apicomplexans.   
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Post Translational Modifications 
Post-translational modifications play important roles in regulating protein stability, 
trafficking, folding, conformation, and activity.  The covalent attachment of phosphates, 
lipids, and carbohydrates to a protein backbone has pronounced effects on many cellular 
processes such as signal transduction, proteolysis, and targeting.  For example, the addition 
of carbohydrates to proteins affects cell-cell interactions and targeting, phosphorylation is 
involved in signal transduction, and attachment of fatty acids promotes membrane 
association.  Advancements in both proteomic and biochemical methods have facilitated our 
understanding of the structure of post-translation modifications and where these 
modifications occur.  The study of post-translational modifications is important in 
understanding protein function in many cellular processes as well as disease states and 
parasite-host interactions.   
 
Glycosylation 
Protein Glycosylation proves to be a common post-translational modification to 
secretory proteins in most eukaryotic cells.  Complex carbohydrates that are linked to 
proteins on Serine or Threonine residues are defined as O-linked Glycosylated,.   N-linked 
Glycosylation occur on Asparagine residues within the motif, Asn-X-Thr (X may not be 
Proline).  Eukaryotic glycoproteins have a variety of functions within the cell, such as 
regulating protein folding and stability, protein trafficking, cell-cell interactions, and in 
particular, parasite-host interaction.  Parasites synthesize carbohydrate structures and 
carbohydrate binding proteins, which play a central role in parasite attachment and invasion 
of host cells.  For instance, the removal of sialic acid structures on the surface of erythrocytes 
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abolishes the binding and invasion of the cell by Plasmodium merozoites.  Given the 
significance of glycoproteins in eukaryotic cell functions, and parasite-host cell interaction, 
little is known about Toxoplasma gondii glycoproteins and their role in Toxoplasma 
pathogenicity.  Through the analysis of genome databases, Toxoplasma homologues 
responsible for the synthesis of the dolichol-linked precursor of N-linked glycans have been 
identified, and the prevalence and the function of Toxoplasma gondii N-linked glycoproteins 
have only been examined in a few studies.   
 
Protein Palmiotylation 
Palmitoylation is the addition of 16 carbon fatty acid chain to cysteine residues via 
thioester bond.  Protein palmitoylation is involved in cellular processes such as protein 
trafficking, stability, microlocalization, and protein-protein interactions.  Protein 
palmitoylation is a post-translational modification that has been compared to 
phosphorylation.  Palmitoylation was first identified in 1969, however it is a poorly 
understood modification due to the practical difficulties and the poor understanding of the 
mechanism of this modification.  Mechanism will be explored in the section below in protein 
palmitoyl transferases.   
1.  Poor prediction of modification 
2. Tedious experimental methods 
3. Modification was thought to occur spontaneously b/c enzymes responsible for 
modification has only recently been identified.   
Although we still have not identified the consensus sequence required for palmitoylation, 
we know that palmitoylation usually occurs on neighboring cysteine residues or cysteine 
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residues positioned next to another acylation sites (myristoylation or prenylation).  Dual 
acylation is thought to promote kinetic trapping.  In this model,  myristoylation promotes 
weak association with membranes, allowing the protein to disassociate and reassocaite with 
its target membrane until it finds a specific  protein palmitoyl transferase that can 
palmitoylated the protein at neighboring cysteine residues; thus trapping the protein in place 
and stably hold the protein at the membrane.  This has been one hypothesis proposed for 
cytoplasmic, soluble proteins.  However, we have come to know that transmembrane proteins 
are also palmitoylated, and palmitoylation plays a role in localization or partitioning into 
microdomains [19].   
Experimental methods have been developed to bypass the difficulties in studying protein 
palmitoylation.  Classical experiments involved [
3
H]palmitate labeling, which has several 
limitations:  1- large amount of label is required because labeling is extremely inefficient; 2- 
requires long autoradiographic exposure times; 3- protein of interest must be 
immunoprecipitated from labeled lysates; thus antibody to the protein of interest must be 
available and analysis if focused on a single protein per experiment.  Although this classical 
approach provides definitive evidence of palmitoylation, it is not conducive to the global 
analysis of palmitoylation.  Drisdel et al [1] developed the acyl-biotin exchange chemistry to 
replace palmitate moieties with thioester reactive biotinylation reagent that can easily purify 
all palmitoylated proteins.  Subsequently, Roth et al. [6] paired this method with a proteomic 
approach that allows for identification of purified proteins.  Together, this approach has been 
applied to yeast, mammalian cells and Drosophila, resulting in the identification of entire 
palmitoyl proteomes along with the protein palmitoyl transferases responsible for this 
modification.   
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Palmitoylation in apicomplexa have only recently begun.  The palmitoyl proteome of 
Trypanosomes was identified, and Emmer et al [2] shows that palmitoylation plays a role in 
trafficking to flagellar membrane.  In Toxoplasma, multiple proteins have been predicted to 
be palmitoylated, and this modification is mostly thought to promote membrane association.  
For example, intermediate-like filament protiens and inner membrane complex protein [3,4]. 
However, as we are exploring Tg palmitoyl proteome, it is likely that we find palmitoylation 
to be involved in critical process necessary for parasite survival.  Although protein 
palmitoylation is involved in many cellular process, membrane trafficking, protein stability, 
protein degradation, we hope explore this modification in Toxoplasma.   
 
Toxoplasma Protein Palmitoyl Transferases (PPTs) 
Many proteins involved in a wide variety of cellular processes are known to be 
palmitoylated, however the mechanism of protein palmitoylation remained poorly understood 
until recently.  Palmitoylation was considered to be an nonenzymatic, spontaneous event 
until the first protein palmitoyl transferase was identified by forward genetic screens in yeast 
[10,11].  Protein palmitoyl transferases (PPTs) are enzymes responsible for the addition of 
palmitate to cysteine residues of proteins.  Although, PPTs have substrate specificity for 
different classes of proteins and are usually localized to the target membrane of their 
substrates [5], a single PPT can palmitoylate multiple substrates and a single substrate can be 
palmitoylated by multiple PPTs; thus the identification of PPT-substrate pairs is difficult and 
involves large scale proteomic analysis after mutation of specific PPTs.   
Since Roth et al. initial discovery, eight additional PPTs have been identified in 
S.cerevisiae and 23 in human and murine genomes. Palmitoyl transferases contain a 
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characteristic DHHC (Asp-His-His-Cys)-CRD (Cysteine Rich Domain) or DHYC-CRD 
motif that is essential for enzyme activity, and these enzymes themselves are often times 
autopalmitoylated within their DHHC-CRD domains [10,11].  Alignment of the 51 amino 
acids encompassing the DHHC-CRD region from a large number of eukaryotic DHHC-CRD 
containing proteins revealed several key characteristics that define this family of proteins [1].  
Most PPTs are 40kD integral membrane proteins with four or more transmembrane domains 
(TM).  The DHHC-CRD region is generally located on the cytoplasmic face of the 
membrane between TM2 and TM3 [1].  Most PPTs have a conserved DPG (Asp-Pro-Gly) 
motif after TM2, as well as TTxE (Thr-Thr-X-Glu) motif after TM4 [1].  However, the 
functional significance of these motifs remains unknown.  As of date, little is known about 
apicomplexan PPTs.  The most extensive analysis of apicomplexan PPTs has been conducted 
by Emmer et al [2] in Trypanosoma brucei to identify the PPT required for protein sorting to 
flagellar membrane.   In Plasmodium falciparum, Seydel et al [9] identified a golgi localized, 
DHHC containing protein, which may play a role in protein sorting to apical organelles. 
Toxoplasma PPTs have not yet been identified or characterized.   
Utilizing the key motifs described above, we conducted a search of all potential 
proteins encoded by the Toxoplasma genome and found 17 proteins containing the DHHC-
CRD or DHYC-CRD motif.  Alignment of these proteins provided a consensus sequence that 
is quite similar to mammalian and yeast palmitoyl transferases, which also possess the 
conserved DPG and TTxE motifs along with several transmembrane domains (Figure 1-2A).  
Through domain analysis of the predicted Toxoplasma DHHC-CRD containing proteins, we 
separated the 17 candidates into two categories based on defining characteristics of known 
protein palmitoyl transferases: typical PPTs and atypical PPTs (Figure 1-2A).  The 10 typical 
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TgPPTs are of immediate interest because these are 40 kDa integral membrane proteins that 
contain at least 4 transmembrane domains, which is representative of known palmitoyl 
transferases.  In contrast, the atypical TgPPTs are extremely large proteins that have less than 
4 transmembrane domains and lack the conserved DPG and TTxE motifs.  These proteins 
may represent errors in the gene prediction program and may not serve as ideal candidates 
for further investigation.  The identification and characterization of Toxoplasma PPTs 
localized specifically at the inner membrane complex are of immediate interest because these 
can potentially palmitoylate members of the myosin XIV motor complex to coordinate 
motility.  
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Figures and Legends 
Figure 1-1.  Toxoplasma life cycle 
The life cycle of Toxoplasma involve both sexual and asexual cycles.  Sexual reproductive 
cycle occurs in the definitive, feline host resulting in the expulsion to oocysts into the 
external environment.  Oocysts can persist in the soil and water for extended periods of time.  
Livestock or humans that come into contact with oocysts either directly in contaminated 
water or soil or through the consumption of undercooked meat harboring tissue cysts 
becomes infected.  Within the intermediate hosts, humans and livestock, parasites rapidly 
invade and replicate during the acute infection until the host immune system attacks forcing 
parasites to differentiate into slow growing bradyzoite.  The cycle continues as feline host 
contacts bradyzoites of livestock or contaminated soil and water.   
 
 
Figure 1-2.  Toxoplasma DHHC-CRD containing proteins 
A) Predicted Toxoplasma proteins were analyzed for the presence of the DHHC/DHYC-CRD 
motif typical of known PPTs. Graphic representation of potential Toxoplasma PPT and the 
location of the conserved DHHC/DHYC-CRD, DPG, and TTxE motifs, and of the putative 
transmembrane domains.  10 candidates are considered typical protein palmitoyl transferases 
(PPTs) that have all domains characteristic of known (PPTs).  B) The highly conserved 
DHHC/DHYC-CRD domains of Toxoplasma PPT candidates were aligned. The conserved 
residues are highlighted in black.  
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Figure 1-1.  Toxoplasma life cycle 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Image adapted with permission from:  Ferguson DJ. Toxoplasma gondii and sex: essential or optional extra? Trends Parasitology 18: 355-
359 (2002) with permission. 
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CHAPTER 2 
 
N-linked glycosylation of proteins in the protozoan parasite 
Toxoplasma gondii
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1
 Chapter modified with permission from:  Flora C. Y. Luk, Terezina M. Johnson, and Con J. Beckers (2008), 
Molecular and Biochemical Parasitology; 157(2): 169–178..   
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Abstract 
 
 Toxoplasma gondii is an obligate intracellular parasite of animal cells. Infection of 
humans is common and may result in devastating disease, especially in immunocompromised 
individuals. Despite previous reports that N-glycosylation of proteins may be a rare post-
translational modification in this and related organisms, we demonstrate that it is actually 
quite prevalent in Toxoplasma. N-glycosylation is completely inhibited by treatment of 
parasites with tunicamycin, but this does not appear to exert its major effect on the parasites 
until they have egressed from their host cells. Although the tunicamycin-treated parasites 
appear structurally normal at this time they are not motile and mostly incapable of invading 
new host cells. The few tunicamycin-treated parasites that do invade are severely affected in 
their ability to replicate and accumulate with a distended endoplasmic reticulum, deformed 
nuclei, and without recognizable late secretory organelles. We provide experimental evidence 
that indicate that Toxoplasma N-glycans differ structurally from those in other eukaryotes. 
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Introduction 
 
 The protozoan parasite Toxoplasma gondii is an obligate intracellular parasite of 
humans and other animals. Infection with this parasite is common and can result in serious 
disease, although this is most likely to occur in individuals with a deficient immune system 
or in first-trimester fetuses [1,2]. Infection is typically initiated by the ingestion of food 
contaminated with either Toxoplasma oocysts or tissue cysts, containing sporozoites and 
bradyzoites respectively. Once inside the host, these differentiate into the rapid replicating 
tachyzoites that spread throughout the infected host [1,2]. Unlike other intracellular parasites 
that gain access to host cells through co-opting their endocytic or phagocytic 
apparatus, Toxoplasma and other apicomplexan parasites actively penetrate their host cells. 
In this process, they attach to the plasma membrane of host cells, and subsequently penetrate 
them while creating a vacuole, the parasitophorous vacuole, that they reside in throughout 
their stay inside the host cell [3]. 
All of these steps are intimately coupled to the secretion of material from the parasite. 
Toxoplasma tachyzoites contain an extensive secretory system consisting of an extensive 
endoplasmic reticulum, a Golgi apparatus, and multiple specialized late secretory organelles: 
micronemes, dense granules, and rhoptries. Microneme proteins are required for parasite 
binding to host cells [4] but the exact function of the numerous rhoptry and dense granule 
proteins is unknown. Most rhoptry proteins are inserted into the PVM [5] but some are 
injected into the host cell proper where they play a clear role in parasite virulence [6-8]. 
Dense granule proteins are secreted post-invasion and are found in the PV space and inserted 
into the PV membrane [3]. Although certain dense granule proteins are believed to be 
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involved in purine salvage from host cells [9], the specific functions for most of these 
proteins or their importance to parasite survival remains unclear. 
The post-translational modification of proteins by the addition of N and O-linked 
oligosaccharides is common in most eukaryotes studied to date. With few exceptions [10], 
these modifications are usually observed on proteins in the secretory pathway of cells. They 
are added onto proteins either during their translocation into the ER, in the case of N-linked 
oligosaccharides, or during their transport through the Golgi complex, in the case of the O-
linked oligosaccharides. The protein-linked oligosaccharides are subsequently modified to 
various extents as they traverse the secretory pathway to their final destination. The type and 
the extent of these modifications vary from species to species and, within a given species, 
from tissue to tissue and during development. The protein-linked oligosaccharides have many 
important roles in eukaryotes. Within individual cells, these oligosaccharides and their 
modifications play a critical role in the correct folding of proteins and their export from the 
ER [11], and in the correct intracellular targeting of proteins [12]. Within the animal, the 
protein-linked oligosaccharides play diverse and important roles in all processes involving 
cell-cell interactions [13]. Finally, protein-linked oligosaccharides also play important roles 
in the interaction of many viral, bacterial and protozoan pathogens with their host organisms 
[13]. 
Despite the importance of N-glycosylation of proteins in other eukaryotic genera, 
several studies have suggested that this post-translational modification is a rare event in 
apicomplexan parasites [14-17]. In spite of this, the apicomplexan genomes do appear to 
contain genes encoding at least a number of the core enzymes required for synthesis of the 
dolichol-linked precursor oligosaccharide as well as the Rft1 flippase and members of the 
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OST complex [18]. However, the number of proteins where the presence of N-linked 
oligosaccharides has been demonstrated experimentally is limited to 2 
in Toxoplasma [14,19], 2-3 in Plasmodium falciparum[17] and none in other apicomplexans. 
In the present study, we demonstrate that N-glycosylation of proteins is actually very 
common in Toxoplasma gondii and that this modification is necessary for parasite growth. 
We also demonstrate that the structure of N-linked oligosaccharides of Toxoplasma differs 
from that in other eukaryotes. 
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Results 
 
N and O-linked glycosylation of proteins is common in Toxoplasma gondii 
 We previously observed that GAP50, the membrane anchor for the myosin XIV 
motor complex in Toxoplasma gondii, contains multiple N-linked oligosaccharides [19]. 
Previous studies by Schwarz and colleagues had demonstrated [
3
H] mannose incorporation 
into only a small number of Toxoplasma proteins, one of which was identified as the cell 
surface protein gp23 [14]. In light of these observations and in the context of devising 
alternative purification strategies for the myosin motor complex from Toxoplasma, we 
analyzed parasites by western blotting and fluorescence microscopy for the presence of 
proteins with N-linked oligosaccharides using biotinylated lectins. Specifically, we used the 
mannose-specific lectin concanavalin-A (con-A) to detect N-glycosylated proteins and the N-
acetylgalactosamine-specific lectin from Dolichos biflorus lectin (DBA) to detect O-
glycosylated proteins. 
 Total Toxoplasma tachyzoite lysates were fractionated by SDS-PAGE, transferred to 
nitrocellulose, and incubated with the biotinylated lectins. Host cell lysates were analyzed in 
parallel to control for possible contamination of the parasite preparation. We also compared 
reactivity of lectins with untreated and PNGase F-treated Toxoplasma protein preparations to 
ensure that all reactivity was due to the presence of N-linked oligosaccharides. To our 
surprise, we found that Toxoplasma tachyzoites contained a large number of proteins reactive 
with con-A and DBA, indicating that N and O-glycosylation of proteins is as common in 
Toxoplasma as it is in other eukaryotes (Figure 2-1). Based on the number of protein species 
reactive with con-A, we estimate that Toxoplasma tachyzoites contain at least 11 major N-
glycosylated proteins and multiple minor ones. The reactivity of con-A with the parasite 
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proteins is due to the presence of N-linked oligosaccharides on these proteins as it is absent 
in parasite lysates pretreated with the N-glycan specific enzyme PNGase F (Figure 2-1). The 
absence of labeling is not due to degradation or loss of protein as the PNGaseF treated and 
non-treated samples contained similar quantities of the membrane skeleton protein IMC1, the 
myosin light chain MLC1, and GAP50. As the latter is known to be N-glycosylated, its 
decrease in MWapp upon PNGase F digestion serves as an internal control for this enzyme. 
Based on a similar analysis with DBA, we estimate that more than 15 Toxoplasma proteins 
contain O-linked oligosaccharides exist in Toxoplasma. The reactivity of DBA 
with Toxoplasma proteins was, as expected, not affected by PNGase F treatment (Figure 2-
1). Surprisingly, the reactivity of DBA with Toxoplasma proteins was not affected by 
digestion with O-glycanase (data not shown). Incubation of parasite proteins with anhydrous 
trifluoromethanesulfonic acid, a treatment that is used to hydrolyze both N and O-linked 
oligosaccharides, also did not affect reactivity with DBA under conditions where all 
reactivity with con-A was lost (data not shown).   
The observations were found to be very consistent between different parasite 
preparations and therefore indicate that both N and O-linked glycosylation of proteins in T. 
gondii is far more common than was previously believed. 
 
N and O-glycosylated proteins are found throughout parasite 
 As stated above, the majority of N and O-glycosylated proteins in other eukaryotes 
are found along the secretory and endocytic/phagocytic pathways, on the plasma membrane 
and in the surrounding medium. In order to determine the general location of N and O-
glycosylated proteins in Toxoplasma tachyzoites, we probed fixed extracellular parasites with 
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the various biotinylated lectins used in Figure 2-1, followed by a Texas Red-conjugated 
streptavidin. We observed con-A-reactive material in multiple structures throughout 
extracellular parasites that overlapped to various extents with all markers for the secretory 
pathway (Supplementary Figure 2-1). It was impossible to determine if any of the con-A 
reactive proteins of Toxoplasma were secreted into the parasitophorous vacuole surrounding 
intracellular parasites as binding of this lectin to host cell glycoproteins effectively obscures 
any interaction with parasite glycoproteins. DBA-reactive material appeared to be confined 
to structures found between the parasite nucleus and the anterior end of the parasites. These 
DBA-positive structures did not obviously co-localize with any makers of known secretary 
organelles in Toxoplasma suggesting they may represent structures that have not been 
characterized to date (data not shown). Together with the data shown in Figure 2-1, these 
data demonstrate that Toxoplasma synthesizes a large number of proteins with N and O-
linked glycans that are found throughout the secretory pathway of the parasite. 
 
N-glycosylation is essential for Toxoplasma viability 
 The data in the previous sections demonstrate that N-linked glycosylation is a 
common post-translational modification of Toxoplasma proteins. To determine if N-
glycosylation of proteins is as critical to Toxoplasma survival as it is in other eukaryotes, we 
tested the effect of tunicamycin on protein glycosylation and parasite growth. 
We monitored the effect of tunicamycin on N-glycosylation of proteins in Toxoplasma using 
GAP50, the only characterized N-glycosylated protein in the parasite. GAP50 was 
immunoprecipitated from parasites that had been metabolically labeled with [
35
S] methionine 
in the absence or presence of 5 μg/ml tunicamycin, a concentration that was sufficient to 
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block glycosylation of HLA class I antigens in uninfected HFF cells (not shown). As can be 
seen in Figure 2-2, this concentration of tunicamycin also suffices to block N-glycosylation 
of GAP50 completely. Treatment of other cells types with tunicamycin typically results in 
the accumulation of non-glycosylated and unfolded proteins in the endoplasmic reticulum 
and cell death [20]. Completely confluent HFF cells, in sharp contrast to non-confluent 
cultures, were not obviously affected by treatment with up to 20 μg/ml tunicamycin for 72 
hours as judged by intactness of the monolayer, cell morphology, cell integrity (as judged by 
trypan blue exclusion and a LIVE/DEAD cell viability assay), and cell viability 
(Supplementary Figure 2-2). As Toxoplasma infection and replication was not affected by 
HFF cell density, the use of confluent HFF cells allowed us to determine the long-term effect 
of tunicamycin on Toxoplasma replication and morphology. 
Treatment of Toxoplasma-infected, confluent HFF cultures with 5 μg/ml tunicamycin 
resulted in the complete inhibition of GAP50 N-glycosylation as judged by immunoblot 
(Figure 2-3A) confirming that the N-glycosylation machinery of Toxoplasma is sensitive to 
tunicamycin under these experimental conditions. To determine how long-term inhibition of 
N-glycosylation affects Toxoplasma viability and structure, we infected confluent HFF 
monolayers with Toxoplasma and treated these with different concentrations of tunicamycin. 
A typical Toxoplasma infection cycle, from the initial infection through parasite egress, lasts 
48 hours in HFF cells. As we did not know the kinetics with which tunicamycin affects the 
parasite, we performed the tunicamycin titrations over a total period of 96 hours. This was 
divided into two 48 hour infection cycles in which parasites obtained from the first 48 hour 
cycle (stage 1) were used to re-infect fresh HFF monolayers and followed for an additional 
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48 hours (stage 2). Tunicamycin concentrations were maintained at identical levels in both 
stages. Parasites were harvested at different time points and counted. 
During the first 48 hour infection cycle (Stage 1, Figure2-3B) treatment with 
increasing concentrations of tunicamycin resulted in a decreased parasite yield. The maximal 
effect was observed with 5 μg/ml tunicamycin but even at higher concentrations we did not 
observe a complete inhibition of parasite replication. This was a surprising finding in that 
inhibition of glycosylation was complete at these concentrations (Figure 2-3A). In stage 2 of 
this experiment, we determined if the parasites that had been grown for 48 hours in various 
tunicamycin concentrations in stage 1 were still capable of host cell infection and replication. 
As can be seen in Figure 2-3B, parasites that were grown in the presence of as little as 5 
μg/ml tunicamycin in stage 1 were incapable of growth in new cultures during stage 2. 
This observation could be explained by tunicamycin inducing more or less specific 
defects in parasite motility, host cell attachment or invasion. As can be seen in Figures 2-3C 
and 2-3D, tunicamycin-treated Toxoplasma tachyzoites appear to be severely defective in all 
three assays. A small fraction of the tunicamycin-treated parasites did infect the new 
monolayer in stage 2 of the experiment but the vast majority (>95%) failed to replicate. The 
few that did replicate only gave rise to small vacuoles containing 4 or less parasites. 
Treatment of Toxoplasma with 10 μg/ml tunicamycin for 48 hours does not result in any 
obvious changes in either the expression level or distribution of GAP50, the one well-
characterized N-glycosylated protein inToxoplasma (Figure 2-4). Similarly, we did not 
observe obvious effects on the amount or localization of marker proteins for the parasite 
plasma membrane, the endoplasmic reticulum, or the three major late secretory organelles: 
the rhoptries, dense granules, and micronemes (Supplementary Figure 2-1B). The apicoplast, 
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a plastid-like organelle embedded in the secretory apparatus of apicomplexan parasites, also 
did not appear to be affected as judged by staining of the organellar DNA with DAPI. The 
same staining also revealed no obvious effects of the tunicamycin treatment on nuclear 
morphology. 
As indicated above, treatment of Toxoplasma tachyzoites with tunicamycin for 48 
hours renders the parasites largely incapable of invading into new host cells. When the few 
parasites that had invaded were analyzed after an additional 48 hours of tunicamycin 
treatment, effects on parasite morphology, protein expression, and protein distribution were 
more pronounced. Expression of GAP50 and the dense granule protein GRA3 were greatly 
diminished compared to untreated parasites (Figure 2-4, Supplementary Figure 2-3). The 
expression level of the plasma membrane protein SAG1 and the microneme protein MIC2 
was not noticeably affected but marked intracellular accumulations of both proteins were 
evident (Supplementary Figure 2-3A). In the case of MIC2, the accumulation appeared to 
occur in the nuclear envelope and endoplasmic reticulum. SAG1, on the other hand, 
accumulated in anterior structures that did not contain marker proteins for any of the known 
secretory organelles in the parasite. Tunicamycin treatment did not have a noticeable impact 
on either the expression level or transport of either Toxoplasma BiP or the rhoptry protein 
ROP2. Nuclear morphology was clearly affected in the vast majority of parasites as was the 
frequency with which DAPI-positive apicoplasts were observed. Unlike what is seen in 
animal cells, tunicamycin treatment did not induce condensed nuclei inToxoplasma. 
We used transmission electron microscopy to analyze the effect of tunicamycin 
treatment on the subcellular structure of Toxoplasma tachyzoites (Figure 2-5). After 48 hours 
treatment with 10 μg/ml tunicamycin, we did observed only one reproducible structural effect 
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on Toxoplasma in that the nuclear envelope of tunicamycin-treated parasites consistently 
appeared slightly distended (Figure 2-5B, inset). After 96 hours, the impact of tunicamycin 
treatment was obvious, with an extensive distension of the nuclear envelope and endoplasmic 
reticulum, and an absence of recognizable dense granules and rhoptries (Figure 2-5C). The 
latter observation indicates that the ROP2-positive structures observed by light microscopy 
either does not represent normal rhoptries or that the structures of these organelles have 
changed beyond recognition. A defined nucleus was also absent from the parasites at this 
stage which is consistent with the light microscopic observations in Supplementary Figure 2-
3. 
 
Other N-glycosylated proteins of Toxoplasma 
 In the experiments described above, we used the integral membrane protein GAP50 
to monitor the effectiveness with which tunicamycin blocks N-glycosylation in 
Toxoplasma tachyzoites. As the data in Figure 2-1 indicate, multiple N-glycosylated proteins 
exist in these organisms. The report by Odenthal-Schnittler et al [14] indicates that gp23 may 
be one of these, although we did not observe an obvious conA-reactive glycoprotein in the 23 
kDa molecular weight range (Figure 2-1A). When we analyzed gp23 directly for the presence 
of N-linked oligosaccharides by PNGase F digestion, however, we did not observe any 
noticeable change in its MWapp in SDS-PAGE (Supplementary Figure 2-4A). The 
MWapp was also not noticeably affected in tunicamycin-treated parasites (data not shown). 
To identify other potential N-glycosylated Toxoplasma proteins, we analyzed 
predicted protein sequences generated form the Toxoplasma genome project (toxodb.org) for 
the presence of additional candidate N-glycosylated proteins. Specifically, we searched the 
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database for protein sequences predicted to possess N-terminal signal sequences and this 
subset was subsequently analyzed for candidates that had consensus N-glycosylation sites 
(N-X-S/T, where X is not a proline). Multiple candidates were identified using this strategy 
including a number of known Toxoplasma secretory or plasma membrane proteins 
(Supplementary Table 2-1). We analyzed a number of these candidates for the presence of N-
linked oligosaccharides by comparing their MWapp before and after digestion with PNGase F. 
As can be seen in Supplementary Table 2-1 and Supplementary Figure 2-4B, none of the 
candidate proteins appeared N-glycosylated based on this criterion. This observation suggests 
that, apart from GAP50, the Toxoplasma glycoproteins identified in Figure 2-1 may represent 
novel parasite proteins. We have initiated the identification of these proteins using mass 
spectroscopy of lectin-affinity purified parasite proteins. 
 
N-linked oligosaccharides of Toxoplasma differ from those in other eukaryotes 
 In most eukaryotes, the N-linked oligosaccharides on proteins exported from the ER 
are modified extensively through the addition and/or removal of sugar residues or their 
derivatives. Typically, this results in noticeable alteration in the apparent molecular weight 
(MWapp) of these proteins during SDS-PAGE. We analyzed whether there were any major 
alterations in the MWapp of GAP50 during a pulse-chase experiment. As can be seen 
in Figure 2-6, there is no obvious change in the motility of GAP50 in this experiment 
suggesting that, although processing the N-linked glycans may be occurring during the 
experiment, these are not substantial enough to alter the MWapp of GAP50. 
 A commonly used method to observe at least part of N-linked glycan processing of a 
protein during its intracellular transport from the ER to the Golgi complex is to incubate the 
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glycoprotein with the enzyme endoglycosidase H (endoH). Whereas the N-linked 
oligosaccharides found on glycoproteins in the ER are sensitive to cleavage by this enzyme, 
processing of the oligosaccharide in the Golgi complex renders it endoH-resistant. This is 
demonstrated in the control experiment shown in Figure 2-6, were we analyzed the endoH-
sensitivity of the N-linked glycans on HLA class I heavy chain that was immunoprecipitated 
in parallel from host cells. When we analyzed whether there was a similar change in the 
sensitivity of N-linked glycans on GAP50 to endoH, we found to our surprise that these were 
endoH-resistant at all times. This effect is not due to their inaccessibility to endoH as the 
oligosaccharides were readily removed by PNGase F, a glycosidase that removes all N-
linked glycans from proteins. Taken together with our previous observations these data 
indicate that N-glycosylation is a common post-translational modification of proteins 
in Toxoplasma gondii but that the structure of these glycans differs substantially from that 
encountered to date in animals, plants, and other unicellular organisms. 
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Discussion 
 
 Protein glycosylation is a common post-translational modification of proteins in all 
eukaryotic cells studied to date and is known to play important roles in the quality control of 
protein folding in the endoplasmic reticulum, in the control of intracellular trafficking of 
proteins, and in the regulation of cell-cell and cell-substrate interactions. Protein 
glycosylation also plays a critical role in the interaction of various pathogens with their host 
cells [13]. Despite this, neither the existence of N-glycosylation in Toxoplasma nor its role in 
the parasite's cellular processes or ability to cause disease has received a lot of attention 
beyond the initial reports by Schwarz and co-workers [14,15]. As a result of this, little 
consideration has been given to the possible role of Toxoplasma N-linked glycans in the 
efficacy of potential vaccine candidates or in the immune response to Toxoplasma in general. 
A careful analysis by Samuelson and colleagues [18] of the genomic and EST 
sequences obtained in the Toxoplasma genome project indicates that Toxoplasma, and its 
close relatives Cryptosporidium and the malaria parasite Plasmodium, do in fact possess the 
general enzymatic machinery to synthesize dolichol-linked precursors for the N-linked 
oligosaccharides as well as the machinery to transfer it to nascent polypeptide chains. Their 
analysis did not result in the identification of homologues for all of the enzymes known to be 
involved in N-glycan synthesis in other eukaryotes. Whether this reflects a true absence of 
these enzyme activities in the parasites, a lack of their evolutionary conservation or the 
incomplete nature of the databases remains to be determined. We have repeated the analysis 
performed by Samuelson et al using more recent versions of the Toxoplasma sequence 
databases. Our analysis largely confirms their findings and in fact gave rise to the 
identification of a homolog for only one additional enzyme (Supplementary Figure 2-5). 
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Our lectin overlay experiments suggest that Toxoplasma tachyzoites contain at least 
11 major and multiple minor N-glycosylated proteins (Figure 2-1). Thus far, only two 
Toxoplasma proteins have been reported to be N-glycosylated. The presence of N-linked 
glycans on GAP50, the membrane anchor for the myosin XIV motor complex in the parasite, 
was demonstrated through digestion with PNGase F and through its sensitivity to 
tunicamycin. (Figures 2-1 and 2-.2). The other protein, gp23, is a GPI-anchored 
Toxoplasma surface protein which has not been characterized by molecular cloning [14]. The 
presence of N-linked oligosaccharides on this protein was based on the incorporation of 
radiolabeled sugars and their release by PNGase F [14]. The authors of that work also found 
that the radiolabeled oligosaccharides were resistant to endo H, but interpreted this to mean 
that, like in higher eukaryotes, the oligosaccharides had matured to a complex type structure. 
In the light of our findings and the analysis by Samuelson et al, it is also possible that the 
gp23 oligosaccharides are endoH-resistant because their structure lacks the prerequisite 
mannose residue. In our hands, gp23 did not appear to be affected by treatment with 
tunicamycin or PNGase F, however. Further analysis of gp23 is needed to address these 
discrepancies. 
Like all in other eukaryote cells studied to date, N-liked glycosylation of proteins is 
essential for the survival of Toxoplasma. Treatment of the parasite with tunicamycin results 
in parasite death although this occurs with unusual kinetics. When extracellular or 
intracellular Toxoplasma tachyzoites are treated with tunicamycin, N-glycosylation is 
immediately inhibited (Figure 2-2). This does not result in an immediate block in the ability 
of the parasites to invade into host cells, but their ensuing replication is blocked by more than 
950% (Figure 2-3B). Apart from having a slightly distended nuclear envelope the resulting 
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parasites appear normal at the ultrastructural level and their major secretory organelles do not 
appear affected (Figure 2-5B). These parasites are almost completely incapable of invading 
new host cells, however (Figure 2-3B). The few parasites that do invade replicate only once 
or twice and accumulate with deformed nuclei, vastly distended endoplasmic reticulum and 
nuclear envelope, and without recognizable late secretory organelles (Figure 2-4, and 2-5C 
and Supplementary Figure 2-3). 
The latter observations are consistent with the general disruption of the secretory 
pathways typically observed in other eukaryotes [12]. There are a number of possible 
explanations for the observation that disruption of N-glycosylation by tunicamycin does not 
result in a large effect on parasite ultrastructure or replication rate during the first 48 hours of 
incubation, but a very substantial effect on the subsequent motility and host cell invasion. 
Our data are most consistent with a model in which most Toxoplasma glycoproteins are not 
important for parasite growth or replication inside animal host cells, but are critical for the 
processes that follow their release from these cells: motility and host cell invasion. 
The analysis of the Toxoplasma genome for the presence of the various enzymes 
(ALG protein homologs) known to be required for the synthesis of the dolichol-linked 
precursor oligosaccharide suggests that the parasite may not be able to synthesize the 
structure typically encountered in animal cells and yeasts (Supplementary Figure 2-5, 
Samuelson et al [18], this study). Specifically, homologs of the genes encoding ALG3p 
(dolichyl-P-Man:Man5GlcNAc2-PP-dolichyl α(1-3)-mannosyltransferase), ALG9p (dolichyl-
P-Man:Man6GlcNAc2-PP-dolichyl α(1-2)-mannosyltransferase) and ALG12p (dolichyl-P-
Man:Man7GlcNAc2-PP-dolichyl-α(1-6)-mannosyltransferase) appear to be lacking from 
the Toxoplasma genome (Supplementary Figure 2-5). As the glucosyltransferase responsible 
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for the addition of the three terminal glucose residues to the precursor oligosaccharide are 
present in the parasite genome, it would suggest that N-glycosylation of proteins 
in Toxoplasma would involve the structure shown in Figure 2-7. The absence of gene 
products with homology to known enzymes from Toxoplasma does not prove, however, that 
a particular enzyme activity is actually absent as it may be supplied by a structurally 
unrelated, parasite-specific enzyme. The experiments shown in Figure 2-6 demonstrate that 
this is unlikely to be the case. Endoglycosidase H requires Man-α(1-3)-Man-α(1-6)-Man-β(1-
4)-GlcNAc-β(1-4)-GlcNAc-Asn as minimal structure in order to cleave the N-linked 
oligosaccharide from a glycoprotein [21]. The observation that the Toxoplasma glycoprotein 
is always resistant to the action of endoglycosidase H, but not PNGase F, indicates that this 
particular mannose is indeed absent from Toxoplasma N-linked oligosaccharides, supporting 
the notion that an ALG3-like enzyme activity is absent from the parasite. 
We have not addressed the presence of N-linked oligosaccharides on protein 
inPlasmodium and Cryptosporidium species at this time. Whereas the 
Cryptosporidium genome is predicted to encode homologs of the same ALG genes present 
in Toxoplasma and is therefore likely to possess similar N-linked oligosaccharides( [18] 
and Supplementary Figure 2-5). This is not the case in Plasmodium species where the 
genome does not appear to encode any of ALG gene homologs except for ALG7 [18]. There 
have been conflicting reports on the presence of N-linked oligosaccharides 
on Plasmodium proteins. Dieckmann-Schnittler et al could not detect any evidence for the 
presence of ALG7 activity in P. falciparum lysates or oligosaccharide transferase activity, 
nor could they detect any evidence for sensitivity to tunicamycin [16]. Although this would 
appear to be in conflict with the analysis of Samuelson et al, it is important to remember that 
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biochemical analyses of Plasmodium extracts is complicated by the small yield and by the 
extensive contamination by host cell material. In contrast to these observations, Kimura et al 
reported that replication of P. falciparum is moderately affected by the presence of 
tunicamycin [17] and that a small number of con-A reactive proteins are present in parasite-
infected erythrocytes. The latter observation is surprising in that the analysis by Samuelson et 
al suggests that the Plasmodium genome does not possess genes encoding the mannosyl 
transferases necessary to generate a con-A-reactive high mannose oligosaccharide are absent 
[18]. 
Our studies indicate that N-glycosylation of proteins is a common post-translational 
modification in Toxoplasma and that the structure of the oligosaccharides lacks a number of 
the elements typically encountered in other species. We do not know, however, the identity 
or location of the N-glycosylated proteins other than GAP50, nor do we know the extent to 
which the N-linked oligosaccharides are modified post-translationally. Considering the 
clinical importance of Toxoplasma and related apicomplexan parasites 
like Plasmodium and Cryptosporidium it is evident that further study of N-glycosylation in 
these organisms may yield novel diagnostic and therapeutic strategies. The analysis of N-
linked oligosaccharide synthesis and structure in these parasites is also likely to shed more 
light on the role of this post-translational modification in general. 
 
 
 
 
 
40 
 
Materials and Methods 
 
Reagents and antibodies 
All reagents were purchased from either Fisher Scientific (Germantown, MD) or 
Sigma (St. Louis, MO) unless indicated otherwise. Monoclonal anti bodies to Gra1 (T52B4), 
Gra2 (T41F5), SAG2 (T43G11), MIC2 (T34A11), MIC3 (T42F3), gp23 (T42E12), and 
ROP8 (T52D1) were generous gifts of Dr. Jean Francois Dubremetz (Université de 
Montpellier, Montpellier, France). The SAG1 monoclonal antibody was purchased from 
Argene (North Massapequa, N.Y.). The generation of antisera to NTPase I and II has been 
described previously [9]. The monoclonal antibody HC10 was a generous gift of Dr. 
Frelinger (University of North Carolina, Chapel Hill, NC). 
Culture of host cells and Toxoplasma tachyzoites 
Toxoplasma gondii tachyzoites of the RH strain were maintained in confluent 
monolayers of human foreskin fibroblasts (HFF). The latter were maintained in α-MEM 
medium with glutamine, penicillin and streptomycin (Invitrogen, Carlsbad, CA ) containing 
2% fetal bovine serum (Hyclone, Logan, UT). Toxoplasma tachyzoites were maintained by 
serial passage on HFF cell monolayers every 2-3 days. 
Tunicamycin treatment 
HFF monolayers to be used for experiments with tunicamycin were used at least 12 
days after seeding 10
5
 freshly trypsinized cells per cm
2
. At this stage, the HFF cells were 
found to be entirely resistant to the effects of tunicamycin for at least 96 h as judged by the 
following criteria: cell morphology, replating efficiency, Trypan blue exclusion, and a 
LIVE/DEAD Viability/Cytotoxicity Kit (Invitrogen, Carlsbad, CA). Tunicamycin titrations 
were performed by incubating 2 × 10
5
 parasites with confluent HFF monolayers in 
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25 cm
2
flasks containing 4 ml complete medium with the indicated concentrations 
of tunicamycin or DMSO for 30 min, after which the medium was replaced with fresh 
medium containing the same concentration of tunicamycin or DMSO. After 2, 24, or 48 h 
of incubation at 37 °C, cells and parasites were collected by scraping, passed through an 18 
and 21 G needles to disrupt clumps, collected by centrifugation for 5 min at 2000 rpm, 
resuspended in 2 ml PBS and counted using a hemocytometer. All incubations were 
performed in triplicate. 
Control or tunicamycin-treated parasites collected after 48 h were subsequently tested 
for their ability to infect and replicate in fresh HFF monolayers in the same manner as 
described above. 
The isolated parasites were also tested for their ability to perform gliding motility and 
to attach to and invade HFF cells as described before [22]. 
Fluorescence and electron microscopy 
For fluorescence microscopy, free parasites attached to poly-L-lysine coated 
coverslips or infected HFF cells were fixed in cold (−20°C) methanol, or in 3% 
paraformaldehyde in PBS followed by permeabilization in 0.5% Triton X-100 in PBS. 
Incubation with primary and secondary antibodies was performed as described [19]. For 
lectin overlays, fixed parasites or parasite-infected cells were incubate with biotinylated 
lectins (Vector Laboratories, Burlingame, CA) diluted 1:500 in 3% BSA in PBS followed by 
incubation with Texas Red-conjugated streptavidin (Invitrogen) diluted 1:1000 in the same 
buffer. Images were captured using an epifluorescence Nikon Eclipse TE-2000 microscope 
(Nikon Inc., Melville, NY) and a Hamamatsu 1394 cooled digital CCD camera (Hamamatsu) 
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and Metamorph
®
 imaging software (Universal Imaging Corp.). Adobe Photoshop
®
 (Adobe 
Systems Inc., San Jose, CA) was used to crop images. 
For electron microscopy, Toxoplasma-infected HFF cells were washed twice in 0.1 M 
sodium cacodylate pH 7.4 and fixed overnight at 4°C in 2% glutaraldehyde in 0.1 M sodium 
cacodylate pH 7.4. After staining in 1% osmium tetroxide and dehydration in 50-100% 
ethanol, the samples were embedded in epon. The polymerized bocks were sectioned at 60 
nm with a Leica Ultracut UCT ultramicrotome (Leica Microsystems Inc., Bannockburn, IL). 
Sections were stained with 2% uranyl acetate and Sato's lead stain, and viewed on an FEI 
Tecnai 12 electron microscope (FEI Company, Hillsboro, OR). Images were collected with a 
Gatan model 794 multi-scan digital camera (Gatan Inc., Pleasanton, CA). 
2.5. Lectin overlays 
Protein samples corresponding to 2 × 10
6
 parasites or 5 × 10
5
 HFF cells were 
separated by SDS-PAGE and transferred to nitrocellulose. This was blocked in 3% BSA in 
Tris-buffered saline with 0.1% Tween 20 (TBST) and incubated for one hour with 
biotinylated concanavalin-A or Dolichos biflorus agglutinin (Vector, Burlingame, CA) 
diluted 1:2000 and 1:1000 in TBST, respectively. Following incubation with IRDye800CW-
conjugated streptavidin (Li-COR Biosciences, Lincoln, NE) the blots were scanned with a 
Li-COR Odyssey (Li-COR Biosciences). 
Where indicated, total parasite lysates were also digested prior to SDS-PAGE with 
PNGase F as suggested by the manufacturer (NEB). 
Metabolic labeling and immunoprecipitation 
For long-term labeling of proteins, Toxoplasma-infected or uninfected HFF cells (in 
25 cm
2
 flasks) were washed twice with cysteine/methionine-free DMEM medium 
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(Invitrogen) and incubated for 16-18 hours at 37°C in 3 ml cysteine /methionine-free DMEM 
medium containing 3% dialyzed fetal bovine serum and 358 μCi [35S] methionine/cysteine 
(Pro-Mix [
35
S] in vitro cell labeling mix, GE Healthcare BioSciences Corp., Piscataway, NJ). 
Tunicamycin (EMD Biochemicals Inc., San Diego, CA) was added to 5 μg/ml where 
indicated. Cells were collected by scraping with a rubber policeman, collected by 
centrifugation for 5 minutes at 400 × g, washed once in PBS and frozen in liquid nitrogen. 
For pulse-chase experiments, Toxoplasma-infected or uninfected HFF cells were washed 
twice in cysteine/methionine-free DMEM and subsequently gently scraped into 2 ml of the 
same medium using a rubber policeman. Cells were collected by centrifugation for 5 minutes 
at 400 × g, resuspended in 1 ml cysteine/methionine-free DMEM containing 3% dialyzed 
fetal bovine serum, and incubated for 30 minutes at 37°C. Pulse labeling was initiated by the 
addition of 358 μCi [35S] methionine/cysteine and incubated at 37°C for 10 minutes. 
Subsequently, methionine and cysteine were added to a final concentration of 0.1 mM. 
Samples (0.45 ml) were removed, placed on ice, centrifuged for 1 minute at 14,000 × g and 
4°C, and the resulting pellets frozen in liquid nitrogen. The remainder was incubated for an 
additional 60 minutes at 37°C after which 0.45 ml was removed, centrifuged as described 
above and also frozen in liquid nitrogen. 
Cell pellets were resuspended in 1% SDS in water and heated for 5 minutes at 95°C. 
Samples were diluted by the addition of 9 volumes of 1% Triton X-100 in 150 mM NaCl, 5 
mM EDTA, 50 mM Tris-HCl pH 8 (TNET) and insoluble material was removed by 
centrifugation for 10 minutes at 14,000 × g and 4°C. GAP50 and HLA class I heavy chains 
were immunoprecipitated by the addition of a rabbit-anti-GAP50 antiserum and the HC10 
monoclonal antibody [23]. After 60 minutes on ice, 25 μl of protein-A agarose (Zymed, S. 
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San Francisco, CA) was added followed by an additional incubation for 30 minutes at 4°C. 
Protein-A beads were washed three times in TNET buffer. 
The immunoprecipitated material was treated where indicated with either 
endoglycosidase H or PNGase F (New England Biolabs, Beverly, MA) according to 
manufacturers' instructions. Samples were analyzed by SDS-PAGE and fluorography with 
EN
3
HANCE (Perkin Elmer, Boston, MA). 
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Figures and Legends 
 
Figure 2-1. N- and O-glycosylation of proteins are common post-translational 
modifications in Toxoplasma tachyzoites  
Lysates of purified tachyzoites were incubated in the absence (control) or presence (PNGase 
F) of PNGase F for 16 h at 37 °C, fractionated by SDS-PAGE on 12% (A) or 7.5% (B) gels, 
and transferred to nitrocellulose. Blots were probed with biotinylated lectins concanavalin-A 
(con-A) and Dolichos biflorusagglutinin (DBA), and with monospecific antisera to 
the Toxoplasma glycoprotein GAP50 and the cytoplasmic proteins MLC1 and IMC1. 
Arrowheads indicate the con-A-reactive parasite proteins that are PNGase F-sensitive. 
GAP50 + OS and GAP50 − OS refer the fully N-glycosylated and enzymatically 
deglycosylated GAP50, respectively. 
 
Figure 2-2. N-glycosylation in Toxoplasma gondii is sensitive to tunicamycin  
GAP50 was immunoprecipitated from Toxoplasma-infected HFF cells that were labeled for 
16 h with [
35
S] methionine/cysteine in the presence or absence of 5 μg/ml tunicamycin. 
GAP50 + OS and GAP50 − OS refer to fully N-glycosylated and non-glycosylated GAP50, 
respectively. 
 
 
Figure 2-3. N-glycosylation is critical for Toxoplasma survival 
(A) GAP50 accumulates in non-glycosylated form after growth of Toxoplasma for 24 h in the 
presence of 5 μg/ml tunicamycin. GAP50 + OS and GAP50 − OS refer to fully N-
glycosylated and non-glycosylated GAP50, respectively. (B) The effect of 
tunicamycin on Toxoplasma cell viability was determined in a two-stage experiment. In stage 
1, confluent HFF monolayers were infected with freshly isolated parasites in the presence of 
the indicated concentration of tunicamycin or DMSO. Unattached parasites were removed by 
washing after 2 h at 37 °C and the incubation continued in the presence or absence 
of tunicamycin. The number of host cell-associated parasites was determined at the indicated 
times. In stage 2, parasites had been isolated after 48 h in the presence or absence 
of tunicamycin and used to infect fresh confluent HFF monolayers. Parasite replication was 
monitored in the same fashion as in stage 1. (C) Parasites treated for 48 h with 5 μg/ml 
tunicamycin are severely defective in gliding motility. The arrowhead indicates the trail 
of cell surface protein left behind by the moving parasite. (D) Tunicamycin-treated 
(48 h) parasites are defective in host cell attachment and invasion. 
 
Figure 2-4. GAP50 expression and nuclear morphology are affected by long-term 
treatment with tunicamycin 
Toxoplasma tachyzoites expressing a GAP50–YFP fusion protein were treated for 48 or 96 h 
in the presence or absence of 5 μg/ml tunicamycin. The membrane skeletal protein IMC1 was 
visualized by indirect immunofluorescence and the nuclear and apicoplast DNA by staining 
with DAPI. The exposure time for GAP50–YFP was 200 ms for the control and 48 h 
incubation, and 2 s for the 96 h incubation. Scale bars: 5 μm. 
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Figure 2-5. Inhibition of N-glycosylation and Toxoplasma ultrastructure 
Toxoplasma tachyzoites were incubated in the presence of DMSO (A) or in the presence of 
(in the text you stated that you used 10μg/ml; not sure which one is which) 
5 μg/ml tunicamycin for (B) 48 h or (C) 96 h. Scale bars: 200 nm. Insets show details of 
the parasite Golgi complex (GC), nuclear membrane (NM), inner membrane 
complex (imc), plasma membrane (PM), dense granules (dg), rhoptries (rh), 
and micronemes (mn). 
 
Figure 2-6. Toxoplasma N-linked oligosaccharides are never sensitive to  
endoglycosidase H 
Uninfected or Toxoplasma-infected HFF cells were pulse-labeled with [
35
S] 
methionine/cysteine for 10 min and subsequently chased for 60 min in the presence of excess 
unlabeled methionine and cysteine. GAP50 and the HLA class I heavy chains were 
immunoprecipitated from the Toxoplasma-infected or uninfected HFF cells, respectively, and 
subjected to digestion with endoglycosidase H or PNGase F. The positions of the fully 
glycosylated (GAP50 + OS, HLAHC + OS) and deglycosylated proteins 
(GAP50 − OS, HLAHC − OS) are indicated. 
 
Figure 2-7. N-linked oligosaccarides of animals and yeast glycoproteins  
(A) Structure of the typical core N-linked oligosaccharide on newly synthesized animal 
and yeast glycoproteins. (B) Minimal N-linked oligosaccharide structure required for 
sensitivity to endoglycosidase H. (C) Predicted structure of N-linked oligosaccharide on 
newly synthesized glycoproteins in Toxoplasma. 
 
Supplementary Figure 2-1. N- and O-glycosylated proteins are found at multiple 
locations in the secretory apparatus of Toxoplasma tachyzoites  
(A) The distribution of con-A and DBA-reactive glycoproteins in 
extracellular Toxoplasma tachyzoites was determined by incubating fixed and 
permeabilized parasites with biotinylated con-A or DBA, followed by Texas Red 
labeled streptavidin. The parasite pellicle was visualized using an antiserum to IMC1 and the 
nucleus and apicoplast (arrow) by staining with DAPI. The streptavidin by itself reacts with 
biotinylated material in the apicoplast (bottom panels). Scale bars: 5 μm. (B) The distribution 
of concanavalin-A-binding protein in Toxoplasma tachyzoites was compared with that of the 
endoplasmic reticulum protein BiP, the microneme protein MIC2, the dense granule protein 
GRA3, and the rhoptry proteins ROP2 and ROP3 by fluorescence microscopy. Scale bars: 
5 μm. 
 
Supplementary Figure 2-2. Sensitivity of HFF cells to tunicamycin is dependent on cell 
density  
Subconfluent or fully confluent monolayers of HFF cells were treated with 
10 μg/ml tunicamycin for 24 h (low density) or 72 h (high density). 
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Supplementary Figure 2-3. Effect of tunicamycin treatment on the secretory apparatus 
of Toxoplasma tachyzoites 
Toxoplasma tachyzoite-infected HFF cells were incubated for 48 or 96 h in the presence of 
DMSO or 5 μg/ml tunicamycin. The distribution of (A) the dense granule marker GRA3, (B) 
the rhoptry marker ROP2, (C) the plasma membrane protein SAG1, (D) 
the microneme protein MIC2, and (E) the endoplasmic reticulum chaperone BiP was 
analyzed in parallel with the membrane skeleton protein IMC1 and the nuclear 
and apicoplast DNA by immunofluorescence microscopy. Scale bars: 5 μm. 
 
Supplementary Figure 2-4. Candidate N-glycosylated Toxoplasma proteins and their 
sensitivity to PNGase F  
Control and PNGase F-digested Toxoplasma tachyzoite lysates were separated by SDS-
PAGE, transferred to nitrocellulose and probed with monospecific antibodies to GAP50 and 
several Toxoplasma secreted proteins predicted to contain or lack N-linked glycans. (A) gp23 
and GAP50, (B) Gra1, Gra2, Sag1, Sag2,Mic2, Mic3, NTPase I & II, and ROP8. 
 
Supplementary Figure 2-5. ALG gene requires for synthesis Toxoplasma N-linked 
glycans 
ALG gene products required for the synthesis of the dolichol-linked precursor for N-linked 
oligosaccharides and their homologs in Toxoplasma gondii EST and genomic databases. 
 
Supplementary Table 2-1. N-glycosylated secretory proteins in Toxoplasma  
Toxoplasma proteins known to reside in the secretory pathway and possessing predicted N-
glycosylation sites were tested for the presence of N-linked oligosaccharides by comparing 
their motility in SDS-PAGE before and after digestion with PNGase F. PV, parasitophorous 
vacuole; PM, plasma membrane; ER, endoplasmic reticulum. NT, not tested due to 
unavailability of antibodies.  
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Figure 2-1. N- and O-glycosylation of proteins are common post-translational 
modifications in Toxoplasma tachyzoites  
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Figure 2-2. N-glycosylation in Toxoplasma gondii is sensitive to tunicamycin  
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Figure 2-3. N-glycosylation is critical for Toxoplasma survival 
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Figure 2-4. GAP50 expression and nuclear morphology are affected by long-term 
treatment with tunicamycin 
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Figure 2-5. Inhibition of N-glycosylation and Toxoplasma ultrastructure  
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Figure 2-6. Toxoplasma N-linked oligosaccharides are never sensitive to   
  endoglycosidase-H 
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Figure 2-7. N-linked oligosaccarides of animals and yeast glycoproteins 
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Supplementary Figure 2-1.                                                                                                                
N- and O-glycosylated proteins are found at multiple locations in the secretory 
apparatus of Toxoplasma tachyzoites 
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Supplementary Figure 2-2.                                                                                       
Sensitivity of HFF cells to tunicamycin is dependent on cell density  
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Supplementary Figure 2-3.                  
Effect of tunicamycin treatment on the secretory apparatus of Toxoplasma tachyzoites  
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Supplementary Figure 2-3.                 
Effect of tunicamycin treatment on the secretory apparatus of Toxoplasma tachyzoites  
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Supplementary Figure 2-3.                     
Effect of tunicamycin treatment on the secretory apparatus of Toxoplasma tachyzoites  
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Supplementary Figure 2-4.                       
Candidate N-glycosylated Toxoplasma proteins and their sensitivity to PNGase F  
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Supplementary Figure 2-5.                  
ALG gene requires for synthesis Toxoplasma N-linked glycans 
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Supplementary Table 2-1.                                  
N-glycosylated secretory proteins in Toxoplasma  
 
Candidate protein Distribution in (host) cell PNGaseF-sensitivity Accession number 
18 kDa cyclophilin Dense granule + PV NT AAA17997 
GRA7 Dense granule + PV - ABF13219 
GRA9 Dense granule + PV NT AAR10290 
NTPase I Dense Granule + PV - Q27893 
NTPase II Dense Granule + PV - Q27895 
MIC2 Microneme + PM - AAB63303 
MIC3 Microneme + PM - CAB56644 
MIC10 Microneme + PM NT AAG32024 
ROP8 Rhoptry + PV - AAC47797 
SAG2 PM - AAO72427 
SRS4 PM NT AAC27649 
Sec61  ER NT AAU93469 
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CHAPTER 3 
 
Global analysis of Toxoplasma gondii palmitoyl proteome
2
 
 
 
 
 
 
                                                 
 
2
 MudPIT analysis performed in collaboration with James Thompson from Dr. John Yates Laboratory at Scripps 
Research Institute  
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Abstract 
Many eukaryotic proteins are post translationally modified by the addition of 
palmitate moieties to cysteine residues.  Given the prevalence of palmitoyl proteins 
eukaryotic cells and its role in essential cellular process such as protein trafficking, protein 
stability, and distribution, this post translational modification has not been extensively 
studied in Toxoplasma.  We have detected the palmitoylation of Myosin XIV motor complex 
subunits, and a few additional proteins in Toxoplasma have been experimentally identified as 
palmitoylated.  However, the functional consequences of palmitoylation beyond membrane 
association have not been explored.  We present the palmitoyl proteome of tachyzoite stage 
of Toxoplasma in this study.  We utilized the acyl-biotin exchange chemistry to replace 
palmitate moieties with thiol-reactive biotinylation reagents to purify proteins, and after 
streptavidin purification proteins were identified by MudPIT.  A total of 400 candidate 
proteins were identified and included motor proteins, inner membrane complex proteins, and 
many pellicle associated proteins.  Therefore protein palmitoylation is a common post 
translational modification in Toxoplasma, which may be required to mediate many cellular 
processes essential for parasite survival.   
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Introduction 
Palmitoylation is the addition of a long chain fatty acid, palmitic acid (C16:0), to 
cysteine thiols to promote membrane association and localized protein function [1-3]. Many 
proteins depend on this post translational modification to mediate important cellular 
processes such as protein trafficking, stability, and intracellular signaling [1-3]. 
Palmitoylation differs from other fatty acid modifications such as myristoylation and 
prenylation in that: 1- no strict consensus sequence has been identified, however it is 
established that clustered cysteine residues or cysteines close to myristoylation or prenylation 
sites are common sites of palmitoylation; and 2- this modification is reversible, which allows 
for regulation of localized protein function as palmitate moieties cycle on and off the protein 
[1-3]. The mechanism of protein palmitoylation remained poorly understood until the first 
protein palmitoyl transferase, enzymes responsible for the addition of palmitate to cysteine 
residues, was identified by forward genetic screens in yeast [4,5].  Since then, multiple 
palmitoyl transferases have been identified and characterized in parallel with entire palmitoyl 
proteome of S.cerevisiae [6,7].  The recent advancement in understanding protein 
palmitoylation has been facilitated by the development of biochemical and proteomic tools to 
analyze this modification on a global scale [6], and here we apply these methods in the 
identification and characterization of Toxoplasma palmitoyl proteome.   
Toxoplasma gondii is an obligate intracellular parasite in the phylum apicomplexa 
[8].  Another member of this phylum is Plasmodium falciparum, the causative agent of 
malaria. Toxoplasma infection occurs either through the ingestion of undercooked meat or 
contact with cat feces harboring parasitic cysts [9].  Toxoplasma is a common cause of 
congenital neurological defects in newborns, and life-threatening secondary infections in 
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immunocompromise individuals.  The pathogenesis associated with Toxoplasmosis is largely 
due to tissue damage caused by repeated cycles of host cell invasion, replication, host cell 
lysis, and reinvasion [9].  These processes are essential to parasite survival, and heavily 
dependent on parasite motility.   
Toxoplasma motility is essential for parasite survival.  Toxoplasma is surrounded by a 
unique organelle known as the pellicle [13].  The pellicle consists of the plasma membrane, 
and underlying inner membrane complex (IMC) composed of series of flattened cisternae 
[13].  Toxoplasma motility is driven by myosin XIV motor complex conserved among 
apicomplexans, and must localize to space between the IMC and plasma membrane [13].  
The myosin XIV motor complex is composed of an integral membrane protein GAP50, an 
unconventional myosin-A heavy chain, a myosin light chain like protein (MLC1), and a 
protein of unknown function, GAP45 [12].  Previously, our lab established that the myosin 
XIV complex is assembled in two stages:  1) GAP50 traffics through the secretory pathway 
to the IMC and 2) the other subunits, myosin-A, MLC1, and GAP45, assemble separately 
into a soluble precursor complex in the cytoplasm.  The final association with the inner 
membrane complex and GAP50 anchors it on the outer face of the inner membrane complex 
[12].  However, the mechanism by which the precursor complex associates with IMC 
remains unknown. We show here that all subunits of the precursor complex are 
palmitoylated, which suggests that this post translational modification may play a critical role 
in mediating myosin XIV motor complex assembly at the IMC to coordinate motility.   
Given that palmitoylation has proven to be a prevalent modification involved in many 
important cellular processes not only in yeast but also in humans and mice, we conducted the 
first palmitoyl proteome analysis in Toxoplasma utilizing the acyl-biotin exchange reaction 
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coupled to MudPIT proteomic methods developed by Roth et. al. [6].  We identified 400 
candidate palmitoyl proteins, which included parasite specific proteins (rhoptries, dense 
granule proteins, MIC proteins, IMC proteins, MORN domain containing proteins, surface 
antigens) as well as common eukaryotic proteins (protein kinases and GTPases).  The top 38 
most abundant protein candidates, defined by spectral count values, were highlighted for 
primary analysis and consist of both soluble and transmembrane proteins.  Upon validation of 
5 candidates, we identified 4 new palmitoylated proteins and shown that palmitoylation plays 
a role in pellicle association.  One candidate, Hsp20, displays unique localization to detergent 
resistant filamentous structures in addition to IMC association.  This current study shows 
palmitoylation is a common post translational modification- as it occurs on many proteins.  
With the identification of Toxoplasma palmitoyl proteome, we can begin to explore the roles 
of palmitoylation in essential parasitic process (motility, invasion, replication and egress), 
and search for routes of intervention.   
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Results 
Palmitoylation of Toxoplasma Myosin XIV Motor Complex  
In our previous studies, we showed that Myosin XIV motor complex assembly occurs 
in 2 stages: 1) GAP50 is delivered to the inner membrane complex (IMC) via the secretory 
pathway, and 2) Myosin-A/MLC1/GAP45 assembles into a precursor, cytoplasmic complex 
that subsequently associates with GAP50 at the outer face of IMC [12].  However, 
association of the precursor complex with GAP50 alone is insufficient to anchor it in the 
membrane.  The myosin-A/MLC1/GAP45 precursor complex must also associate with the 
IMC, but the mechanism of association remains unknown.   Acylation is a common post-
translational modification known to mediate membrane attachment of proteins, and this 
modification may promote the association of precursor complex with IMC.  Sequence 
analysis of Toxoplasma GAP45 reveals a putative N-myristoylation site and multiple putative 
palmitoylation sites [12]. Subsequently, Rees-Channer et al. [14] demonstrated that the 
GAP45 homolog in the malaria parasite P. falciparum was indeed modified by incorporation 
of these fatty acids.  
 To test if members of myosin XIV motor complex are modified by protein acylation, 
we metabolically labeled Toxoplasma-infected cells with [
3
H]-myristate, -palmitate, or 
[
35
S]Met/Cys as a control.  Motor complex subunits do not have prenylation motif CaaX, 
thus we omitted this modification from our analysis.  GAP45 immunoprecipitate from 
[
35
S]Met/Cys labeled TX-lysate also pulls down associated subunits of the myosin XIV 
motor complex (Figure3-1).  After labeling Toxoplasma-infected cells with [
3
H] myristate or 
palmitate, incorporation of both [
3
H]-labeled fatty acids into immunoprecipitated GAP45 is 
readily detected, indicating that GAP45 is indeed dually acylated.  However, Myosin-A and 
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MLC1 were only labeled in cells incubated with [
3
H] palmitate.  We detected no labeling of 
GAP50.  Taken together, members of the precursor motor complex (GAP45/Myosin-
A/MLC1) are palmitoylated and GAP45 is myristoylated, which suggests that palmitoylation 
may play an essential role in complex association with IMC; a process critical for parasite 
motility.  
 
Purification and identification of Toxoplasma palmitoyl proteins 
Protein palmitoylation may play a key role in many cellular processes essential to 
parasite survival, given that essential proteins GAP45, Myosin-A, and MLC1 mediating 
motility are palmitoylated; thus we searched for additional palmitoyl proteins in Toxoplasma.  
Although [3H]-palmitate incorporation into proteins is a definitive indication of 
palmitoylation, this method requires large quantities of radioactive label, 
immunoprecipitation, and long autoradiographic exposure times.  And the focus is always 
limited to individual proteins per experiment, thus this method is not conducive to the 
analysis of an entire palmitoyl proteome of Toxoplasma.   
 We adopted the acyl-biotin exchange (ABE) followed by proteomic analysis with 
MudPIT, a method developed by Roth et. al. [6].  To purify palmitoyl proteins, enriched in 
membranes, we performed ABE chemistry on total membrane fractions of extracellular 
tachyzoites (Figure3-2).  First free thiols, not covalently bound to palmitate moieties, were 
blocked with N-ethylmaleimide (NEM) to prevent non-specific labeling with biotinylation 
reagent.  Thereafter the thioester-linked palmitate moieties were released by hydroxylamine 
treatment, and newly exposed thiols were labeled by co-incubation with N-[6-
(biotinamido)hexyl]-3-(2-pyridyldithio)propionamide (biotin-HPDP).  A control sample, 
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processed in parallel, was incubated with biotin-HPDP minus hydroxylamine to identify 
proteins that were nonspecifically labeled.  Biotinylated proteins from both samples were 
purified with streptavidin agarose, and eluted proteins were either separated by SDS-PAGE 
or processed for MudPIT. The plus-HA sample represented proteins biotinylated in a 
hydroxylamine dependent manner, as opposed to proteins in minus-HA control sample, 
which were labeled in hydroxylamine independent manner (Figure3-3A).  Proteins unique to 
plus-HA sample represented candidate palmitoyl proteins, and proteins present in both plus- 
and minus- HA control samples were presumably purified nonspecifically.  The presence of 
known palmitoylated proteins (MyoA, GAP45, and MLC1) exclusively in plus-HA sample 
demonstrates the specificity of acyl-biotin exchange approach in Toxoplasma (Figure 3-3B).     
 To identify candidate palmitoyl proteins, plus- and minus- HA treated samples from 
triplicate trials were subjected to multidimensional protein identification technology 
(MudPIT).  This proteomic approach allows us to identify thousands of proteins in a complex 
mixture by two dimensional liquid chromatography followed by tandem MS/MS [6]. A total 
of 400 proteins were identified, 270 of which are known proteins and 130 are hypothetical 
proteins (Supplementary Table 1).  Spectral count is the total number of peptide 
identifications, redundant and non-redundant, for each protein.  We used this value as a 
quantitative measure to compare relative protein abundance in plus- versus minus-HA 
samples (the plus- to minus- HA spectral count ratio), and to distinguish candidate proteins 
from contaminant background proteins [16,17].  Proteins with higher ratios of plus/minus-
HA spectral count should have a greater abundance in plus-HA sample and therefore likely to 
be palmitoylated [15,17].  The combined protein identifications from three independent trials 
were plotted by relative protein abundance.  The plus- (x-axis) versus minus-HA samples (y-
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axis) (Figure 3C).  Most identified proteins have similar plus- and minus-HA sample 
representation, and gathered close to xy-diagonal (plus-to minus-HA spectral count ratio =1) 
or the y-axis (ratio <1).  This group included abundant proteins purified in HA independent 
manner, such as cytoskeletal proteins, chaperones, ribosomal proteins, and glycolytic 
enzymes.  In contrast, proteins with a relatively greater abundance in plus-HA sample (ratio 
>1) were clustered close to the x-axis, and include known palmitoylated proteins such as 
GAP45 and MLC1 as well as candidate palmitoyl proteins.   
 To select candidate palmitoyl proteins for validation and further analysis, proteins 
were ranked according to their plus- to minus-HA spectral count ratios.  Known palmitoyl 
proteins GAP45 and MLC1 had plus/minus-HA spectral count ratios greater than 15.  Thus, 
we designated the top 38 proteins having plus/minus-HA spectral count ratios greater than 15 
as the first group of candidates for primary analysis (Table 3-1).  This group of candidates 
included 21 identified proteins and 17 hypothetical proteins. Given that the annotation of 
Toxoplasma genome is incomplete, many parasite specific proteins with no obvious 
homologue in other organisms are designated as hypothetical.  Within the list of top 38 
proteins, 2 are known to be palmitoylated (GAP45 and MLC1), 4 are predicted palmitoyl 
proteins IMC-4, -5,-6, -10 [18], and 5 were selected for further analysis (MORN2, PhiL1, 
Hsp20, Hypothetical proteins: 55.m08184, 59.m03599).  GAP50 (Gene ID 38.m01061) was 
eliminated from this group because we have previously shown that this motor complex 
subunit was not labeled with [3H] palmitate (Figure 3-1).  The biotin-requiring domain 
protein (Gene ID 20.m00373) was likely purified nonspecifically with streptavidin, therefore 
we also eliminated the protein from our list of top 38 candidates.  The baseline of 
significance was established with Myosin A heavy chain (ratio = 1.9), who had the lowest 
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spectral count ratio out of the known palmitoyl proteins.  Therefore, candidates with ratios 
between 15 and 5.4 will be validated in subsequent analysis.  Although we designated the 
ratio of 1.9 as a baseline of significance, it is not a strict cut-off point.  We recognize that 
some palmitoyl proteins in the list of 400 proteins may have ratios less than 1.9. However 
distinguishing these low abundance candidates from background may require subsequent 
trials rather than validation. 
 
Validation of Candidate Palmitoyl Proteins 
From the group of 38 proteins designated for primary analysis, 5 were chosen for 
further validation based on practical characteristics that facilitate genetic and biochemical 
manipulations i.e. relatively small yet manageable molecular weight; presence of clustered 
cysteine residues indicative of palmitoylation motif.  The protein function of candidates: 
MORN2, hypothetical proteins 55.m08184 and 59.m03599, have not been previously 
characterized in Toxoplasma.  MORN2 contains the multiple membrane occupation and 
recognition nexus motif [19].  Hsp20 is one of five small heat shock proteins in Toxoplasma 
[20]. 55.m08184 and 59.m03599 are hypothetical proteins designated by their gene 
identification numbers, and may be parasite specific proteins with no obvious homologues in 
other eukaryotic cells.   
Prior to validation by small scale acyl-biotin exchange and [
3
H] palmitate 
incorporation, candidates were epitope tagged with YFP.  All candidates were purified in 
plus-hydroxylamine dependent manner (Figure 3-4), and [
3
H] palmitate labeling further 
confirmed palmitoylation of MORN2, Hsp20, 59.m03599, and 55.m08184 (Figure 3-4).  
Palmitoylation of these proteins plays a role in membrane association given that candidates 
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localized to the pellicle of Toxoplasma (Figure 3-4).  MORN2 and 50.m03599 associate with 
the plasma membrane.  And Hsp20 and 55.m08184 associates with Inner Membrane 
Complex (IMC) as shown by co- localization to immature IMC of daughter cells.  Also, 
55.m08184 appears to only localize to two-thirds the length of the parasite IMC from the 
apical end, excluding the basal end of parasite; thus suggesting that palmitoylation mediates 
protein association to specific regions of the IMC.   Although PhiL1 was highly abundant in 
plus-hydroxylamine sample, this protein was not labeled by [
3
H] palmitate which indicates 
that PhiL1 may have been nonspecifically purified in ABE procedure and not palmitoylated. 
Mutation of potential acylation sites of MORN2 and Hsp20 disrupted membrane 
association as shown by indirect immunofluorescence (Figure 3-4).  Mutant MORN2 G2A C4A 
was cytoplasmic, thus both N-myristoylation at Glycine-2 and palmitoylation at Cysteine-4 
are required for plasma membrane association.  Additionally, palmitoylation of cysteines 3 
and 4 plays a role in Hsp20 IMC association, given that Hsp20 C3,4A localizes to unknown 
structure.  Taken together, 4 of the 5 candidates were confirmed as true palmitoyl proteins 
and palmitoylation plays a role in Toxoplasma pellicle association.   
 
Toxoplasma small heat shock protein 20 localizes to “stripe-like” structures 
Hsp20 is a small heat shock protein, previously shown to be palmitoylated.  The 
localization of Hsp20 in Toxoplasma is confined to IMC, specifically to discontinuous 
“stripe” like structures along length of IMC.  This localization pattern can be observed in 
intact cells and live cells (Figure 3-5A), thus structures are not likely to be fixation artifacts.  
Additionally, these “stripe” like structures are more pronounced after Triton-X100 extraction 
as well as after deoxycholate extraction.  Hsp20 remains largely insoluble after TX-100 
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extraction, and solubilized after 25mM deoxycholate extraction (Figure 3-5B); thus 
suggesting that Hsp20 localized “stripes” are either detergent resistant themselves or 
associates with detergent resistant membranes.  At the ultrastructural level, “Hsp20 localized 
stripes” are pronounced structures that seem to be organized at the posterior end and wrap 
along the length of the parasites (Figure 3-5C, Supplementary Figure 3-2).  These structures 
are distinct from microtubules with dimensions close to ~30 nm in width as seen by Field 
Emission –Scanning EM. At the time, it is not clear as to what these structures represent.  
The stripes observed by FE-SEM may be membrane structures that are stabilized by Hsp20-
YFP during detergent extractions.  Subsequent analysis of these structures are required, 
however this phenotype does suggest that Hsp20 may play a role in stabilizing membrane 
structures in Toxoplasma.   
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Discussion 
Protein palmitoylation has been implicated in many cellular processes, and the 
development of biochemical and proteomic methods to purify and identify palmitoyl proteins 
have facilitated our understanding of this modification.  In Toxoplasma, only a few proteins 
have been shown to be palmitoylated  (through mutational analysis) or predicted to be 
palmitoylated based on sequence analysis; thus the implications of this modification remains 
unknown.  Here we present the first analysis of the Toxoplasma palmitoyl proteome. We 
utilized acyl-biotin exchange chemistry coupled with MudPIT proteomic analysis to purify 
and identify Toxoplasma palmitoyl proteome.  400 candidate palmitoyl proteins were 
identified.  Candidates were designated for further analysis based on their relative abundance 
in plus-versus minus-Hydroxylamine sample (plus/minus spectral count ratio), and the 
palmitoylation status of five candidates were confirmed.    
The 400 candidates included both soluble and transmembrane proteins that had 
multiple and single acylation sites.   Known palmitoyl proteins as well as predicted 
palmitoylate proteins were identified, suggesting that the acyl biotin exchange chemistry was 
efficient in purifying palmitoyl proteins from total cellular membranes.  Inner membrane 
complex proteins-1, 10, 6, and 4 [19] as well as “IMC Sub-Compartment Proteins (ISP)” 
ISP1, ISP [22] previously predicted to be palmitoylated are present in our list of candidates.  
Inner membrane complex proteins 1, 4, 6, and 10 were found in the top 38 proteins 
designated for primary analysis with plus/minus HA ratios greater than 15.  Known 
palmitoylated proteins GAP45 and MLC1 have ratios above 15; thus this ratio value was use 
to designate proteins for primary analysis.  The baseline of significance was established with 
Myosin-A heavy chain, one of the known palmitoylated proteins with the lowest ratio value 
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of 1.9; thus proteins with ratios greater than 1.9 may likely be palmitoylated and included in 
subsequent analysis.  Let us stress that the plus/minus spectral count ratio used to designate 
significance is only a guideline, and is not a definitive indication that proteins with lower 
ratios are not palmitoylated.  Many proteins have low spectral count values, which is largely 
due to the experimental difficulties in obtaining sufficient starting material for analysis.  Low 
spectral count values make it difficult to discriminate between candidates and false positives, 
thus additional trials are needed to increase the confidence of these protein identifications.   
Several identified proteins are known as false positives.  These included abundant 
proteins and proteins that utilize thioester chemistries for modifications other than 
palmitoylation ie. ubiquitin, cytoskeletal proteins, mitochondrial proteins, and glycolytic 
enzymes [17].  Protein palmitoyl transferases are enzymes responsible for protein 
palmitoylation, and contain characteristic DHHC-CRD domains.  Toxoplasma genome has 
17 DHHC-CRD containing proteins, and several were present in our analysis.  However, we 
considered these to be false positives because the palmitate moieties are transiently bound to 
PPTs during catalysis [21].   
Here we showed that 4 of the 5 candidates selected for validation by small scale acyl-
biotin exchange and [3H] palmitate incorporation are palmitoylated.  The 3 candidates, 
MORN2, hypothetical proteins 55.m08184 and 59.m03599 have not been previously 
characterized in Toxoplasma.  Here we established that they localize to parasite pellicle 
indicating that palmitoylation may play a role in membrane association.   
Hsp20 is a small heat shock protein that displays a unique localization pattern.  Hsp20 
localized to detergent resistant filamentous like structures that run along the length of the 
parasite.  These filaments are distinct from microtubules, and the composition of which we 
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do not know at this time.  It is possible that filaments may also be detergent resistant 
membrane domains exaggerated by overexpression of Hsp20 or the presence of YFP.   
Perhaps Hsp20 localizes to specific microdomains in the IMC and promotes membrane 
overall structural integrity for the parasite.  There are no known hsp proteins localized to this 
space, which brings forth the question of how essential proteins are stabilized/protected from 
denaturation under consistent stress conditions –egress, invasion, differentiation. 
In Toxoplasma, many identified palmitoyl proteins were localized to membranes of 
the pellicle (which consists of plasma membrane and inner membrane complex).  The space 
between the IMC and plasma membrane is relatively small, and how proteins are regulated 
and targeted within this space remains unknown. It is well established that palmitoylation 
functions beyond simply promoting membrane association.  We may find that palmitoylation 
regulates protein-protein interactions, protein trafficking and partitioning to IMC 
compartments, and protein orientation within this small space to coordinate parasite motility, 
invasion, and egress.  The analysis presented here may help us elucidate the function of the 
many hypothetical and known proteins, and expand our knowledge of palmitoyl biology in 
Toxoplasma.   
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Materials and Methods 
Parasite culture 
The RH(HXGPRT-) strain of Toxoplasma gondii  and strains expressing fusion 
proteins were maintained by serial passage in confluent monolayer of human foreskin 
fibroblasts (HFF) in α-minimal essential medium (Gibco) supplemented with 2% fetal bovine 
serum (Hyclone), 2 mM glutamine, 100 IU/ml penicillin, and 100μg/ml streptomycin. 
Cellular Fractionation 
Palmitoylated proteins were purified from total membrane fractions, and subsequently 
used for acyl-biotin exchange reactions.  Parasites (2x10
9
 for ABE/MudPIT analysis or 
1.5x10
8
 for ABE/SDS-PAGE and immunoblot analysis) in LB buffer (150mM NaCl, 50mM 
Tris-HCl pH7.4, 5mM EDTA) containing 25mM NEM were subjected to 3 cycles of 
freeze/thaw in LN2, and centrifuged at 14000 x g, 4°C, for 15 minutes to separated soluble 
proteins from membrane fractions.  The pellet containing total membranes were detergent 
solubilized with LB buffer containing 0.5% TX-100 and 25mM N-Ethylmaleimide (NEM, 
Pierce) for 60minutes at 4°C with rotation.  After removal of particulates by centrifugation at 
14000 x g, 4°C for 10 minutes, supernatants were transferred to clean tubes.  Proteins were 
chloroform/methanol precipitated as described by [6] and prepared for acyl-biotin exchange 
chemistry. 
Acyl-Biotin Exchange 
To detect palmitoylated proteins from total membrane fractions, we adapted the acyl 
biotin exchange protocol from [17]  Twelve individual parasite pellets (1.5 x 10
8 
parasites/pellet) were initially resuspended in 150 μL of LB buffer (150 mM NaCl, 50 mM 
Tris-HCl pH7.4, 5 mM EDTA) containing 100 mM NEM for 3 freeze/thaw cycles in LN2. 
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Thereafter, volume of lysates were increased to 1.5 mL with the above buffer, and 
centrifuged at 14000 x g, 4°C for 10 minutes to separate soluble proteins from insoluble 
membrane fractions.  Membrane fractions were resuspended in 200 μL LB with 0.5% TX-
100 and 100 mM NEM, and incubated at 4°C for 60 minutes with rotation to solubilize 
proteins.  Particulates were removed by centrifugation at 14000 xg, 4°C for 10 minutes, and 
supernatants from all 12 samples were combined yielding 2.4mL total volume.   
Chloroform/methanol precipitation of proteins was initiated upon addition of 4x 
volume of methanol, 1x volume of chloroform, and 3x volume of water.  Sample was 
vortexed and centrifuged at 14000 x g for 5 minutes, the upper was disposed and 3x volume 
of methanol was added.  Again, sample was vortexed and centrifuged at 14000 x g for 15 
minutes, the supernatant aspirated and protein pellet air dried for 5-10 minutes before 
resuspension in 600 uL of solubiliziation buffer (2% SDS, 50 mM Tris-Cl, pH 7.4, 5 mM 
EDTA) supplemented with 10 mM NEM.  To facilitate resuspension, sample was placed into 
water bath sonicator followed by incubation at 37°C for 10 minutes to denature proteins. 
Sample was diluted with 2.4 mL with LB (150 mM NaCl, 50 mM Tris-HCl pH7.4, 5 mM 
EDTA) containing 1mM NEM and 0.2% TX-100, and incubated overnight at 4°C with 
rotation to block free thiols.   
NEM was removed from samples by chloroform/methanol precipitation as described 
above and protein pellet was resuspended in 1.2 mL of SB buffer (2% SDS, 50 mM Tris-Cl, 
pH 7.4, 5 mM EDTA) containing protease inhibitors.  Sample was placed in water bath 
sonicator followed by incubation at 37°C for 10 minutes to denature proteins.  Thereafter, 
sample was equally divided into two 600 μL aliquots for plus and minus (control) 
hydroxylamine treatment.  To the plus hydroxylamine sample, 900 μL of hydroxylamine-
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biotin label buffer (0.7M hydroxylamine pH7.4, 1mM biotin-HPDP, 0.2% TX-100) was 
added.  To the minus (control) hydroxylamine sample, 900 μL of Tris-biotin label buffer (50 
mM Tris-HCl pH7.4, 1 mM biotin-HPDP, 0.2% TX-100) was added. Following incubation 
for 60 minutes at room temperature with rotation, the reactions were stopped by 
chloroform/methanol precipitation as described above.  The final protein pellets were 
resuspended in 480 μL of solubilization buffer ( 2% SDS, 50 mM Tris-HCl pH7.4, 100 mM 
NaCl, 8 M urea), and incubated at 37°C for 10 minutes to facilitate resuspension.   
Prior to affinity purification, the samples were diluted with 1 mL TX-100 wash buffer 
(1% TX-100, 150 mM NaCl, 5 mM EDTA, 25 mM Tris-HCl pH 7.6), incubated for 15 
minutes with rotation, and centrifuged at 14000 x g, 4°C for 10 minutes to remove 
particulates.  The supernatants were transferred to clean tube, 300 μL of streptavidin agarose 
beads were added to each sample and incubated for 90 minutes at room temperature with 
rotation.  Unbound proteins were removed by 3 sequential washes in TX-100 wash buffer, 
and a final wash in LB buffer removed any excess TX-100 left in samples.  Proteins were 
eluted following the addition of 1.2 mL of elution buffer ( LB, 0.1% SDS, 0.2% TX-100, and 
1% BME), incubation at 37°C for 10 minutes, and centrifugation at 4000 x g, room 
temperature for 5 minutes.  The supernatants were transferred to clean tube, and samples 
were TCA precipitated to concentrate proteins.  10% of TCA (v/v) was added to samples, 
vortexed, and placed on ice for 20 minutes.  Following centrifugation at 14000 x g, 4°C for 
10 minutes, the protein pellets were resuspended in 75 μL LB buffer.  1% of proteins from 
plus and minus hydroxylamine samples were separated onto SDS-PAGE and silvered 
stained.  The remaining protein samples were subjected to a final chloroform/methanol 
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precipitation, and protein pellets were resuspended in 80 μL of 8M urea/100mM Tris-HCl pH 
8.5 buffer prior to submission for MS analysis.   
For small scale ABE analysis, 4.5 x 10
8 
parasites were manipulated as described 
above with volumes 4 fold less than indicated.  After affinity purification, proteins were 
eluted from streptavidin agarose beads with SDS-PAGE sample buffer.  Proteins were 
separated by SDS-PAGE and immunoblot for proteins of interest.   
Construction of expression vectors and transfection of Toxoplasma gondii 
The open reading frame of candidate palmitoyl proteins MORN2, PhiL1, Hsp20, 
Hypothetical proteins 59.m03599, 76.m00010, and 55.m08184 were amplified from 
Toxoplasma gondii cDNA following the manufacturer instructions (Thermoscript RT PCR, 
Invitrogen) using the following primer pairs:  MORN2 (Accession AAZ99886), 5‟- 
agatctaaaATGGGCGCCTGCAAAAGC-3‟ and 5‟-cctaggAGCTGTGACAGGAGCGC-3‟; 
PhIL1 (Accession ABA26842), 5‟-agatctaaaATGTCGCAGCCAAACCTC-3‟ and 5‟-
cctaggCCGAGAGAAGTCGAGTGTGGT-3‟; Hsp20 (Accession AAT66039), 5‟-
agatctaaaATGAGTTGCTGTGGCGGT-3‟ and 5‟-cctaggATTTTTTGAGGCCTTCTCGCC-
3‟; Hypothetical Protein 59.m03599 (Accession XP_002365837), 5‟-
agatctaaaATGGAAAACCCTCCGCAAATCCC-3‟ and 5‟- 
cctaggCGACGTGCAGCTGTCCA-3‟; Hypothetical Protein 76.m00010 (Accession 
XP_002369110), 5‟- agatctATGGACTGCTGCGGACTGTG-3‟ and 5‟- 
cctaggCTGCCGCTTATCTTTTCTGG-3‟; Hypothetical Protein 55.m08184 (Accession 
XP_002364870), 5‟- agatctATGTTCTGGTGCTGCTGC-3‟ and 5‟- 
cctaggTGCATTAAGAGACTCCAGCAA-3‟. The BglII site was introduced upstream of the 
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start codon, and AvrII restriction site was place immediately upstream of stop codon.  Both 
restriction sites are underline, and non-coding sequences are shown in lowercase. 
Mutagenesis of designated cysteine residues of MORN2, PhiL1, and Hsp20 was 
performed with the following oligonucleotide pairs (Quikchange Site-Directed Mutagenesis 
Kit, Stratagene):  PhIL1 C133, 135A YFP, 5‟-
AGGGTAGACCCGGCTGAAGCCGGCTACCCCGAGG-3‟ and 5‟-
CCTCGGGGTAGCCGGCTTCAGCCGGGTCTACCCT-3‟; MORN2 G2A, C4A YFP, 5‟- 
gcccttagatctaaaATGGCCGCCGCCAAAAGCAAGCCAAAGAC-3‟ and 5‟- 
GTCTTTGGCTTGCTTTTGGCGGCGGCCATtttagatctaagggc-3‟; Hsp20 C3,4A YFP, 5‟- 
gcccttagatctaaaATGAGTGCCGCTGGCGGTACGGTCG-3‟ and 5‟- 
CGACCGTACCGCCAGCGGCACTCATtttagatctaagggc-3‟.  Nucleotides highlighted in 
bold were mutated to generate Alanine residues.   
All PCR products were digested with BlgII and AvrII followed by insertion between 
the BglII and AvrII sites in ptubIMC1-YFP/sagCAT [23]; thus generating in-frame fusions of 
candidate palmitoyl proteins or their respective mutants with C-terminal YFP.  Constructs 
were transfected into Toxoplasma gondii RH(HXGPRT-) strain by electroporation, and 
stable transfectants expressing YFP fusion proteins were selected by chloramphenicol as 
previously described [24].   
SDS-PAGE and Immunoblotting 
Protein preparations were separated by SDS-PAGE on 12% polyacrylamide gels 
using the Protean II minigel system (Bio-Rad). Where indicated, proteins were transferred to 
nitrocellulose and probed with antisera (used at 1:1000 dilution in 5% Blotto) as described 
previously [13]. Bound antibodies were detected using the Super Signal kit (Pierce) or the 
85 
 
Lic-Cor Odyssey Infrared Imaging system to detect IRDye 800CW goat anti-rabbit IgG 
secondary antibodies.   
Immunofluorescence microscopy 
Parasite-infected HFF cells were fixe d in cold methanol, or in 3% PFA in PBS for 10 
minutes followed by a 5 minute extraction with 1% Triton X-100 in PBS. The indicated 
antibodies were used at 1:1000 dilution in 3% BSA in PBS for 30 minutes. Bound antibodies 
were visualized using Alexa-conjugated secondary antibodies at the dilutions suggested by 
the manufacturer (Invitrogen). Samples were examined using a Nikon Eclipse TE2000-U 
epifluorescence microscope. Stacks of images were acquired using a Hamamatsu digital 
CCD camera (IEEE1394) directed by Metamorph (version 6.2r5, Sunnyvale, CA) software 
and processed for optical deconvolution by Auto deblur + Auto visualize program (version 
9.3.3, Watervliet, NY) using 10 to iterations and low noise level for the algorithm settings. 
Further image processing was limited to cropping and the conversion of gray-scale to color 
images using Adobe Photoshop (Adobe Photosystems). 
Metabolic labeling of Toxoplasma gondii and immunoprecipitation 
Metabolic labeling of parasite infected monolayers was performed 16-20 hours post-
infection.  Labeling with [
35
S] methionine/cysteine was performed as described [12].  Prior to 
labeling with [
3
H] palmitate or [
3
H] myristate, infected monolayers were incubated in serum 
free medium containing 1mg/mL fatty acid free BSA for 30minutes at 37°C in 5% CO2.  
40Ci/mmol of [
3
H] palmitate or [
3
H] myristate (GE Healthcare) was added to the medium 
and incubated for an additional 4 hours at 37°C in 5% CO2.  Parasites were released from 
HFF cells by passage through 18G followed by 27G needle, collected by centrifugation for 
5minutes at 400 x g, and washed once in PBS.  Parasites are lysed in 0.1mL of 1% SDS in 
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water containing protease inhibitors (Sigma) at 95°C for 5minutes.  Addition of 0.9mL of 
wash buffer (1%TX-100 in 150mM NaCl, 5mM EDTA, 25mM Tris-HCl pH7.6) was 
required to dilute SDS, and lysates were incubated at 4°C for 10minutes.  Lysates were 
centrifuged at 14000 x g for 10minutes at 4°C, and the supernatants were transferred to clean 
microcentrifuge tube for immunoprecipitation.  To monitor the incorporation of labeled 
palmitate or myristate into proteins of interest, lysates were incubated with either rabbit-anti-
YFP or rabbit-anti-GAP45 antiserum at 1:200 dilution for 1 hour at 4°C.  Lysates were 
subsequently incubated with protein-A agarose (zymed) for 60 minutes at 4°C under rotation.  
Protein complexes were pulled down by centrifugation at 14000 x g for 5minutes at 4°C, and 
washed 3 times with wash buffer (1%TX-100 in 150mM NaCl, 5mM EDTA, 25mM Tris-
HCl pH7.6).  Upon addition of 2x SDS-PAGE sample buffer and 5minute incubation at 
95°C, labeled proteins were released from agarose beads and separated by SDS-PAGE and 
fluorography.    
Immuno electron microscopy 
Extracellular parasites were allowed to adhere to acid washed coverslips for 20 
minutes at room temperature, and detergent extracted with either 0.5% TX-100 or 10mM 
deoxycholate for 10 minutes at room temperatures.  After PBS wash, parasites were fixed in 
3% PFA in PBS for 10minutes at room temperature, followed by another PBS wash.  
Samples were incubated with primary antibodies against YFP at 1:200 dilution into PBS for 
1 hour in humid chamber.  After PBS wash, samples were incubated with 10nm gold-
conjugated goat anti-rabbit IgG secondary antibody at in humid chamber at room temperature 
for 1 hour.  Samples were fixed in 2% glutaraldehyde with 0.2% tanic acid in 100mM 
sodium cacodylate buffer pH7.4 for 2 hours at room temperature.  After (3) 5 minute washes 
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with 100mM sodium cacodylate buffer pH7.4, samples were treated with 1% osmium 
tetoxide in water for 10 minutes, and washed 3 times, 5 minute each in water.  Samples were 
additionally treated with 1% uranyl acetate for 10minutes at room temperature.  After three 
5minute washes in water, samples underwent ethanol dehydration series 50%, 75%, three 
times in 100% at 5minutes in each ethanol concentration.  After critical point drying, samples 
were mounted and coated with 3nm chromium.   
Detergent Extractions 
Parasites pellets (1.5x10
7
) resuspended in 0.5% TX-100/PBS or 25mM deoxycholate 
for  10minutes at room temperature.  Samples were centrifuged at 14,000rpm, for 10minutes 
at room temperature and the supernatant and pellet fractions were separated on SDS-PAGE 
and immuno-blot with anitbodies against YFP.  
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Figure and Legends 
Figure 3-1.Palmitoylation of precursor Myosin XIV motor complex subunits 
Immunoprecipitation of GAP45 from TX100 or SDS-lysates of [
3
H]-myristate labeled 
parasites revealed the presence of only GAP45, and no other motor complex subunits.  
However, when GAP45 was immunoprecipitated from TX100 lysates of [
3
H]-palmitate 
labeled parasites, we readily detected all members of the precursor complex: MLC1, myosin-
A, and a 45-50kD protein.  By immunoprecipitating GAP45 and GAP50 individually from 
SDS-lysates, we can only detect [
3
H]-myristate and -palmitate incorporation into GAP45.  
Therefore, GAP45 is dually modified by both myristoylation and palmitoylation; and 
myosin-A and MLC1 are both modified by palmitoylation.   
 
 
Figure 3-2. Acyl-Biotin Exchange Reaction (ABE) 
Proteins from total cellular membrane fractions were subjected to ABE.  I) Free thiols on 
proteins are blocked with N-ethylmaleimide (NEM) to prevent non-specific labeling with 
biotinylation reagent.  II) Hydroxylamine cleaved the thioester linkage releasing palmitate 
moieties, and newly exposed thiols are susbsequently III) labled with thiol reactive 
biotinylation reagent HPDP-biotin.  A parallel sample not treated with hydroxylamine will 
have attached palmitate moieties, and not labeled with HPDP-biotin.  Biotinylated proteins 
were purified with streptavidin and eluted proteins were subjected to proteomic analysis.   
 
 
Figure 3-3. Toxoplasma palmitoyl proteome 
A. Proteins purified by acyl biotin exchange reactions from samples, were separated by SDS-
PAGE and silver staining to compare the number of proteins purified from plus- and minus-
HA samples.B. Proteins purified by ABE, were separated by SDS-PAGE and immune-blot 
for known palmitoylated proteins – GAP45, MyosinA, and MLC1.  Known palmitoyl 
proteins were found exclusive in plus-hydroxylamine sample, and purified in hydroxylamine 
depending manner.  GAP50 control not present in either plus or minus-HA indicating that 
non-palmitoyl proteins were not purified in HA-dependent manner.  C.  XY scatter plot 
shows the relative abundance of each palmitoyl protein candidate in plus (x-axis) and minus 
(y-axis) samples. Individual candidates are represented in x,y scatter plot.  Each candidate 
was plotted by its averaged, normalized plus-HA spectral count (x-coordinate) vs. minus-HA 
spectral count.  Abundant proteins have higher plus-HA spectral count values, as well as 
higher plus/minus-HA ratios.  These proteins cluster close to the x-axis, along with known 
palmitoyl proteins, and represent candidates likely to be palmitoylated.    
  
 
Figure 3-4. Candidate proteins are palmitoylated and localized to Toxoplasma pellicle 
Palmitoylation of candidates were confirmed with small scale ABE reactions and 
[3H]palmitate labeling experiments.  A) Candidate proteins were epitope tagged with YFP, 
and subjected to small scale ABE reaction, separated by SDS-PAGE, and immune-blot with 
YFP antibody.  All candidates were detected in plus-HA samples, and specifically purified in 
plus-hydroxylamine dependent manner.  The specific detection of epitope-tagged candidates 
with YFP antibody, decreases the possibility that these were statistical false positives 
89 
 
identified from the initial screen.  Known palmitoyl protein, GAP45 was used as control. B)  
Parasites expressing candidate proteins were labeled with [3H] palmitate.  Individual 
candidates were immune-precipitated with YFP antibody from SDS treated lysates. A small 
percentage of the immunoprecipitate were transferred to nitrocellulose and immuno-blot with 
YFP antibody to detect the presence of all candidates in each sample.  All candidates with 
exception of PhIL1 were labeled with [3H] palmitate, indicated with red arrows.  GAP45 
control was also labeled.   
C) 16-20 hours post infection of host cell monolayers, parasites were fixed with MeOH or 
PFA for immuno-fluoresence.  All proteins associate with the pellicle, as indicated by co-
localization with pellicle specific antibody, IMC1.  MORN2 and hypothetical protein 
59m03599 are plasma membrane associated, because we find no daughter cell co-
localization.  Mutation of potential acylation sites of MORN2, PHiL1, and Hsp20 disrupted 
pellicle association; thus indicating that palmitoylation of Hsp20 may occur at Cysteine 3 and 
4, and the myristoylation and palmitoylation of MORN2 at Glycine 2 and Cysteine 4 to 
mediate pellicle association.  Cysteine 133 and 134 of PhiL1 may be necessary for pellicle 
association, however these Cysteines are not palmitoylated.  D)  Hsp20 and hypothetical 
protein 55m08184-YFP also localizes to daughter cells, indicating that these two proteins are 
IMC associated.   
 
 
Figure 3-5.  Toxoplasma Hsp20 localizes to “Stripe-like” Structures 
Toxoplasma Hsp20 localizes to discontinuous stripe-like structures along the length of the 
IMC.  A) Stripes are clearly visible in intact cells, not previously fixed, thus structures are 
not likely artifacts of fixation.  Structures are more pronounced after TritonX-100 or 
deoxycholate extracted followed by paraformaldehyde fixation. B)  Parasites were extracted 
with 0.5% TX-100 and 25mM DOC, and Hsp20 was found largely in the pellet fraction after 
TX-100 extraction and solubilized after 25mM DOC extraction; thus suggesting that Hsp20 
either detergent resistant or localized to membrane domains that are detergent resistant.  C)  
Ultrastructure of “stripes” are observed by immuno-Field Emissions Scanning EM.   
 
 
Table 3-1.  Top 38 candidates designated for primary analysis 
Candidates were ranked according to their averaged, normalized plus/minus-hydroxylamine 
spectral count ratios from 3 trials of MudPIT analysis.  To normalize, individual raw spectral 
counts were divided by the total spectral count for the sample, and multiplied by arbitrary 
multiplier 1,000.  The normalized spectral counts for the three trials were averaged, and 
presented as “average,normalized spectral count.”  To calculate the ratio of plus/minus-HA, 
divide the averaged, normalized plus-HA by averaged,normalized minus-HA spectral count 
value.  To avoid division by 0, we used 0.2 as an arbitrary value.  Proteins known to be 
palmitoylated were highlighted in blue.  Proteins previously predicted to be palmitoylated are 
highlighted in grey.  And proteins selected for further validation were highlighted in yellow.   
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Supplementary Figure 3-1.  Toxoplasma palmitoyl protein candidates 
The list of 400 candidate palmitoyl proteins identified by 3 trials of ABE/MudPIT are ranked 
according to their averaged, normalized plus/minus-hydroxylamine spectral count ratios, and 
presented in this table.   
 
 
Supplementary Figure 3-2.  Expressors of Toxoplasma Hsp20 have detergent resistant 
“stripe-like” structures 
Parasites expressing Hsp20 display detergent resistant “stripe-like” structures after 0.5% TX-
100 extraction at room temperature, as seen byfield- emissions scanning EM.   
 
Supplementary Table 3-1. Functional Grouping of Toxoplasma Palmitoyl Proteome   
Candidate palmitoyl proteins were grouped according to predicted cellular function, and 
listed by TOXO DB 4.3 Gene ID number and protein description.  The cytoskeletal/ubiquitin 
proteins identified most likely represent abundant proteins, nonspecifically identified.  
DHHC-CRD containing proteins may be palmitoyl-transferases that are classified as false 
positives because they transiently bind palmitate moieties during catalysis.  Several parasite 
specific proteins (rhoptry proteins, dense granule proteins, IMC, and MORN proteins) and 
general eukaryotic proteins (Myosins, inositols, and membrane proteins) were identified.  
The candidates are involved in many different cellular processes suggesting that protein 
palmitoylation may regulate various parasite specific functions.   
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Figure 3-1. Palmitoylation of precursor Myosin XIV motor complex 
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Figure 3-2. Acyl-Biotin Exchange Reaction (ABE) 
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Figure 3-3. Toxoplasma Palmitoyl Proteome 
 
 
 
 
 
A. B. 
C. 
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Figure 3-4. Candidate proteins are palmitoylated and localized to Toxoplasma pellicle 
 
 
  
A. B. 
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Figure 3-4. Candidate proteins are palmitoylated and localized to Toxoplasma pellicle 
 
 
 
 
 
 
 
 
 
  
C. 
D. 
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Figure 3-5. Toxoplasma Hsp20 localizes to “Stripe-like” Structures 
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Supplementary Figure 3-1. Toxoplasma Palmitoyl Proteome Candidates 
 
ToxoDB 4.3 
GENE ID 
PROTEIN 
COMBINED 
DATA 
MudPIT SPECTRAL COUNTS 
Average 
Normalized 
Spectral Counts 
MudPIT 
#1 
MudPIT 
#2 
MudPIT   
#3 
(+)   
HA 
(-) 
HA Ratio 
(+) 
HA 
(-)  
HA 
(+) 
HA 
(-) 
HA 
(+)  
HA 
(-)  
HA 
55.m00021 
myosin light chain 1 
(TgMLC1) 
45.0 0.0 224.8 13 0 4 0 36 0 
44.m00020 pfs77-related/IMC10 36.3 0.0 181.3 8 0 8 0 4 0 
44.m00004 
membrane skeletal 
protein IMC1 
32.6 0.0 163.1 7 0 7 0 10 0 
42.m08072 
gliding-associated 
protein (GAP45) 
31.8 0.0 159.2 4 0 11 0 0 0 
49.m00003 
cAMP dependent 
protein kinase 
regulatory subunit, 
putative 
28.3 0.0 141.3 0 0 5 0 135 0 
44.m00031 IMC4 22.7 0.0 113.7 3 0 7 0 10 0 
42.m03357 
inner membrane 
complex associated 
protein 5 
21.4 0.0 106.9 3 0 7 0 0 0 
55.m10265 PhIL1 19.8 0.0 98.8 8 0 0 0 0 0 
39.m00350 pfs77-related/ IMC6 19.8 0.0 98.8 8 0 0 0 0 0 
49.m00003 
cAMP dependent 
protein kinase 
regulatory subunit, 
putative 
18.3 0.0 91.4 0 0 0 0 135 0 
583.m05526 Hypotethical Protein 15.8 0.0 79.0 1 0 6 0 10 0 
55.m08184 Hypotethical Protein 15.3 0.0 76.3 2 0 3 0 32 0 
583.m00634 hypothetical protein 13.7 0.0 68.3 1 0 5 0 9 0 
80.m02353 
membrance 
occupation and 
recognition nexus 
protein 2 (MORN2) 
12.9 0.0 64.6 2 0 4 0 0 0 
59.m03599 
Conserved 
Hypotheical Protein 
12.3 0.0 61.7 5 0 0 0 0 0 
44.m00039 Hypotheical Protein 8.9 0.0 44.7 2 0 2 0 0 0 
46.m01667 hypothetical protein 8.0 0.0 39.9 0 0 4 0 0 0 
76.m00010 Hypotheical Protein 7.8 0.0 39.1 3 0 0 0 3 0 
80.m00012 
microneme protein 1 
(MIC1) 
7.5 0.0 37.4 0 0 3 0 11 0 
55.m04722 
histone deacetylase, 
putatuve 
7.4 0.0 37.0 3 0 0 0 0 0 
44.m02618 mucin, putative 6.7 0.0 33.7 1 0 2 0 2 0 
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ToxoDB 4.3 
GENE ID 
PROTEIN 
COMBINED 
DATA 
MudPIT SPECTRAL COUNTS 
Average 
Normalized 
Spectral Counts 
MudPIT 
#1 
MudPIT 
#2 
MudPIT   
#3 
(+)   
HA 
(-) 
HA Ratio 
(+) 
HA 
(-)  
HA 
(+) 
HA 
(-) 
HA 
(+)  
HA 
(-)  
HA 
83.m01215 hypothetical protein 6.2 0.0 30.8 2 0 0 0 9 0 
56.m00005 
apical membrane 
antigen 1, putative 
6.1 0.0 30.5 0 0 0 0 45 0 
25.m00204 
conserved hypothetical 
protein 
5.6 0.0 28.1 2 0 0 0 5 0 
38.m01061 
acid phosphatase, 
putative (this is 
GAP50) 
5.3 0.0 26.7 0 0 2 0 10 0 
59.m03635 
Conserved 
Hypotheical Protein 
5.3 0.0 26.7 2 0 0 0 3 0 
44.m02644 Hypotethical Protein 4.9 0.0 24.7 2 0 0 0 0 0 
25.m00204 Hypotethical Protein 4.9 0.0 24.7 2 0 0 0 0 0 
20.m00373 
biotin-requiring 
domain protein 
4.8 0.0 24.0 0 0 2 0 6 0 
50.m00028 hypothetical protein 4.7 0.0 23.7 0 0 0 0 35 0 
46.m02877 hypothetical protein 4.7 0.0 23.3 0 0 2 0 5 0 
50.m05651 
surface protein PspC-
related 
4.4 0.0 22.0 0 0 2 0 3 0 
59.m03645 hypothetical protein 4.0 0.0 20.0 0 0 2 0 0 0 
55.m04802 lecting-domain protein 4.0 0.0 20.0 0 0 2 0 0 0 
44.m02755 Hsp20 79.1 4.7 16.9 11 0 21 0 74 3 
52.m01649 Hypotethical Protein 3.3 0.0 16.4 1 0 0 0 6 0 
44.m02701 
Conserved 
Hypothetical Protein 
3.3 0.0 16.4 1 0 0 0 6 0 
55.m00168 
ATP synthase beta 
chain, putative 
3.1 0.0 15.6 0 0 0 0 23 0 
113.m00755 
duplicated carbonic 
anhydrase 
3.0 0.0 15.1 1 0 0 0 4 0 
80.m02240 
ubiquitin / ribosomal 
protein CEP52 fusion 
protein 
2.9 0.0 14.4 1 0 0 0 3 0 
83m.m01211 hypothetical protein 2.6 0.0 12.9 0 0 0 0 19 0 
59.m00008 
"Surface Angtigen 
P22"/SAG2A 
2.5 0.0 12.3 1 0 0 0 0 0 
44.m05934 Hypotethical Protein 2.5 0.0 12.3 1 0 0 0 0 0 
86.m00365 hypothetical protein 2.5 0.0 12.3 1 0 0 0 0 0 
41.m00021 Articulin 4 2.5 0.0 12.3 1 0 0 0 0 0 
55.m04760 Hypotethical Protein 2.5 0.0 12.3 1 0 0 0 0 0 
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ToxoDB 4.3 
GENE ID 
PROTEIN 
COMBINED 
DATA 
MudPIT SPECTRAL COUNTS 
Average 
Normalized 
Spectral Counts 
MudPIT 
#1 
MudPIT 
#2 
MudPIT   
#3 
(+)   
HA 
(-) 
HA Ratio 
(+) 
HA 
(-)  
HA 
(+) 
HA 
(-) 
HA 
(+)  
HA 
(-)  
HA 
55.m00224 
Conserved 
Hypothetical Protein 
2.5 0.0 12.3 1 0 0 0 0 0 
44.m02763 
Myosin A docking 
protein, putative 
2.5 0.0 12.3 1 0 0 0 0 0 
50.m03082 
Conserved 
Hypothetical Protein 
2.5 0.0 12.3 1 0 0 0 0 0 
83.m01212 Hypotethical Protein 2.5 0.0 12.3 1 0 0 0 0 0 
33.m01294 protein antigen,  2.5 0.0 12.3 1 0 0 0 0 0 
145.m00604 
threonyl-tRNA 
synthetase, putative 
2.5 0.0 12.3 1 0 0 0 0 0 
645.m00328 Hypotethical Protein 2.5 0.0 12.3 1 0 0 0 0 0 
42.m03540 
ubiquitin carboxyl-
terminal hydrolase, 
putative 
2.5 0.0 12.3 1 0 0 0 0 0 
76.m01627 Hypotethical Protein 2.5 0.0 12.3 1 0 0 0 0 0 
57.m01761 
200kD antigen p200 
putative 
2.5 0.0 12.3 1 0 0 0 0 0 
25.m01837 
HECT-domain 
(ubiquitin-transferase) 
containing protein 
2.5 0.0 12.3 1 0 0 0 0 0 
80.m02225 
adipocyte plasma 
membrane-associated 
protein-related 
2.2 0.0 10.8 0 0 0 0 16 0 
44.m00026 
conserved hypothetical 
protein 
2.0 0.0 10.2 0 0 0 0 15 0 
583.m00669 
phosphatidylinositol-
4-phosphate 5 kinase, 
putative 
2.0 0.0 10.2 0 0 0 0 15 0 
50.m03235 ubiquitin-related 2.0 0.0 10.2 0 0 0 0 15 0 
113.m00782 
myosin light chain 2, 
putative 
2.0 0.0 10.2 0 0 0 0 15 0 
541.m00141 hypothetical protein 2.0 0.0 10.2 0 0 0 0 15 0 
55.m00278 
Conserved 
Hypothetical Protein 
1.8 0.0 8.8 0 0 0 0 13 0 
583.m05329 
long-chain-fatty-acid 
CoA ligase, putative 
1.8 0.0 8.8 0 0 0 0 13 0 
583.m00692 
protein of unknown 
function domain-
containing protein 
1.8 0.0 8.8 0 0 0 0 13 0 
59.m03391 
rhomboid family 
domain-containing 
protein 
1.6 0.0 8.1 0 0 0 0 12 0 
583.m000605 
long-chain-fatty-acid 
CoA ligase, putative 
1.6 0.0 8.1 0 0 0 0 12 0 
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ToxoDB 4.3 
GENE ID 
PROTEIN 
COMBINED 
DATA 
MudPIT SPECTRAL COUNTS 
Average 
Normalized 
Spectral Counts 
MudPIT 
#1 
MudPIT 
#2 
MudPIT   
#3 
(+)   
HA 
(-) 
HA Ratio 
(+) 
HA 
(-)  
HA 
(+) 
HA 
(-) 
HA 
(+)  
HA 
(-)  
HA 
41.m01323 hypothetical protein 1.6 0.0 8.1 0 0 0 0 12 0 
76.m01665 
lysophospholipase, 
putative 
35.1 4.7 7.5 0 0 14 0 53 3 
641.m00177 
lipoamide 
acyltransferase 
component of 
branched-chain alpha-
keto dehydrogenase 
complex, putative 
1.5 0.0 7.4 0 0 0 0 11 0 
20.m03715 hypothetical protein 1.5 0.0 7.4 0 0 0 0 11 0 
583.m00022 tubulin alpha chain 1.5 0.0 7.4 0 0 0 0 11 0 
641.m00010 
UPD-N-acetyl-D-galactosamine-
polypeptideacetylgalactosamytransfer
ase T3, putative 
1.4 0.0 6.8 0 0 0 0 10 0 
55.m04791 hypothetical protein 1.4 0.0 6.8 0 0 0 0 10 0 
83.m01215 hypothetical protein 1.2 0.0 6.1 0 0 0 0 9 0 
80.m00003 
glyceraldehyde-3-
phosphate 
dehydrogenase 
1.2 0.0 6.1 0 0 0 0 9 0 
49.m03405 hypothetical protein 1.2 0.0 6.1 0 0 0 0 9 0 
72.m00380 
3',5'-cyclic 
phosphodiesterase, 
putative 
1.2 0.0 6.1 0 0 0 0 9 0 
42.m00006 
serine/threonine 
protein phosphatase, 
putative 
1.2 0.0 6.1 0 0 0 0 9 0 
583.m05758 
Intermediate 
Subcompartment 
Protein 3 (ISP3) 
1.1 0.0 5.4 0 0 0 0 8 0 
57.m00027 thioredoxin, putative 1.1 0.0 5.4 0 0 0 0 8 0 
33.m01303 
ras-related protein, 
putative 
1.1 0.0 5.4 0 0 0 0 8 0 
44.m02716 hypothetical protein 1.1 0.0 5.4 0 0 0 0 8 0 
55.m00144 
Intermediate 
Subcompartment 
Protein 1 (ISP1) 
1.1 0.0 5.4 0 0 0 0 8 0 
59.m00072 hypothetical protein 1.1 0.0 5.4 0 0 0 0 8 0 
583.m00596 
lung seven 
transmembrane 
receptor domain-
containing protein 
1.1 0.0 5.4 0 0 0 0 8 0 
50.m00058 thioredoxin, putative  1.1 0.0 5.4 0 0 0 0 8 0 
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ToxoDB 4.3 
GENE ID 
PROTEIN 
COMBINED 
DATA 
MudPIT SPECTRAL COUNTS 
Average 
Normalized 
Spectral Counts 
MudPIT 
#1 
MudPIT 
#2 
MudPIT   
#3 
(+)   
HA 
(-) 
HA Ratio 
(+) 
HA 
(-)  
HA 
(+) 
HA 
(-) 
HA 
(+)  
HA 
(-)  
HA 
20.m03912 
elongation factor 2, 
putative 
1.1 0.0 5.4 0 0 0 0 8 0 
52.m02675 hypothetical protein 1.1 0.0 5.4 0 0 0 0 8 0 
65.m01111 
nucleoside- 
triphosphatase II 
1.1 0.0 5.4 0 0 0 0 8 0 
583.m00694 
protein of unknown 
function domain-
containing protein 
1.1 0.0 5.4 0 0 0 0 8 0 
44.m02708 
UBA/TS-N domain 
(ubiquitin-associated 
domain)-containing 
protein 
1.1 0.0 5.4 0 0 0 0 8 0 
583.m05637 
myosin-
related/MyosinG 
1.1 0.0 5.4 0 0 0 0 8 0 
50.m03374 Hypotethical Protein 16.1 3.1 5.2 4 0 3 0 2 2 
55.m00250 
Armadillo/beta-
catenin-like repeat 
containing protein 
0.9 0.0 4.7 0 0 0 0 7 0 
44.m04617 hypothetical protein 0.9 0.0 4.7 0 0 0 0 7 0 
67.m00007 hypothetical protein 0.9 0.0 4.7 0 0 0 0 7 0 
55.m00017 
DnaJ domain-
containing protein 
0.9 0.0 4.7 0 0 0 0 7 0 
20.m03934 hypothetical protein 0.9 0.0 4.7 0 0 0 0 7 0 
55.m05049 hypothetical protein 0.9 0.0 4.7 0 0 0 0 7 0 
541.m00134 
calcium-dependent 
protein kinase putative 
0.8 0.0 4.1 0 0 0 0 6 0 
55.m08191 
protein kinase domain 
containing 
protein/ROP17 
0.8 0.0 4.1 0 0 0 0 6 0 
38.m01096 
eukaryotic porin 
domain-containing 
protein 
0.8 0.0 4.1 0 0 0 0 6 0 
80.m00020 
pyridine nucleotide-
disulphide 
oxidoreductase, 
putative 
0.8 0.0 4.1 0 0 0 0 6 0 
36.m01050 
conserved hypothetical 
protein 
0.8 0.0 4.1 0 0 0 0 6 0 
42.m00048 
conserved hypothetical 
protein 
0.8 0.0 4.1 0 0 0 0 6 0 
113.m00760 hypothetical protein 0.8 0.0 4.1 0 0 0 0 6 0 
50.m03085 
MORN repeat protein, 
putative 
0.8 0.0 4.1 0 0 0 0 6 0 
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ToxoDB 4.3 
GENE ID 
PROTEIN 
COMBINED 
DATA 
MudPIT SPECTRAL COUNTS 
Average 
Normalized 
Spectral Counts 
MudPIT 
#1 
MudPIT 
#2 
MudPIT   
#3 
(+)   
HA 
(-) 
HA Ratio 
(+) 
HA 
(-)  
HA 
(+) 
HA 
(-) 
HA 
(+)  
HA 
(-)  
HA 
80.m00026 
casein kinase I 
epsilon, putative 
0.8 0.0 4.1 0 0 0 0 6 0 
25.m00219 
pyridine nucleotide-
disulphide 
oxidoreductase 
domain-containing 
protein 
0.8 0.0 4.1 0 0 0 0 6 0 
72.m00001 
non-transmembrane 
antigen 
0.8 0.0 4.1 0 0 0 0 6 0 
50.m03233 
L-type amino acid 
transporter-related 
0.8 0.0 4.1 0 0 0 0 6 0 
44.m02554 
neurofilament triplet H 
protein-related 
0.8 0.0 4.1 0 0 0 0 6 0 
37.m00765 
neurofilament triplet H 
protein-related 
0.8 0.0 4.1 0 0 0 0 6 0 
44.m02613 lipin, putative 0.8 0.0 4.1 0 0 0 0 6 0 
33.m00005 rhoptry antigen ROP8 0.8 0.0 4.1 0 0 0 0 6 0 
541.m01146 
guanylate binding 
protein, putative 
0.8 0.0 4.1 0 0 0 0 6 0 
44.m02601 
phosphatidylinositol-
4-phosphate 5-kinase, 
putative 
0.8 0.0 4.1 0 0 0 0 6 0 
44.m00009 
major surface antigen 
p30 (SAG1) 
17.8 4.7 3.8 3 0 4 0 18 3 
583.m00014 
ribosomal protein L11, 
putative 
0.7 0.0 3.4 0 0 0 0 5 0 
25.m02951 
formate/nitrite 
transporter-related 
0.7 0.0 3.4 0 0 0 0 5 0 
35.m00026 
ATP-dependent RNA 
helicase, putative 
0.7 0.0 3.4 0 0 0 0 5 0 
83.m01196 
eukaryotic translation 
initiation factor 4A 
0.7 0.0 3.4 0 0 0 0 5 0 
41.m00036 
tubulin beta chain, 
putative 
0.7 0.0 3.4 0 0 0 0 5 0 
46.m02875 hypothetical protein 0.7 0.0 3.4 0 0 0 0 5 0 
80.m02244 
transmembrane 
trafficking protein, 
transmembrane protein 
Tmp21 precursor, 
putative 
0.7 0.0 3.4 0 0 0 0 5 0 
26.m00242 RNA helicase-1 0.7 0.0 3.4 0 0 0 0 5 0 
641.m01548 
L-type amino acid 
transporter-related 
0.7 0.0 3.4 0 0 0 0 5 0 
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59.m00061 
mitochondrial 2-
oxoglutarate/malate 
carrier protein, 
putative 
0.7 0.0 3.4 0 0 0 0 5 0 
50.m03109 
conserved hypothetical 
protein 
0.7 0.0 3.4 0 0 0 0 5 0 
38.m01106 
acetyltransferase 
domain-containing 
protein 
0.7 0.0 3.4 0 0 0 0 5 0 
39.m00334 
L-type amino acid 
transporter-related 
0.7 0.0 3.4 0 0 0 0 5 0 
641.m00178 
ubiquinol-cytochrome 
c reductase, putative / 
Rieske iron-sulfur 
protein, putative 
0.7 0.0 3.4 0 0 0 0 5 0 
50.m03277 
endonuclease/exonucl
ease/phosphatase 
domain-containing 
protein 
0.7 0.0 3.4 0 0 0 0 5 0 
113.m00789 
serine/threonine 
protein phosphatase, 
putative 
0.7 0.0 3.4 0 0 0 0 5 0 
83.m02709 
WW domain 
containing protein 
0.7 0.0 3.4 0 0 0 0 5 0 
583.m05652 hypothetical protein 0.7 0.0 3.4 0 0 0 0 5 0 
49.m03397 
2-oxoglutarate 
dehydrogenase, 
putative 
0.7 0.0 3.4 0 0 0 0 5 0 
80.m02297 
endomembrane 
domain-containing 
protein 
0.7 0.0 3.4 0 0 0 0 5 0 
80.m03969 
BNR/Asp-box repeat 
domain-containing 
protein 
0.7 0.0 3.4 0 0 0 0 5 0 
50.m03154 
thrombospondin type 1 
domain-containing protein 
0.7 0.0 3.4 0 0 0 0 5 0 
50.m03297 
zinc finger DHHC 
domain-containing 
protein 
0.7 0.0 3.4 0 0 0 0 5 0 
65.m01193 
glucose-6-phosphate 
dehydrogenase, 
putative 
0.7 0.0 3.4 0 0 0 0 5 0 
20.m03885 hypothetical protein 0.7 0.0 3.4 0 0 0 0 5 0 
583.m00019 hypothetical protein 0.7 0.0 3.4 0 0 0 0 5 0 
42.m00026 hypothetical protein 0.7 0.0 3.4 0 0 0 0 5 0 
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583.m00625 
Conserved 
Hypothetical Protein 
9.9 3.1 3.2 0 0 4 0 14 2 
46.m02889 hypothetical protein 0.5 0.0 2.7 0 0 0 0 4 0 
50.m05646 
ras-related protein, 
RAB7 putative 
0.5 0.0 2.7 0 0 0 0 4 0 
50.m00067 
40S ribosomal protein 
S8, putative 
0.5 0.0 2.7 0 0 0 0 4 0 
80.m00017 
60S ribosomal protein 
L10, putative 
0.5 0.0 2.7 0 0 0 0 4 0 
583.m05672 
SRS domain 
containing surface 
antigen, putative 
0.5 0.0 2.7 0 0 0 0 4 0 
583.m00619 
60S ribosomal protein 
L4, putative 
0.5 0.0 2.7 0 0 0 0 4 0 
57.m01773 
conserved hypothetical 
protein 
0.5 0.0 2.7 0 0 0 0 4 0 
25.m01827 
mitochondrial carrier 
domain-containing 
protein 
0.5 0.0 2.7 0 0 0 0 4 0 
20.m03896 
rhoptry protein, 
putative / protein 
kinase domain-
containing 
protein/ROP18 
0.5 0.0 2.7 0 0 0 0 4 0 
55.m05083 
glycerol-3-phosphate 
dehydrogenase 
0.5 0.0 2.7 0 0 0 0 4 0 
55.m00008 
UDP-N-acetyl-D-
galactosamine:polypep
tide N-
acetylgalactosaminyltr
ansferase T2 
0.5 0.0 2.7 0 0 0 0 4 0 
44.m02699 
DnaJ domain-
containing protein 
0.5 0.0 2.7 0 0 0 0 4 0 
38.m00017 
dihydrolipoamide 
succinyltransferase 
component of 2-
oxoglutaratedehydroge
nase complex, putative 
0.5 0.0 2.7 0 0 0 0 4 0 
44.m04628 
kinesin heavy chain-
related 
0.5 0.0 2.7 0 0 0 0 4 0 
44.m02753 
vacuolar proton-
translocating ATPase 
subunit, putative 
0.5 0.0 2.7 0 0 0 0 4 0 
551.m00439 
Gpi16 subunit, GPI 
transamidase domain-
containing protein 
0.5 0.0 2.7 0 0 0 0 4 0 
583.m00655 nucleoredoxin-related 0.5 0.0 2.7 0 0 0 0 4 0 
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129.m00252 
sodium/hydrogen 
exchanger, putative 
0.5 0.0 2.7 0 0 0 0 4 0 
83.m01276 
PH domain-containing 
protein 
0.5 0.0 2.7 0 0 0 0 4 0 
33.m02213 
centromere/microtubul
e binding protein, 
putative 
0.5 0.0 2.7 0 0 0 0 4 0 
41.m01272 
conserved hypothetical 
protein 
0.5 0.0 2.7 0 0 0 0 4 0 
55.m00188 hypothetical protein 0.5 0.0 2.7 0 0 0 0 4 0 
42.m03455 hypothetical protein 0.5 0.0 2.7 0 0 0 0 4 0 
50.m03311 exportin, putative 0.5 0.0 2.7 0 0 0 0 4 0 
33.m01334 hypothetical protein 0.5 0.0 2.7 0 0 0 0 4 0 
55.m04819 
Na+/H+ antiporter-
related 
0.5 0.0 2.7 0 0 0 0 4 0 
35.m00846 hypothetical protein 0.5 0.0 2.7 0 0 0 0 4 0 
42.m00070 hypothetical protein 0.4 0.0 2.0 0 0 0 0 3 0 
541.m01203 hypothetical protein 0.4 0.0 2.0 0 0 0 0 3 0 
41.m00001 18kd cyclophilin 0.4 0.0 2.0 0 0 0 0 3 0 
42.m03282 hypothetical protein 0.4 0.0 2.0 0 0 0 0 3 0 
50.m00042 
GPT-binding nuclear 
protein RAN/TC4, 
putative 
0.4 0.0 2.0 0 0 0 0 3 0 
37.m00747 hypothetical protein 0.4 0.0 2.0 0 0 0 0 3 0 
42.m00018 hypothetical protein 0.4 0.0 2.0 0 0 0 0 3 0 
72.m00405 
signal peptidase, 
putative 
0.4 0.0 2.0 0 0 0 0 3 0 
42.m05857 hypothetical protein 0.4 0.0 2.0 0 0 0 0 3 0 
65.m00004 
zinc finger DHHC 
domain containing 
protein 
0.4 0.0 2.0 0 0 0 0 3 0 
583.m05736 hypothetical protein 0.4 0.0 2.0 0 0 0 0 3 0 
25.m01782 
MORN repeat 
containing protein 
0.4 0.0 2.0 0 0 0 0 3 0 
35.m00867 hypothetical protein 0.4 0.0 2.0 0 0 0 0 3 0 
541.m01194 hypothetical protein 0.4 0.0 2.0 0 0 0 0 3 0 
46.m01634 transporter, putative 0.4 0.0 2.0 0 0 0 0 3 0 
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641.m03153 
SRS domain 
containing protein 
0.4 0.0 2.0 0 0 0 0 3 0 
25.m00203 thioredoxin, putative 0.4 0.0 2.0 0 0 0 0 3 0 
83.m02714 hypothetical protein 0.4 0.0 2.0 0 0 0 0 3 0 
583.m00645 hypothetical protein 0.4 0.0 2.0 0 0 0 0 3 0 
49.m00051 prohibitin, putative 0.4 0.0 2.0 0 0 0 0 3 0 
42.m00084 
60S ribosomal protein 
L3, putative 
0.4 0.0 2.0 0 0 0 0 3 0 
42.m00079 
cAMP-dependent 
protein kinase 
catalytic subunit, 
putative 
0.4 0.0 2.0 0 0 0 0 3 0 
83.m01196 
inositol phosphatase, 
putative/"endonucleas
e/exonuclease/phospha
tase domain-
containing protein" in 
Toxodb 
0.4 0.0 2.0 0 0 0 0 3 0 
41.m01364 hypothetical protein 0.4 0.0 2.0 0 0 0 0 3 0 
25.m01905/2
5.m01904 
protein kinase domain-
containing 
protein/"ROP43 
(incomplete catalytic 
triad)" 
0.4 0.0 2.0 0 0 0 0 3 0 
20.m00392 
fatty acid elongation 
protein-related 
0.4 0.0 2.0 0 0 0 0 3 0 
57.m01859 hypothetical protein 0.4 0.0 2.0 0 0 0 0 3 0 
52.m02682 hypothetical protein 0.4 0.0 2.0 0 0 0 0 3 0 
583.m05347 calnexin, putative 0.4 0.0 2.0 0 0 0 0 3 0 
59.m06091 
proteasome PCI 
domain-containing 
protein 
0.4 0.0 2.0 0 0 0 0 3 0 
27.m00001 
dihydroorotate 
dehydrogenase 
0.4 0.0 2.0 0 0 0 0 3 0 
583.m05389 apyrase, putative 0.4 0.0 2.0 0 0 0 0 3 0 
83.m00004 
glucose-6-phosphate 
dehydrogenase 
0.4 0.0 2.0 0 0 0 0 3 0 
583.m09158 hypothetical protein 0.4 0.0 2.0 0 0 0 0 3 0 
83.m02691 hypothetical protein 0.4 0.0 2.0 0 0 0 0 3 0 
20.m00331 hypothetical protein 0.4 0.0 2.0 0 0 0 0 3 0 
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50.m00069 thioredoxin, putative 0.4 0.0 2.0 0 0 0 0 3 0 
129.m00256 
cleft lip and palate 
transmembrane protein 
1-related 
0.4 0.0 2.0 0 0 0 0 3 0 
42.m03331 thioredoxin, putative 0.4 0.0 2.0 0 0 0 0 3 0 
52.m00010 
asparagine synthase, 
putative 
0.4 0.0 2.0 0 0 0 0 3 0 
583.m00636 hypothetical protein 0.4 0.0 2.0 0 0 0 0 3 0 
50.m00091 
zinc finger DHHC 
domain-containing 
protein 
0.4 0.0 2.0 0 0 0 0 3 0 
583.m11446 hypothetical protein 0.4 0.0 2.0 0 0 0 0 3 0 
33.m01331 hypothetical protein 0.4 0.0 2.0 0 0 0 0 3 0 
72.m00396 
signal recognition 
particle protein, 
putative 
0.4 0.0 2.0 0 0 0 0 3 0 
38.m01067 
alanyl-tRNA 
synthetase, putative 
0.4 0.0 2.0 0 0 0 0 3 0 
50.m03350 
microtubule-binding 
protein, putative 
0.4 0.0 2.0 0 0 0 0 3 0 
44.m02777 hypothetical protein 0.4 0.0 2.0 0 0 0 0 3 0 
76.m01543 hypothetical protein 0.4 0.0 2.0 0 0 0 0 3 0 
583.m05501 
conserved hypothetical 
protein 
0.4 0.0 2.0 0 0 0 0 3 0 
55.m04664 
glycerol-3-phosphate 
acyltransferase, 
putative 
0.4 0.0 2.0 0 0 0 0 3 0 
52.m01670 hypothetical protein 0.4 0.0 2.0 0 0 0 0 3 0 
59.m03518 
asparaginyl-tRNA 
synthetase, putative 
0.4 0.0 2.0 0 0 0 0 3 0 
41.m00006 
eukaryotic translation 
initiation factor 3 
subunit 9, putative 
0.4 0.0 2.0 0 0 0 0 3 0 
641.m01580 
outer membrane 
protein romA 
0.4 0.0 2.0 0 0 0 0 3 0 
49.m00004 adenosine transporter 0.4 0.0 2.0 0 0 0 0 3 0 
50.m03414 hypothetical protein 0.4 0.0 2.0 0 0 0 0 3 0 
55.m00118 
cell division protein, 
putative 
0.4 0.0 2.0 0 0 0 0 3 0 
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55.m05030 
26S proteasome non-
ATPase regulatory 
subunit 1, putative 
0.4 0.0 2.0 0 0 0 0 3 0 
59.m03503 hypothetical protein 0.4 0.0 2.0 0 0 0 0 3 0 
57.m01772 hypothetical protein 0.4 0.0 2.0 0 0 0 0 3 0 
113.m00762 
MORN repeat-
containing protein 
0.4 0.0 2.0 0 0 0 0 3 0 
125.m00072 
SPX domain-
containing protein 
0.4 0.0 2.0 0 0 0 0 3 0 
42.m00068 
acid 
sphingomyelinase-like 
phosphodiesterase-
related 
0.4 0.0 2.0 0 0 0 0 3 0 
27.m00854 
CBS domain-
containing protein 
0.4 0.0 2.0 0 0 0 0 3 0 
59.m03689 
kinesin motor domain-
containing protein 
0.4 0.0 2.0 0 0 0 0 3 0 
83.m00020 
translocation protein 
Sec62, putative 
0.4 0.0 2.0 0 0 0 0 3 0 
80.m02286 
vacuolar proton-
translocating ATPase 
subunit, putative 
0.4 0.0 2.0 0 0 0 0 3 0 
52.m01648 
adenylate and 
guanylate cyclase 
catalytic domain-
containing protein 
0.4 0.0 2.0 0 0 0 0 3 0 
27.m00003 
Protein disulfide 
isomerase, putative 
14.6 7.8 1.9 0 0 7 0 5 5 
25.m01804 myosin heavy chain 5.9 3.1 1.9 1 0 0 0 25 2 
25.m00007 Actin 10.9 6.2 1.8 2 0 3 0 0 4 
42.m07364 Hypotethical Protein 0.3 0.0 1.4 0 0 0 0 2 0 
27.m00099 hypothetical protein 0.3 0.0 1.4 0 0 0 0 2 0 
49.m03342 hypothetical protein 0.3 0.0 1.4 0 0 0 0 2 0 
49.m00006 
40S ribosomal protein 
S5, putative 
0.3 0.0 1.4 0 0 0 0 2 0 
583.m00666 
ras-related protein 
RAB18 putative 
0.3 0.0 1.4 0 0 0 0 2 0 
541.m01250 hypothetical protein 0.3 0.0 1.4 0 0 0 0 2 0 
42.m00116 
adenylate kinase, 
putative 
0.3 0.0 1.4 0 0 0 0 2 0 
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76.m01626 
SRS domain 
containing surface 
antigen, putative 
0.3 0.0 1.4 0 0 0 0 2 0 
20.m00005 
dense granule protein 
7 
0.3 0.0 1.4 0 0 0 0 2 0 
27.m00091 hypothetical protein 0.3 0.0 1.4 0 0 0 0 2 0 
64.m00002 
ADP ribosylation 
factor 1, putative 
0.3 0.0 1.4 0 0 0 0 2 0 
641.m01460 
major sperm protein 
domain-containing 
protein 
0.3 0.0 1.4 0 0 0 0 2 0 
55.m04645 
glycerophosphoryl 
diester 
phosphodiesterase 
protein, 
0.3 0.0 1.4 0 0 0 0 2 0 
583.m05525 hypothetical protein 0.3 0.0 1.4 0 0 0 0 2 0 
83.m02145 
rhoptry antigen 
putative 
0.3 0.0 1.4 0 0 0 0 2 0 
44.m00008 
GPI-anchored surface 
protein/ " GPI-
anchored surface 
protein; SAG1-related 
sequence 1" by 
Toxodb 
0.3 0.0 1.4 0 0 0 0 2 0 
33.m00006 
MIC2-associated 
protein (M2AP) 
0.3 0.0 1.4 0 0 0 0 2 0 
49.m03175 hypothetical protein 0.3 0.0 1.4 0 0 0 0 2 0 
583.m00705 
cytochrome p450, 
putative 
0.3 0.0 1.4 0 0 0 0 2 0 
27.m01468 
TB2/DP1, HVA22 
domain-containing 
protein 
0.3 0.0 1.4 0 0 0 0 2 0 
551.m00001 surface antigen 0.3 0.0 1.4 0 0 0 0 2 0 
41.m01282 hypothetical protein 0.3 0.0 1.4 0 0 0 0 2 0 
76.m01670 
peroxiredoxin family 
protein/glutaredoxin, 
putative 
0.3 0.0 1.4 0 0 0 0 2 0 
55.m00240 hypothetical protein 0.3 0.0 1.4 0 0 0 0 2 0 
41.m00015 
dual-specificity 
phosphatase, catalytic 
domain-containing 
protein 
0.3 0.0 1.4 0 0 0 0 2 0 
41.m01269 hypothetical protein 0.3 0.0 1.4 0 0 0 0 2 0 
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44.m02804 
integral membrane 
transporter 
0.3 0.0 1.4 0 0 0 0 2 0 
583.m05265 hypothetical protein 0.3 0.0 1.4 0 0 0 0 2 0 
583.m09194 
protein tyrosine 
phosphatase-like 
domian-containing 
protein 
0.3 0.0 1.4 0 0 0 0 2 0 
57.m01682 
ADP-ribosylation 
factor 
0.3 0.0 1.4 0 0 0 0 2 0 
59.m00005 
protein transport 
protein Sec61 alpha 
subunit isoform 1, 
putative 
0.3 0.0 1.4 0 0 0 0 2 0 
59.m00038 hypothetical protein 0.3 0.0 1.4 0 0 0 0 2 0 
641.m00193 
phosphoglycerate 
kinase, putative 
0.3 0.0 1.4 0 0 0 0 2 0 
57.m03127 hypothetical protein 0.3 0.0 1.4 0 0 0 0 2 0 
31.m00896 
conserved hypothetical 
protein 
0.3 0.0 1.4 0 0 0 0 2 0 
76.m00007 
peptidyl-prolyl 
isomerase, putative 
0.3 0.0 1.4 0 0 0 0 2 0 
57.m03088 hypothetical protein 0.3 0.0 1.4 0 0 0 0 2 0 
59.m00091 
glyceraldehyde-3-
phosphate 
dehydrogenase 
0.3 0.0 1.4 0 0 0 0 2 0 
55.m04649 
ATP-dependent 
helicase, putaive 
0.3 0.0 1.4 0 0 0 0 2 0 
145.m00347 
26S protease 
regulatory subunit 6a, 
putative 
0.3 0.0 1.4 0 0 0 0 2 0 
57.m01690 
heterogeneous nuclear 
ribonucleoproteins-
related 
0.3 0.0 1.4 0 0 0 0 2 0 
80.m00005 
aspartate 
carbamoyltransferase 
0.3 0.0 1.4 0 0 0 0 2 0 
55.m04808 
vacuoloar ATP 
synthase subunit D, 
putative 
0.3 0.0 1.4 0 0 0 0 2 0 
38.m01889 
vacuolar ATP 
synthase subunit B, 
putative 
0.3 0.0 1.4 0 0 0 0 2 0 
52.m02678 hypothetical protein 0.3 0.0 1.4 0 0 0 0 2 0 
35.m00899 
conserved hypothetical 
protein 
0.3 0.0 1.4 0 0 0 0 2 0 
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48.m00095 
Intermediate 
Subcompartment 
Protein 2 (ISP2) 
0.3 0.0 1.4 0 0 0 0 2 0 
42.m00071 hypothetical protein 0.3 0.0 1.4 0 0 0 0 2 0 
76.m00009 
60S ribosomal protein 
L9, putative 
0.3 0.0 1.4 0 0 0 0 2 0 
583.m00695 hypothetical protein 0.3 0.0 1.4 0 0 0 0 2 0 
55.m10278 hypothetical protein 0.3 0.0 1.4 0 0 0 0 2 0 
20.m00387 
subtilase family serine 
protease, putative 
0.3 0.0 1.4 0 0 0 0 2 0 
83.m01255 hypothetical protein 0.3 0.0 1.4 0 0 0 0 2 0 
55.m08197 hypothetical protein 0.3 0.0 1.4 0 0 0 0 2 0 
65.m00005 
phosphate carrier 
protein, putative 
0.3 0.0 1.4 0 0 0 0 2 0 
41.m01266 
DEAD/DEAH box 
helicase, putative 
0.3 0.0 1.4 0 0 0 0 2 0 
49.m03292 
glucoamylase S1/S2-
related 
0.3 0.0 1.4 0 0 0 0 2 0 
541.m01165 hypothetical protein 0.3 0.0 1.4 0 0 0 0 2 0 
44.m00056 hypothetical protein 0.3 0.0 1.4 0 0 0 0 2 0 
55.m00280 
60S ribosomal protein 
L7a, putative 
0.3 0.0 1.4 0 0 0 0 2 0 
64.m00001 p97 protein 0.3 0.0 1.4 0 0 0 0 2 0 
50.m00025 
DnaJ domain-
containing protein 
0.3 0.0 1.4 0 0 0 0 2 0 
59.m03643 
translation initiation 
factor eIF-2B epsilon 
subunit, putative 
0.3 0.0 1.4 0 0 0 0 2 0 
83.m00009 
DHHC zinc finger domain-
containing protein 
0.3 0.0 1.4 0 0 0 0 2 0 
80.m00002 
phosphoenolpyruvate 
carboxykinase, 
putative 
0.3 0.0 1.4 0 0 0 0 2 0 
44.m04679 hypothetical protein 0.3 0.0 1.4 0 0 0 0 2 0 
76.m02655 hypothetical protein 0.3 0.0 1.4 0 0 0 0 2 0 
541.m01159 
sodium/hydrogen 
exchanger, putative 
0.3 0.0 1.4 0 0 0 0 2 0 
57.m01697 hypothetical protein 0.3 0.0 1.4 0 0 0 0 2 0 
583.m05333 hypothetical protein 0.3 0.0 1.4 0 0 0 0 2 0 
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ToxoDB 4.3 
GENE ID 
PROTEIN 
COMBINED 
DATA 
MudPIT SPECTRAL COUNTS 
Average 
Normalized 
Spectral Counts 
MudPIT 
#1 
MudPIT 
#2 
MudPIT   
#3 
(+)   
HA 
(-) 
HA Ratio 
(+) 
HA 
(-)  
HA 
(+) 
HA 
(-) 
HA 
(+)  
HA 
(-)  
HA 
540.m00203 protein kinase-related 0.3 0.0 1.4 0 0 0 0 2 0 
52.m01617 
GNS1/SUR4 family 
domain-containing 
protein 
0.3 0.0 1.4 0 0 0 0 2 0 
76.m00001 
glucose-6-phosphate 
isomerase, putative 
0.3 0.0 1.4 0 0 0 0 2 0 
583.m05498 hypothetical protein 0.3 0.0 1.4 0 0 0 0 2 0 
28.m00307 hypothetical protein 0.3 0.0 1.4 0 0 0 0 2 0 
583.m05298 hypothetical protein 0.3 0.0 1.4 0 0 0 0 2 0 
39.m00357 
FAD-depdendent 
monooxygenase, 
putative 
0.3 0.0 1.4 0 0 0 0 2 0 
41.m00005 exportin 7, putative 0.3 0.0 1.4 0 0 0 0 2 0 
37.m00735 hypothetical protein 0.3 0.0 1.4 0 0 0 0 2 0 
583.m00674 
isocitrate 
dehydrogenase, 
putative 
0.3 0.0 1.4 0 0 0 0 2 0 
540.m00205 
collagen alpha 1(III)-
related 
0.3 0.0 1.4 0 0 0 0 2 0 
50.m03165 hypothetical protein 0.3 0.0 1.4 0 0 0 0 2 0 
80.m00089 
patched 
transmembrane 
domain-containing 
protein 
0.3 0.0 1.4 0 0 0 0 2 0 
65.m01186 hypothetical protein 0.3 0.0 1.4 0 0 0 0 2 0 
49.m03226 
coatomer alpha 
subunit, putative / 
COPA protein, 
putative 
0.3 0.0 1.4 0 0 0 0 2 0 
52.m01560 
actin, putative  "actin-
like family protein 
ARP4a, putative" 
0.3 0.0 1.4 0 0 0 0 2 0 
20.m03745 
RNA-binding protein, 
putative 
0.3 0.0 1.4 0 0 0 0 2 0 
42.m03491 hypothetical protein 0.3 0.0 1.4 0 0 0 0 2 0 
33.m01287 
peptidase M16 inactive 
domain-containing protein / 
insulinase (peptidase family 
M16) domain-containing 
protein 
0.3 0.0 1.4 0 0 0 0 2 0 
55.m1032 hypothetical protein 0.3 0.0 1.4 0 0 0 0 2 0 
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ToxoDB 4.3 
GENE ID 
PROTEIN 
COMBINED 
DATA 
MudPIT SPECTRAL COUNTS 
Average 
Normalized 
Spectral Counts 
MudPIT 
#1 
MudPIT 
#2 
MudPIT   
#3 
(+)   
HA 
(-) 
HA Ratio 
(+) 
HA 
(-)  
HA 
(+) 
HA 
(-) 
HA 
(+)  
HA 
(-)  
HA 
80.m00095 
leucyl-tRNA 
synthetase, putative 
0.3 0.0 1.4 0 0 0 0 2 0 
583.m05517 
ATP-dependent RNA 
helicase, putative 
0.3 0.0 1.4 0 0 0 0 2 0 
49.m03081 thioredoxin, putative 0.3 0.0 1.4 0 0 0 0 2 0 
583.m05415 hypothetical protein 0.3 0.0 1.4 0 0 0 0 2 0 
83.m01186 hypothetical protein 0.3 0.0 1.4 0 0 0 0 2 0 
69.m00143 hypothetical protein 0.3 0.0 1.4 0 0 0 0 2 0 
72.m00395 
histidyl-tRNA 
synthetase, putative 
0.3 0.0 1.4 0 0 0 0 2 0 
76.m01637 
U5 small nuclear 
ribonucleoprotein, 
putative 
0.3 0.0 1.4 0 0 0 0 2 0 
52.m01645 hypothetical protein 0.3 0.0 1.4 0 0 0 0 2 0 
641.m01541 hypothetical protein 0.3 0.0 1.4 0 0 0 0 2 0 
50.m05603 
phosphatidylinositol-
4-phosphate 5-Kinase, 
putative 
0.3 0.0 1.4 0 0 0 0 2 0 
583.m05718 hypothetical protein 0.3 0.0 1.4 0 0 0 0 2 0 
583.m05283 
retinol dehydrogenase, 
putative 
0.3 0.0 1.4 0 0 0 0 2 0 
641.m02564 
rab proteins 
geranylgeranyltransfer
ase component-related 
0.3 0.0 1.4 0 0 0 0 2 0 
42.m03350 
aminopeptidase N, 
putative 
0.3 0.0 1.4 0 0 0 0 2 0 
80.m03996 hypothetical protein 0.3 0.0 1.4 0 0 0 0 2 0 
63.m00265 
myb-like DNA-
binding domain-
containing protein 
0.3 0.0 1.4 0 0 0 0 2 0 
44.m02709 
sec7 domain-
containing protein 
0.3 0.0 1.4 0 0 0 0 2 0 
583.m05400 hypothetical protein 0.3 0.0 1.4 0 0 0 0 2 0 
55.m00168 
ATP synthase beta 
chain, putative 
8.1 6.2 1.3 2 0 0 0 23 4 
46.m01692 
mitochondrial 
processing peptidase 
beta subunit, putative 
3.9 3.1 1.3 0 0 0 0 29 2 
42.m00123 
phosphofructokinase, 
putative 
16.2 15.6 1.0 0 0 2 0 90 10 
551.m00238 rhoptry protein 5 4.8 6.2 0.8 0 0 2 0 6 4 
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GENE ID 
PROTEIN 
COMBINED 
DATA 
MudPIT SPECTRAL COUNTS 
Average 
Normalized 
Spectral Counts 
MudPIT 
#1 
MudPIT 
#2 
MudPIT   
#3 
(+)   
HA 
(-) 
HA Ratio 
(+) 
HA 
(-)  
HA 
(+) 
HA 
(-) 
HA 
(+)  
HA 
(-)  
HA 
80.m02161 hypothetical protein 8.0 10.9 0.7 0 0 3 0 15 7 
20.m00382 
ATP synthase alpha 
chain, putative 
4.2 6.2 0.7 0 0 0 0 31 4 
65.m00001 
nucleoside- 
triphosphatase I 
1.8 3.1 0.6 0 0 0 0 13 2 
33.m01380 
succinate 
dehydrogenase 
[ubiquinone] 
flavoprotein subunit, 
mitochondria, putative 
1.8 3.1 0.6 0 0 0 0 13 2 
49.m03219 hypothetical protein 1.6 3.1 0.5 0 0 0 0 12 2 
50.m00009 
ADP/ATP carrier, 
putative 
3.9 7.8 0.5 0 0 0 0 29 5 
55.m08198 porin, putative 3.0 6.2 0.5 0 0 0 0 22 4 
76.m00016 
elongation factor 1-
alpha putative 
1.2 3.1 0.4 0 0 0 0 9 2 
55.m00020 Myosin D 1.2 3.1 0.4 0 0 0 0 9 2 
145.m00331 
conserved hypothetical 
protein 
1.2 3.1 0.4 0 0 0 0 9 2 
80.m02347 hypothetical protein 1.2 3.1 0.4 0 0 0 0 9 2 
44.m00006 lactate dehydrogenase 1.1 3.1 0.3 0 0 0 0 8 2 
20.m03919 
conserved hypothetical 
protein 
1.1 3.1 0.3 0 0 0 0 8 2 
52.m00001 
importin alpha, 
putative 
0.8 3.1 0.3 0 0 0 0 6 2 
20.m00004 
mitochondrial 
processing peptidase 
alpha subunit, putative 
0.8 3.1 0.3 0 0 0 0 6 2 
50.m00006 heat shock protein 60 0.9 4.7 0.2 0 0 0 0 7 3 
44.m00030 
Conserved 
Hypothetical Protein 
1.4 7.8 0.2 0 0 0 0 10 5 
25.m00006 
microneme protein 4 
(MIC4) 
0.8 4.7 0.2 0 0 0 0 6 3 
59.m03410 enolase, putative 0.5 3.1 0.2 0 0 0 0 4 2 
59.m03408 
Conserved 
Hypothetical Protein 
0.5 3.1 0.2 0 0 0 0 4 2 
59.m03597 
oxidoreductase, 
putative 
0.5 3.1 0.2 0 0 0 0 4 2 
25.m01850 
pyridine nucleotide-
disulphide 
oxidoreductase, 
putative 
0.5 3.1 0.2 0 0 0 0 4 2 
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GENE ID 
PROTEIN 
COMBINED 
DATA 
MudPIT SPECTRAL COUNTS 
Average 
Normalized 
Spectral Counts 
MudPIT 
#1 
MudPIT 
#2 
MudPIT   
#3 
(+)   
HA 
(-) 
HA Ratio 
(+) 
HA 
(-)  
HA 
(+) 
HA 
(-) 
HA 
(+)  
HA 
(-)  
HA 
42.m03533 
oxygen-regulated 
protein-related / heat 
shock protein-related 
0.5 3.1 0.2 0 0 0 0 4 2 
83.m01278 
eukaryotic translation 
initiation factor 3, 
putative 
0.5 3.1 0.2 0 0 0 0 4 2 
25.m00211 
cyotchrome c oxidase, 
putative 
0.7 4.7 0.1 0 0 0 0 5 3 
49.m00060 
heat shock proten 90, 
putative 
1.5 10.9 0.1 0 0 0 0 11 7 
57.m00003 tubulin beta chain 0.5 4.7 0.1 0 0 0 0 4 3 
44.m02594 
calcium-transporting 
ATPase, putative 
0.7 6.2 0.1 0 0 0 0 5 4 
583.m00009 
heat shock protein 70, 
putative 
3.7 34.3 0.1 0 0 0 0 27 22 
59.m00077 
protein phosphatase 
2C, putative 
0.4 4.7 0.1 0 0 0 0 3 3 
33.m01354 
iron-sulfur subunit of 
succinate 
dehydrogenase, 
putative 
0.3 3.1 0.1 0 0 0 0 2 2 
76.m01581 hypothetical protein 0.3 3.1 0.1 0 0 0 0 2 2 
76.m01551 
endomembrane 
domain-containing 
protein 
0.3 3.1 0.1 0 0 0 0 2 2 
55.m10286 
conserved hypothetical 
protein 
0.3 3.1 0.1 0 0 0 0 2 2 
46.m00023 
KH domain-containing 
protein 
0.3 3.1 0.1 0 0 0 0 2 2 
65.m01195 
WD-40 repeat myosin-
like protein, putative 
0.3 3.1 0.1 0 0 0 0 2 2 
33.m00313 hypothetical protein 0.3 3.1 0.1 0 0 0 0 2 2 
57.m01692 
SRS domain-
containing, N-
acetylglucosamine-
phosphate mutase, 
putative 
0.3 3.1 0.1 0 0 0 0 2 2 
583.m00712 
adenylyl cyclase 
associated protein 
0.8 10.9 0.1 0 0 0 0 6 7 
113.m00794 hypothetical protein 0.5 7.8 0.1 0 0 0 0 4 5 
59.m03661 
cell division protein 
48, putative 
0.4 6.2 0.1 0 0 0 0 3 4 
33.m00002 
facilitative glucose 
transporter, putative 
0.4 6.2 0.1 0 0 0 0 3 4 
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ToxoDB 4.3 
GENE ID 
PROTEIN 
COMBINED 
DATA 
MudPIT SPECTRAL COUNTS 
Average 
Normalized 
Spectral Counts 
MudPIT 
#1 
MudPIT 
#2 
MudPIT   
#3 
(+)   
HA 
(-) 
HA Ratio 
(+) 
HA 
(-)  
HA 
(+) 
HA 
(-) 
HA 
(+)  
HA 
(-)  
HA 
20.m00002 
microneme protein 2 
(MIC2) 
0.3 4.7 0.1 0 0 0 0 2 3 
83.m01310 hypothetical protein 0.3 4.7 0.1 0 0 0 0 2 3 
541.m01209 
vacuolar protein 
sorting-associated 
protein-related 
0.3 4.7 0.1 0 0 0 0 2 3 
52.m02689 hypothetical protein 0.3 6.2 0.0 0 0 0 0 2 4 
65.m01184 
P-type ATPase, 
putative 
0.5 14.0 0.0 0 0 0 0 4 9 
44.m00036 
splicing factor 3B 
subunit 3, putative 
0.3 7.8 0.0 0 0 0 0 2 5 
Total Spectral 
Counts     
135 0 167 0 2461 214 
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Supplementary Table 3-1: Functional Grouping of 
Toxoplasma Palmitoyl Proteome   
 
Cytoskeletal/Ubiquitin Proteins  
50.m03235 ubiquitin-related 
583.m00022 tubulin alpha chain 
44.m02708 UBA/TS-N domain (ubiquitin-associated domain)- 
containing protein 
641.m00178 ubiquinol-cytochrome c reductase, putative /  iron-
sulfur protein, putative 
41.m00036 tubulin beta chain, putative 
57.m00003 tubulin beta chain 
44.m04628 kinesin heavy chain-related 
80.m02240  ubiquitin / ribosomal protein CEP52 fusion protein 
59.m03689 kinesin motor domain-containing protein 
50.m03350 microtubule-binding protein, putative 
25.m00007 Actin 
52.m01560 actin, putative  "actin-like family protein ARP4a,  
putative" 
 
DNA Replication/Translation Proteins/Ribosomal Proteins  
35.m00026 ATP-dependent RNA helicase, putative 
50.m05680 eukaryotic translation initiation factor 4A 
26.m00242 RNA helicase-1 
50.m00067 40S ribosomal protein S8, putative 
80.m00017 60S ribosomal protein L10, putative 
583.m00619 60S ribosomal protein L4, putative 
83.m01278 eukaryotic translation initiation factor 3, putative 
42.m00084 60S ribosomal protein L3, putative 
38.m01067 alanyl-tRNA synthetase, putative 
59.m03518 asparaginyl-tRNA synthetase, putative 
41.m00006 eukaryotic translation initiation factor 3 subunit 9,  
putative 
49.m00006 40S ribosomal protein S5, putative 
76.m00009 60S ribosomal protein L9, putative 
55.m00280 60S ribosomal protein L7a, putative 
59.m03643 translation initiation factor eIF-2B epsilon subunit,  
putative 
20.m03745  RNA-binding protein, putative 
80.m00095  leucyl-tRNA synthetase, putative 
72.m00395 histidyl-tRNA synthetase, putative 
583.m00014 ribosomal protein L11, putative 
 
Mitochondrial Proteins  
46.m01692 mitochondrial processing peptidase beta subunit, 
putative 
55.m00168 ATP synthase beta chain, putative 
33.m01380 succinate dehydrogenase [ubiquinone] flavoprotein 
subunit, mitochondria, putative 
59.m00061 mitochondrial 2-oxoglutarate/malate carrier protein,  
putative 
59.m03597 oxidoreductase, putative 
25.m01827 mitochondrial carrier domain-containing protein 
 
Protein Kinase  
49.m00003 cAMP dependent protein kinase regulatory subunit,  
putative 
42.m00006 serine/threonine protein phosphatase, putative 
72.m00380 3',5'-cyclic phosphodiesterase, putative 
80.m00026 casein kinase I epsilon, putative 
541.m00134 "CAM kinase, CDPK family TgCDPK1_2 
(TGTPK4) " 
583.m00712 adenylyl cyclase associated protein 
113.m00789 serine/threonine protein phosphatase, putative 
42.m00079 cAMP-dependent protein kinase catalytic subunit,  
putative 
59.m00077 protein phosphatase 2C, putative 
52.m01648 adenylate and guanylate cyclase catalytic domain- 
containing protein 
42.m00116 adenylate kinase, putative 
1
2
0
 
  
41.m00015 dual-specificity phosphatase, catalytic domain- 
containing  
protein 
583.m09194 protein tyrosine phosphatase-like domian-containing  
protein 
 
 
Metabolic Proteins  
641.m00010 UDP-N-acetyl-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase T3, putative 
80.m00003 glyceraldehyde-3-phosphate dehydrogenase 
44.m00006 lactate dehydrogenase 
49.m03397 2-oxoglutarate dehydrogenase, putative 
65.m01193 glucose-6-phosphate dehydrogenase, putative 
55.m05083 glycerol-3-phosphate dehydrogenase 
55.m00008  UDP-N-acetyl-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase T2 
83.m00004 glucose-6-phosphate dehydrogenase 
59.m00091 glyceraldehyde-3-phosphate dehydrogenase 
80.m00002 phosphoenolpyruvate carboxykinase, putative 
76.m00001 glucose-6-phosphate isomerase, putative 
57.m01692 SRS domain-containing, N-acetylglucosamine-
phosphate mutase, putative 
42.m00123 phosphofructokinase, putative 
 
DHHC containing Proteins  
50.m03297 zinc finger DHHC domain-containing protein 
65.m00004 zinc finger DHHC domain containing protein 
50.m00091 zinc finger DHHC domain-containing protein 
83.m00009 DHHC zinc finger domain-containing protein 
  
  
GTPases  
33.m01303 ras-related protein, putative 
50.m05646 ras-related protein, RAB7 putative 
50.m00042 GTP-binding nuclear protein RAN/TC4, putative 
583.m00666 ras-related protein RAB18 putative 
 
Surface Antigen (SAG)  
44.m00009 major surface antigen p30 (SAG1) 
583.m05672 SRS domain containing surface antigen, putative 
551.m00439 Gpi16 subunit, GPI transamidase domain-containing 
protein 
641.m03153 SRS domain containing protein 
76.m01626 SRS domain containing surface antigen, putative 
551.m00001 "SRS57 (= SAG3, P43) ...surface antigen; surface  
antigen SAG3" 
  
  
Rhoptry Proteins  
83.m02145 rhoptry antigen, putative 
33.m00005 rhoptry antigen ROP8 
551.m00238 ROP5 
55.m08191 Rhoptry kinase family protein ROP17/"protein 
kinase domain-containing protein"  
20.m03896  rhoptry protein, putative / protein kinase domain-
containing protein/ROP18 
25.m01905/25.m01904  
protein kinase domain-containing protein/"Rhoptry 
kinase family protein ROP44 (incomplete catalytic 
triad)" by Toxodb 
 
 
Dense Granule Proteins  
20.m00005 dense granule protein 7 
 
 
 
 
 
1
2
1
 
  
MIC Proteins  
80.m00012 microneme protein 1 (MIC1) 
25.m00006 microneme protein MIC4  
33.m00006 MIC2-associated protein (M2AP) 
20.m00002 microneme protein 2 (MIC2) 
  
  
IMC  
44.m00031 alveolin domain containing intermediate filament 
(IMC4) 
44.m00020 Alveolin domain containing intermediate filament 
(IMC10)/"pfs77-related" 
44.m00004 IMC1 alveolin domain containing intermediate 
filament  
 
Pyrine/Pyrimidine  
25.m01850 pyridine nucleotide-disulphide oxidoreductase, 
putative 
 
Heat Shock  
44.m02755 small heat shock protein 20  
583.m00009 heat shock protein 70, putative 
49.m00060 heat shock proten 90, putative 
50.m00006 heat shock protein 60  
42.m03533 DnaK family protein/"Heat shock protein-related) 
  
  
Inositols/Lipid Metabolism  
76.m01665 lysophospholipase, putative 
583.m00669 phosphatidylinositol-4-phosphate 5 kinase, putative 
44.m02601 phosphatidylinositol-4-phosphate 5-kinase, putative 
83.m01196 inositol phosphatase, 
putative/"endonuclease/exonuclease/phosphatase 
domain-containing protein" in Toxodb  
50.m05603 phosphatidylinositol-4-phosphate 5-Kinase, putative 
583.m05329 long-chain-fatty-acid CoA ligase, putative 
583.m00605 long-chain-fatty-acid-CoA ligase, putative 
20.m00392 fatty acid elongation protein-related 
Surface Proteins  
50.m05651 surface protein PspC-related 
44.m00008 GPI-anchored surface protein/ " GPI-anchored 
surface protein; SAG1-related sequence 1" by 
Toxodb 
  
  
Membrane Proteins  
55.m00005 TgAMA1, Apical Membrane Protein 1 
59.m00005 protein transport protein Sec61 alpha subunit  
isoform 1, putative 
  
  
Myosins  
55.m00021 myosin light chain 1 (TgMLC1) 
46.m00001 myosin A, putative  
113.m00782 myosin light chain 2, putative 
55.m00020 Myosin D 
583.m05637 myosin-related/MyosinG 
65.m01195 WD-40 repeat myosin-like protein, putative 
25.m01804 myosin heavy chain 
  
  
MORN Proteins:  
50.m03085 MORN repeat protein, putative 
25.m01782 MORN repeat containing protein 
113.m00762 MORN repeat-containing protein 
 
1
2
2
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CHAPTER 4 
 
Host cell egress and invasion induce marked relocations of  
 
glycolytic enzymes in Toxoplasma gondii tachyzoites
3
                                                 
 
3
 Chapter modified from:  Sebastien Pomel, Flora C.Y. Luk, Con J. M. Beckers (2008), Plos Pathogens 4(10):  
e1000188 
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Abstract 
 
Apicomplexan parasites are dependent on an F-actin and myosin-based motility 
system for their invasion into and escape from animal host cells, as well as for their general 
motility. In Toxoplasma gondii and Plasmodium species, the actin filaments and myosin 
motor required for this process are located in a narrow space between the parasite plasma 
membrane and the underlying inner membrane complex, a set of flattened cisternae that 
covers most the cytoplasmic face of the plasma membrane. Here we show that the energy 
required for Toxoplasma motility is derived mostly, if not entirely, from glycolysis and lactic 
acid production. We also demonstrate that the glycolytic enzymes of Toxoplasma tachyzoites 
undergo a striking relocation from the parasites‟ cytoplasm to their pellicles upon 
Toxoplasma egress from host cells. Specifically, it appears that the glycolytic enzymes are 
translocated to the cytoplasmic face of the inner membrane complex as well as to the space 
between the plasma membrane and inner membrane complex. The glycolytic enzymes 
remain pellicle-associated during extended incubations of parasites in the extracellular milieu 
and do not revert to a cytoplasmic location until well after parasites have completed invasion 
of new host cells. Translocation of glycolytic enzymes to and from the Toxoplasma pellicle 
appears to occur in response to changes in extracellular [K
+
] experienced during egress and 
invasion, a signal that requires changes of [Ca
2+
]c in the parasite during egress. Enzyme 
translocation is, however, not dependent on either F-actin or intact microtubules. Our 
observations indicate that Toxoplasma gondii is capable of relocating its main source of 
energy between its cytoplasm and pellicle in response to exit from or entry into host cells. 
We propose that this ability allows Toxoplasma to optimize ATP delivery to those cellular 
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processes that are most critical for survival outside host cells and those required for growth 
and replication of intracellular parasites. 
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Introduction 
 
Toxoplasma gondii is an obligate intracellular protozoan parasite of humans and other 
warm-blooded animals, and is closely related to Plasmodium sp., the causative agent of 
malaria. Although the majority of Toxoplasma infections in humans are asymptomatic, 
severe disease and death can occur in developing fetuses and in immunocompromised 
individuals. Infection of and spread between host cells by Toxoplasma and its close relatives 
Plasmodium, Cryptosporidium, and Eimeria is critically dependent on actin-myosin based 
motility systems in the parasite.  
The actin filaments required for host cell invasion and for general parasite motility 
are believed to be associated with the cytoplasmic tails of adhesins in the parasite plasma 
membrane. Specifically, the microneme proteins thrombospondin-related anonymous protein 
(TRAP) of Plasmodium sp. and MIC2 of Toxoplasma are believed to interact with F-actin 
through the glycolytic enzyme aldolase-1 [1, 2]. Myosin-A, a type XIV myosin, is also 
critical for gliding motility [3]. This protein is found in a complex with an atypical myosin 
light chain [4] and two accessory proteins, GAP45 and the integral membrane glycoprotein 
GAP50 [5], of which the latter is responsible for anchoring the motor complex in the 
parasite‟s inner membrane complex (IMC). This organelle consists of flattened membrane 
cisternae that are closely apposed to the parasite plasma membrane and extends from the 
anterior end of the parasite to the posterior end. The only obvious connection between the 
main body of the parasite cytoplasm and the space between its plasma membrane and IMC is 
found at the extreme anterior end of the parasite. At this location, the IMC is clearly 
interrupted, creating a gap through which the conoid and rhoptries protrude [6]. It is also 
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believed that it is through this gap that the parasites‟ micronemes access and fuse with the 
plasma membrane. 
Both actin polymerization and myosin action are ATP dependent processes. Most 
eukaryote cells are capable of generating ATP through multiple mechanisms: glycolysis and 
the oxidative phosphorylation of acetyl-CoA derived from pyruvate, b-oxidation of fatty 
acid, or from certain amino acids. It is evident that apicomplexan parasites possess a 
complete glycolytic pathway [7] as well as all enzymes for the TCA cycle and mitochondrial 
electron transport chain. It was therefore very surprising that the only obvious homolog of 
pyruvate dehydrogenase in Plasmodium and Toxoplasma is targeted to the apicoplast, a 
plastid-like organelle, along with several glycolytic enzymes [7–9]. In other eukaryotes, 
pyruvate dehydrogenase is targeted to mitochondria where it is involved in the conversion of 
glycolysis- derived pyruvate into acetyl-CoA and thus occupies a critical link between 
glycolysis and oxidative phosphorylation. The apparent absence of pyruvate dehydrogenase 
from apicomplexan mitochondria therefore suggests that glycolysis and oxidative 
phosphorylation are not coupled in Toxoplasma and Plasmodium sp. It remains possible, 
however, that these organisms have evolved a structurally distinct pyruvate dehydrogenase. 
In other cells, acetyl-CoA can also be produced through the b-oxidation of fatty acids or the 
catabolism of amino acids. This process is also unlikely to occur in apicomplexan parasites 
as, at least in the case of Plasmodium sp., the genome does not appear to encode the requisite 
enzymes for these processes [9]. 
In this study, we investigated the likely sources of the ATP that is critical for gliding 
motility of Toxoplasma tachyzoites. Our data indicate that glycolysis is the major source of 
energy for parasite motility and that oxidative phosphorylation, if it occurs at all, makes only 
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a minor contribution. We also demonstrate that the glycolytic enzymes of Toxoplasma are 
distributed smoothly over the cytoplasm of intracellular parasites. In a surprising finding, we 
found that the glycolytic enzymes undergo a translocation from the parasite cytoplasm to the 
pellicle upon egress from host cells and remain pellicle-associated throughout the 
extracellular phase of Toxoplasma and during invasion of host cells. Only after host cell 
invasion is complete do the enzymes revert to a smooth cytoplasmic distribution. This 
translocation of the glycolytic enzymes between the parasite cytoplasm and the pellicle 
appears to be triggered by the changes in potassium concentrations experienced by the 
parasites during egress from and invasion into host cells. These findings suggest that 
Toxoplasma gondii tachyzoites are able to relocate their major source of ATP production to 
the site where energy is required at each stage during their life cycle. 
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Results 
 
Glycolysis is a major source of energy for Toxoplasma motility  
Toxoplasma invasion into and egress from its animal host cells are dependent on an 
actin-myosin-based motility system and thus require ATP for myosin action as well as actin 
filament formation. In most cells, the ATP necessary for these processes can be generated by 
glycolysis and by oxidative phosphorylation. The Toxoplasma genome encodes all the 
enzymes required for ATP production by glycolysis. It is not clear, however, whether 
apicomplexan parasites can produce ATP by oxidative phosphorylation given that pyruvate 
dehydrogenase, a key enzyme in coupling glycolysis and oxidative phosphorylation, appears 
to be absent from the parasite‟s mitochondria [7–11] as are some subunits of the ATP 
synthase [12,13]. In order to better understand the roles of both metabolic pathways in 
supplying energy for parasite movement, we performed parasite motility assays under 
conditions where the parasites either had to rely on glycolysis for most of their energy 
production or on oxidative phosphorylation. Our observations are summarized in Figure 4-1. 
When assays were performed in the presence of glucose, a carbon source for both glycolysis 
and oxidative phosphorylation, we observed robust movement in a majority of the parasites 
(71.6±7.4%). Omission of glucose resulted in a drastic decrease in the fraction of mobile 
parasites (2.7±2.9%). When experiments were performed in the presence of glucose but 
under a nitrogen atmosphere or in the presence of KCN, conditions where any oxidative 
phosphorylation should be inhibited, Toxoplasma motility was not significantly affected with 
70.5±12.4% and 63.1±16.1% of parasites moving, respectively. Although these observations 
indicate already that glycolysis is the major source of energy for parasite movement, they do 
not exclude the possibility that oxidative phosphorylation does make some contribution. To 
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test this possibility, Toxoplasma motility experiments were performed in the absence of 
glucose but in the presence of potential substrates for the parasites‟ TCA cycle: pyruvate, 
lactate, or glutamine, both individually and in combination. As can be seen in Figure 4-1, 
only a small fraction of the parasites demonstrated motility (8.4±5.8%) and, as we observed 
in the absence of any substrate, this was limited to trails that were barely longer than the 2 
μm cut-off limit (see Materials and Methods). 
Additional evidence against a role for oxidative phosphorylation in generating energy 
for Toxoplasma motility was derived from motility experiments performed in the presence or 
absence of atovaquone, a potent antiparasitic agent that acts as an inhibitor of the cytochrome 
bc1 complex in apicomplexan parasites [14–16]. As can be seen in Figure 4-1, atovaquone 
does not have an obvious effect on Toxoplasma motility at a concentration of 0.5 μM in our 
typical experimental setup. Prolonged treatment of intracellular Toxoplasma with the same 
concentration atovaquone resulted in parasite death as had been previously observed [14–16] 
(data not shown). 
Together, these observations suggest that glycolysis is the major source of energy for 
Toxoplasma motility and that oxidative phosphorylation, if it occurs at all, makes at best a 
very small contribution. 
 
The Toxoplasma glucose transporter GT1 is found throughout the plasma membrane 
The plasma membrane of apicomplexan parasites is found in close association with 
large flattened cisternae, referred to as the inner membrane complex or IMC. The IMC 
extends beneath the entire plasma membrane of the parasites, except at the extreme anterior 
end where the plasma membrane is in direct contact with the cytoplasm (Mann and Beckers, 
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2001). The space between the plasma membrane and IMC is only 18.4±0.6 nm 
(Supplementary Figure 4-1) and no trans-IMC transport mechanisms have been identified to 
date. It is therefore not clear whether nutrients like glucose enter parasites only at the anterior 
end, where there is direct contact between the plasma membrane and the cytoplasm, or if 
import occurs all over the parasite plasma membrane. To test which of these scenarios is used 
for glucose acquisition, we expressed a myc-tagged version of the Toxoplasma hexose 
transporter TgGT1 in the parasite. TgGT1 is a high affinity facilitative hexose transporter 
[17] and appears to be the only hexose transporter encoded by the Toxoplasma genome. As 
can be seen in Figure 4-2, TgGT1 is found exclusively in the parasite plasma membrane and 
is distributed evenly over the parasite surface. This result suggests that glucose transport into 
the parasite is not confined to a particular part of its plasma membrane. 
 
The subcellular location of aldolase-1 is different in intra and extracellular Toxoplasma 
The actin-myosin XIV based motile apparatus of apicomplexan parasites is found in 
the narrow space between the parasite plasma membrane and IMC which extends from the 
anterior to the posterior part of the organisms [1,5]. Given that parasite motility appears to be 
powered primarily by glycolysis and that the glucose transporter TgGT1 is found along the 
entire surface of Toxoplasma tachyzoites (Figure 4-2), we wondered whether part or all of 
the Toxoplasma glycolytic apparatus was also present in close proximity to the parasite 
pellicle and therefore its motile apparatus. Jewett and Sibley had, in fact, shown that a 
fraction of the glycolytic enzyme aldolase is found in this space [1]. Specifically, aldolase 
was reported to form a bridge between F-actin and the cytoplasmic tail of the adhesin MIC2. 
Given the critical role of aldolase in glycolysis, we sought to repeat these observations. As 
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the observations of Jewett and Sibley were based on crossreactivity of commercial anti-rabbit 
aldolase antisera with Toxoplasma aldolase, we initially employed similar antisera. The 
Toxoplasma genome contains two potential aldolase-encoding sequences, but only one of 
these, aldolase-1, is expressed in Toxoplasma tachyzoites and the second appears to represent 
a pseudogene ([7], data not shown). As the commercial anti-rabbit aldolase antisera do not 
cross-react with Toxoplasma aldolase-1 in our hands (Supplementary Figure 4-2A), we 
generated an antiserum that is specific to Toxoplasma aldolase-1 and that does not cross-react 
with mammalian aldolases (Supplementary Figure 4-2B). As an alternative strategy, we also 
generated a Toxoplasma line that stably expresses myc-tagged Toxoplasma aldolase-1.  
As can be seen in Supplementary Figure 4-2B, the anti-Toxoplasma aldolase-1 
antiserum reacts with a single protein of the expected MWapp in immunoblots of parasite 
lysates. In parasites expressing myc-tagged aldolase-1, the antiserum detects the same protein 
as in non-transfected parasites, as well as a slightly larger protein species that represents the 
myc-tagged enzyme. A monoclonal anti-myc antibody only reacts with the larger protein 
species, which is only present in parasites expressing myc-aldolase-1. Based on the blot with 
anti-aldolase-1, it appears that the myc-aldolase-1 is expressed at a level that is 
approximately three times higher than endogenous aldolase-1. 
 Jewett and Sibley found that the anti-rabbit aldolase antiserum reacted with material 
found in the anterior part of the parasite and that this signal overlapped substantially with that 
of the microneme protein MIC2 [1]. When we used our affinity-purified antibodies to 
Toxoplasma aldolase-1 to localize this enzyme in intracellular parasites, we found it to be 
distributed throughout the parasites‟ cytoplasm (Figure 4-3A and Figure 4-4), irrespective of 
the fixation conditions used. In extracellular parasites, on the other hand, the protein 
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localized to the parasite periphery (Figure 4-3A, C) where it overlapped with IMC1, a 
membrane skeleton protein of the Toxoplasma IMC [18]. The peripheral location of the 
Toxoplasma aldolase-1 in extracellular parasites is specific; other cytoplasmic proteins, such 
as the calcium-dependent protein kinase CDPK1 [19] (Figure 4-3B) and YFP (Figure 4-4), 
retain their normal cytoplasmic distribution in both intracellular and extracellular parasites. 
The observed redistribution of aldolase-1 is also unlikely to be a fixation artifact. We 
compared the distribution of both aldolase-1 and YFP in intra and extracellular parasites 
fixed with -20°C methanol or paraformaldehyde and glutaraldehyde. As can be seen in 
Figure 4-4, aldolase-1 is found at the pellicle of extracellular Toxoplasma and in the 
cytoplasm of intracellular parasites, irrespective of the fixation condition used. As expected, 
the cytoplasmic distribution of YFP was also not affected by the fixation method used. 
To further assure ourselves that we were observing a relocation of aldolase-1, we 
repeated the experiments in Figure 4-3A with parasites expressing myc-tagged aldolase-1. As 
can be seen in Figure 4-5A and C, myc-aldolase-1 displays a similar change in distribution 
between intracellular and extracellular parasites. It is interesting to note that we did not 
observe an overlap between the aldolase-1 or mycaldolase-1 signal with that of the 
microneme protein MIC2 (Supplementary Figure 4-3) which stands in contrast to the 
previous observations [1]. 
 
Subcellular distribution of Toxoplasma aldolase-1 during the tachyzoite life cycle 
 Given the striking difference in aldolase-1 distribution we observed between 
intracellular and extracellular Toxoplasma tachyzoites, we sought to determine if the 
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redistribution of this enzyme occurred at a specific stage in parasite development or a 
particular point in parasite-host cell interaction. 
 As Toxoplasma aldolase-1 reverts to a smooth cytoplasmic distribution at some point 
after host cell invasion we first tested whether this occurred during or shortly after host cell 
invasion, or if it occurred at a later stage. We therefore allowed freshly isolated extracellular 
parasites to interact with new host cells for 2 minutes and monitored the aldolase-1 
distribution immediately after this incubation and after various lengths of incubation at 37°C. 
Extracellular and intracellular parasites could be distinguished by the inability of the latter to 
be recognized by an antibody to the surface antigen SAG1 in intact host cells. After short 
incubations, numerous parasites were captured in the process of invading host cells as judged 
by the fact that only a part of their surface reacted with the SAG1 antiserum (Figure 4-5B). In 
these parasites, the aldolase-1 remains located at the parasite periphery. The aldolase-1 
distribution was also not affected in parasites that had just completed host cell invasion 
(Figure 4-6A). The peripheral location of the aldolase-1 was maintained in a large fraction 
(74±5%) of parasites at 30 minutes after invasion but decreased to less than 10% after 4 
hours (Figure 4-6B) and was no longer detectable after parasites had undergone one round of 
replication (Figure 4-5C; Supplementary Figure 4-4). The cytoplasmic distribution of 
aldolase-1 was maintained as long as the parasites remained inside host cells, irrespective of 
the number of parasites per vacuole or the stage of parasite replication (Figure 4-5C; 
Supplementary Figure 4-4). 
The pellicle of Toxoplasma consists of three membranes, the plasma membrane and 
the membranes of the IMC. During parasite replication, two immature daughter parasites are 
formed in the cytoplasm of the mother cell. These daughters possess all structural elements 
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of the mature parasite except for the plasma membrane, which they only acquire from the 
mother parasite at the final stage of replication. Typical preparations of extracellular 
Toxoplasma always contain a few parasites that are released from host cells at various stages 
of daughter cell formation. When the distribution of aldolase-1 was analyzed in such 
parasites, it was evident that the enzyme is only associated with the pellicle of mature 
parasites and not with the IMC of the immature daughters (Figure 4-5D). This finding 
suggests that IMC association of aldolase-1 is not only controlled by the parasite‟s 
environment but is also under strict developmental control by limiting pellicle association to 
mature parasites only. 
 
Regulation and mechanism of aldolase-1 redistribution during host cell invasion and 
egress 
We considered the possibility that the change in location of aldolase-1 between 
intracellular and extracellular Toxoplasma reflected the proteolytic destruction of preexisting 
enzyme pool and the synthesis of a novel pool of protein that was targeted to a new location, 
possibly through differences in post-translational modifications. Pretreatment of parasites 
with 10 μM cycloheximide, a concentration sufficient to block .98% of de novo protein 
synthesis in Toxoplasma [19], did not affect translocation of aldolase-1 to the pellicle upon 
egress or its translocation to the cytoplasm after host cell invasion (data not shown), 
indicating that we are indeed detecting the translocation of preexisting enzyme.  
It appears that translocation of aldolase-1 from the cytoplasm to the pellicle only 
occurs at or shortly after Toxoplasma egress from its host cells. Egress is not synchronous or 
predictable under physiological conditions but is readily induced by the physical disruption 
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of the host cells [20]. Although earlier time points could not be obtained for practical 
reasons, aldolase-1 translocation to the Toxoplasma pellicle could be detected as early as 30 
seconds after parasite egress and was essentially complete by 60 minutes (Figure 4-7A). 
This finding implies that the parasite can sense whether it is inside or outside of a host 
cell and can translocate aldolase and presumably the rest of its glycolytic apparatus 
accordingly. We have previously described that parasite egress from its decaying host cells is 
triggered by the reduction in the [K
+
] of the surrounding host cytoplasm, which in turn results 
in an increase in cytoplasmic [Ca
2+
] [20]. As the relocation of Toxoplasma aldolase-1 also 
occurs upon host cell egress, we wondered whether it might also be controlled by changes in 
environmental [K
+
]. We therefore broke Toxoplasma-infected HFF cells in media containing 
[K
+
] consistent with the environment inside or outside animal host cells and monitored 
changes in aldolase-1 distribution. As can be seen in Figure 4-7A, disruption of parasite-
infected HFF cells in a medium mimicking the extracellular environment (EC medium) 
results in translocation of aldolase-1 to the parasite pellicle with half-maximal translocation 
observed at about 15 minutes. When parasite-infected host cells are disrupted in medium 
with a high [K
+
] (IC medium) this translocation does not occur and aldolase-1 remains 
distributed evenly over the parasite cytoplasm (Figure 4-7B, stage 1). This effect is entirely 
reversible in that a subsequent exposure to extracellular medium results in rapid translocation 
of aldolase-1 to the parasite pellicle (Figure 4-7B, stage2). These findings indicate that 
translocation of aldolase-1 from the Toxoplasma cytoplasm to its pellicle is controlled by the 
[K
+
] in the surrounding medium and requires increases in [Ca
2+
]. 
The transfer of aldolase-1 from the parasite periphery to the cytoplasm that we 
observed after host invasion also appears to be triggered by a change in extra parasitic [K
+
]. 
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When extracellular Toxoplasma are transferred to a medium with [K
+
] similar to the 
intracellular milieu, aldolase-1 is transferred from the parasite pellicle to its cytoplasm 
(Figure 4-7C). As was observed during normal infection of host cells, this occurred with 
substantially slower kinetics than the forward reaction. Reversal had occurred in only, 60% 
of parasites after 1 hour in high [K
+
] medium and was essentially complete after 4 hours. The 
translocation of aldolase-1 from the Toxoplasma pellicle to its cytoplasm in response to high 
[K
+
] medium was also entirely reversed upon transfer of parasites to EC medium (data not 
shown). 
Activation of Toxoplasma motility in response to a reduction of environmental [K
+
] 
requires an increase in [Ca
2+
]c in the parasite [20]. To determine if an increase in [Ca
2+
]c is 
also required to trigger translocation of glycolytic enzymes in response to [K
+
] changes, we 
incubated parasites for 30 minutes in high [K
+
] medium with BAPTA/AM, a chelator of 
cytoplasmic Ca
2+
, followed by a 30 minute incubation in extracellular medium containing the 
same compound. Chelation of cytoplasmic Ca
2+
 did not affect the cytoplasmic distribution of 
Toxoplasma aldolase-1 while in high [K
+
] medium (Figure 4-7C). When the BAPTA/AM 
treated parasites were subsequently transferred to EC medium, the aldolase-1 remained 
evenly distributed throughout the parasite cytoplasm whereas aldolase-1 in mock-treated 
parasites had translocated to the pellicle (Figure 4-7C). 
When parasites that had been previously incubated in EC medium and uniformly 
displayed pellicle-associated aldolase-1 were subsequently treated with BAPTA/AM, we did 
not observe any change in pellicle-association of aldolase-1 compared to untreated parasites 
(Figure 4-7C). When these BAPTA/AM-treated parasites were subsequently transferred to IC 
140 
 
medium, aldolase-1 reverted to a cytoplasmic distribution that was indistinguishable from 
untreated parasites (Figure 4-7C). 
Aldolase-1 translocation from the parasite cytoplasm to its pellicle does not require 
either F-actin or microtubules. When intracellular parasites were pre-treated with 
cytochalasin-D and subsequently released from their host cells, aldolase-1 relocation to the 
parasite pellicle was not affected (Figure 4-7D). Disruption of Toxoplasma microtubules with 
oryzalin had, as described before [21], a profound effect on parasite morphology but also did 
not affect aldolase-1 translocation to the pellicle after egress from host cells (Figure 4-7E). 
As cytochalasin-D and oryzalin-treated parasites are incapable of host cell invasion [22, 23], 
we could not determine whether F-actin or microtubules played a role in the pellicle-
tocytoplasm translocation after this process. 
Pellicle association of aldolase-1 in intact extracellular Toxoplasma is very stable, 
even during incubations of up to 24 hours at 37°C in complete medium. The distribution of 
the enzyme in the parasite pellicle was also not noticeably affected during this incubation 
(data not shown). Jewett and Sibley had reported that Toxoplasma aldolase appeared to 
undergo an anterior-to-posterior translocation in moving parasites [1]. We did not observe 
such a translocation irrespective of whether we monitored the endogenous enzyme with anti-
Toxoplasma aldolase-1 antiserum or the myc-aldolase-1; the enzyme was found evenly 
distributed along the pellicle of both motile and non-motile parasites (Figure 4-7D). 
These observations demonstrate that the translocation of aldolase-1 from the 
Toxoplasma cytoplasm to its pellicle is triggered by the decrease in [K
+
] surrounding the 
parasites in compromised host cells and that this response is mediated by an increase in 
[Ca
2+
]c in the parasite. Aldolase-1 translocation from the parasite pellicle to its cytoplasm 
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upon host cell invasion is also triggered by the increased [K
+
] in its environment. Unlike 
what occurs during parasite egress, however, this process does not appear to be mediated by 
an increase in [Ca
2+
]c in the parasite. Although the molecular mechanism underlying 
aldolase-1 translocation is not known at this time, it is clear that neither F-actin nor 
microtubules are essential. 
 
Localization of other glycolytic enzymes in intra and extracellular Toxoplasma 
 Although we did not detect any redistribution of aldolase-1 in motile Toxoplasma 
tachyzoites and the translocation of aldolase-1 to the parasite periphery was not affected by 
cytochalasin-D (Figure 4-7D), these findings do not necessarily conflict with a role of 
peripheral aldolase-1 in providing a link between the adhesion MIC2 and F-actin as was 
suggested by Jewett and Sibley [1]. We did, however, want to consider an alternative 
possibility in which translocation of aldolase-1 from the Toxoplasma cytoplasm to its 
periphery was only one element in the relocation of the entire glycolytic apparatus and hence 
a major source of ATP. To test this model, we expressed epitope-tagged versions of other 
enzymes along the glycolytic pathway of Toxoplasma tachyzoites and monitored their 
distribution in intracellular and extracellular parasites. As can be seen in Figure 4-8 and 
Supplementary Figure 4-5, enzymes at the beginning (hexokinase), in the middle 
(glyceraldehyde-3-phosphate dehydrogenase-1), and at the end of the glycolytic pathway 
(pyruvate kinase-1) demonstrated subcellular distribution patterns that are very similar to 
those of aldolase-1. All three enzymes are found throughout the cytoplasm of intracellular 
Toxoplasma and associated with the pellicles of extracellular parasites.  
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During glycolysis, a single NAD
+
 is converted to NADH for each conversion of 
glyceraldehyde-3-phosphate to 1,3-bisphosphoglycerate. As cells contain only a limited 
amount of NAD
+
 this critical compound needs to be regenerated constantly to ensure 
continuation of glycolysis. In the absence of oxidative phosphorylation, NAD
+
 is regenerated 
in most eukaryotes by lactic acid fermentation. In this process, the end product of glycolysis, 
pyruvate, is converted to lactic acid by lactate dehydrogenase (LDH), converting a single 
NADH to NAD
+
 in the process. Given that the data in Figure 4-8B demonstrate that all tested 
glycolytic enzymes in extracellular Toxoplasma are found in close association with the 
parasite‟s pellicle, we wondered whether Toxoplasma LDH was found in the same location. 
The Toxoplasma genome encodes two isoforms of this enzyme, LDH1 and LDH2, of which 
the latter is only expressed in bradyzoites [24]. When myc-tagged Toxoplasma LDH1 was 
expressed in tachyzoites we found that, like the glycolytic enzymes, this protein is also found 
in the cytoplasm of intracellular parasites and in close association with the pellicle in 
extracellular organisms (Figure 4-8).  
In summary, hexokinase, aldolase-1, glyceraldehyde-3-phosphate dehydrogenase-1, 
pyruvate kinase, and lactate dehydrogenase-1 translocate from the Toxoplasma cytoplasm to 
its pellicle upon parasite egress, and back to the cytoplasm after host cell invasion. This 
finding suggests that all enzymes required for ATP production by glycolysis are translocated 
in a concerted fashion between the Toxoplasma cytoplasm and its pellicle depending on 
whether the parasite is inside or outside of its host cell. 
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Pellicle association of glycolytic enzymes in Toxoplasma 
 To characterize this pellicle association in more detail we fractionated Toxoplasma 
homogenates at different salt concentrations and monitored the distribution of aldolase-1 
between the soluble and insoluble fractions.  
Association of aldolase-1 with the pellicle in extracellular parasites does not appear to 
involve a covalent or otherwise stable interaction with the IMC membrane or associated 
cytoskeletal elements. When extracellular parasites are mechanically disrupted at 
approximate physiological salt concentrations (150 mM) and subjected to differential 
centrifugation, the majority of aldolase-1 is recovered in the supernatant. We noticed, 
however, that 20–30% of aldolase-1 was consistently recovered in the pellet fraction (Figure 
4-9A). This association was sensitive to the salt concentration in the extraction buffer. When 
extractions were performed at higher KCl concentration (300 mM) all aldolase was recovered 
in the soluble fraction. At 25 mM KCl, on the other hand, we recovered 70–80% of aldolase-
1 in the pellet fraction. To analyze this phenomenon in greater detail we compared the 
fractionation of aldolase-1 in intracellular and extracellular Toxoplasma at 25 mM KCl. As 
can be seen in Figure 4-9B, pellicle association of aldolase-1 is only observed in extracellular 
parasites under these conditions. The association is specific in that the cytoplasmic enzyme 
CDPK1 is completely solubilized under these conditions. Pellicle-association of aldolase-1 
appears to require intact membranes as addition of Triton –X100 result in the complete 
solubilization of aldolase-1.  
To determine if the salt-resistant fraction of aldolase-1 in extracellular Toxoplasma is 
indeed IMC associated, we homogenized parasites in 25 mM or 300 mM KCl buffer and 
performed pre-embedding immuno-electron microscopy on the isolated membrane fractions. 
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It should be noted that association of the plasma membrane with the outer face of the IMC 
did not appear to be affected at the KCl concentrations used in this study. As can be seen in 
Figure 4-10 (panels A, B), no aldolase was detected in association with the pellicle of 
intracellular Toxoplasma prepared in 25 mM KCl. In pellicles isolated from extracellular 
parasites at 25 mM KCl labeling of the cytoplasmic face of the IMC was readily detected 
(Figure 4-10, panels C and D). This labeling was absent from pellicles in samples prepared in 
the presence of 300 mM KCl (Figure 4-10, panel E). Taken together with the data shown in 
Supplementary Figure 4-3, -4, and -5 these findings indicate that a substantial fraction of 
aldolase-1 in extracellular Toxoplasma is intimately associated with the cytoplasmic face of 
the IMC membrane. 
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Discussion 
 
 Obligate intracellular parasites like Toxoplasma gondii and other apicomplexa face 
vastly different environments during their normal life cycles in that they move between 
different host animals, different organ systems, and between the extracellular and 
intracellular milieu. It is therefore critical that these parasites have the ability to sense and 
adapt to changes in their environment. One of the most striking of these differences is found 
between extracellular and intracellular apicomplexan parasites. Whereas extracellular 
parasites are highly motile they are incapable of replication. Intracellular parasites, on the 
other hand, are non-motile but replicate efficiently with doubling times of as little as 8 hours. 
This observation suggests that Toxoplasma needs to have the ability to adjust numerous 
cellular processes that support these processes depending on the environment it finds itself in. 
Considering its central role in all cellular processes, we reasoned that the production 
of ATP in Toxoplasma might be one process that would be tightly regulated with respect to 
overall activity and location as the parasite moves between the intracellular and extracellular 
environment. The Toxoplasma genome encodes all the enzymes required for energy 
production by glycolysis. It is not certain, however, if the parasite can generate energy by 
oxidative phosphorylation since the only recognizable homolog of pyruvate dehydrogenase 
appears to be targeted to the parasite‟s apicoplast where it is hypothesized to play a role in 
fatty acid biosynthesis [8,9]. To determine the contribution of glycolysis and oxidative 
phosphorylation to the production of energy needed for Toxoplasma motility, we analyzed 
parasite movement under conditions where either glycolysis or the mitochondrial electron 
transport chain was blocked. It was clear from these experiments that glycolysis is 
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responsible for supplying the majority of energy required for parasite movement (Figure 4-
1). 
Further analysis revealed that all glycolytic enzymes tested underwent a striking 
change in their cellular distribution after Toxoplasma egress from host cells (Supplementary 
Figure 4-3, -8, and Supplementary Figure 4-5). Specifically, the enzymes were found 
throughout the parasite cytoplasm in intracellular Toxoplasma but relocated to the parasite 
pellicle after egress from the host cell. They remained at the parasite pellicle as long as 
parasites were extracellular or undergoing host cell invasion (Figure 4-5). In almost all cases, 
theglycolytic enzymes were distributed evenly along the pellicle of extracellular Toxoplasma 
and we did not detect any translocation of aldolase-1 along the anterior-to-posterior axis of 
the parasite during motility or host cell invasion (Figure 4-5A and 4-7D). The glycolytic 
enzymes reverted to a smooth cytoplasmic distribution upon completion of host cell invasion 
(Figure 4-6). While a fairly uniform cytoplasm-to-pellicle translocation was observed during 
Toxoplasma egress, the pellicle-to-cytoplasm translocation occurred over a variable period of 
time, ranging from several minutes up to several hours, but was essentially complete 4 hours 
after invasion. The observation that aldolase-1 distribution along the anterior-to posterior axis 
is not obviously altered in motile or invading parasites differs from what was reported by 
Jewett and Sibley [1]. The reason for this difference is unclear at this time but it may well be 
that different detection reagents recognize different pools of aldolase-1. 
Translocation of the glycolytic enzymes between the Toxoplasma cytoplasm and its 
pellicle is controlled by [K
+] in the parasites‟ environment (Figure 4-7). Incubation of 
isolated parasites in a medium with a [K
+
] consistent with the intracellular milieu of animal 
host cells (~145 mM) results in a cytoplasmic location of the enzymes tested. Transfer of 
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these parasites to medium with a [K
+
] that is consistent with the extracellular milieu (~5 mM) 
results in the rapid translocation of the enzymes to the parasite pellicle (Figure 4-7A). This 
translocation is completely reversed upon reincubation of the parasites in media with 
intracellular levels of [K
+
].  We previously described that Toxoplasma egress is also activated 
in response to a transient increase in [Ca
2+
]c that is triggered by a reduction of the [K
+
] in the 
decaying host cell [20]. The translocation of glycolytic enzymes from the parasite cytoplasm 
to its pellicle that occurs in response to lower [K
+
] also appears to require an increase in 
[Ca
2+
]c as it is blocked by pre-incubation of parasites with BAPTA/AM (Figure 4-7C). The 
reverse process, in which the glycolytic enzymes are translocated from the Toxoplasma 
pellicle to its cytoplasm, is induced by the increase in [K
+
] experienced by the invading 
parasite, but this process does not require an increase in [Ca
2+
]c in the parasite (Figure 4-7C).  
The mechanism that brings about the actual translocation of the glycolytic enzymes 
between the Toxoplasma cytoplasm and its pellicle is not known at this time. Although 
Jewett and Sibley have demonstrated an interaction between aldolase-1 and F-actin, 
disruption of the latter with cytochalasin-D did not affect aldolase-1 translocation from the 
cytoplasm to the pellicle (Figure 4-7D). The translocation of glycolytic enzymes is also not 
affected by the disruption of parasite microtubules with oryzalin (Figure 4-7E). Although 
these observations rule out a major contribution of F-actin and microtubules in translocation 
of glycolytic enzymes in Toxoplasma, the possibility remains that a different active transport 
mechanism drives this process. Our observations are also consistent with a model that does 
not require such mechanisms, however. In this model, glycolytic enzymes diffuse freely 
through the cytoplasm of intracellular parasites. Toxoplasma egress and the accompanying 
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increase in [Ca
2+
]c would then result in the generation of binding sites for the glycolytic 
enzymes on the IMC, resulting in their eventual immobilization on that structure. 
The specific mechanism through which the glycolytic enzymes are associated with 
the Toxoplasma pellicle is not clear at this time. The observation that association is disrupted 
at higher KCl concentrations suggests that it is not mediated by covalent modification of the 
protein by, for example, palmitoylation. The ease with which aldolase-1 is solubilized with 
detergents also argues against a high affinity interaction with the parasite‟s cytoskeleton. 
Instead, pellicle association appears to depend on ionic interactions with either lipids or 
proteins in the IMC membrane. It is interesting to note in this context that placement of a 
YFP tag at either the carboxy or amino-terminus of aldolase-1 disrupts relocation of the 
enzyme (data not shown). Although this effect could well be due to disruption of the tertiary 
or quaternary structure of the enzyme, it is also possible that the presence of a large fusion 
partner disrupts the interaction of aldolase-1 with factors that are critical for its translocation 
or pellicle association.  
The pellicle of apicomplexan parasites consists of three membranes: the plasma 
membrane and the two membranes of the IMC. The space between the plasma membrane 
and IMC is only 18±0.6 nm wide (Supplementary Figure 4-1) yet it houses multiple 
processes that are critical to parasite survival such as the myosin XIV motor complex [5], F-
actin filaments [1], transporters for nutrients and ion homeostasis, as well as systems that 
control these processes. Sustained Toxoplasma motility and general survival therefore 
requires a reliable supply of ATP into the space between the parasite plasma membrane and 
IMC. As we have demonstrated here, the glycolytic apparatus of Toxoplasma tachyzoites is 
closely associated with the pellicle in extracellular parasites. Specifically, we have found that 
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a substantial fraction of aldolase-1 is closely associated with the cytoplasmic face of the 
IMC. It is very important to note here that our data are not inconsistent with the presence of 
aldolase-1 in the space between the plasma membrane and IMC as proposed by Jewett and 
Sibley [1]. Given that these two structures remain intimately associated with each other 
during our subcellular fractionation experiments (Figure 4-10) it is unlikely that any aldolase-
1 found in this space would be completely removed during extractions at higher KCl 
concentrations. This suggests then that only a small fraction of total aldolase-1 is likely to be 
present between the plasma membrane and IMC. This fraction could then be dedicated 
specifically to establishing an interaction between MIC2 and F-actin as proposed by Jewett 
and Sibley [1].  
Our demonstration that Toxoplasma egress triggers a redistribution of its glycolytic 
enzymes from the cytoplasm to the IMC brings to mind the recent observation by 
Campanella et al [25] that multiple glycolytic enzymes, including aldolase, are intimately 
associated with the inner face of the plasma membrane of freshly isolated erythrocytes, but 
are cytoplasmic in deoxygenated cells [25]. These authors argued that close association of 
glycolytic enzymes with the erythrocyte plasma membrane could result in the generation of a 
highly compartmentalized pool of ATP, thus allowing for its direct and efficient consumption 
by e.g. nutrient or ion transporters. They also proposed that placing glycolytic enzymes in 
close proximity to each other at a membrane could improve the overall efficiency of ATP 
production by channeling reaction intermediates between individual enzymes. Our finding 
that glycolytic enzymes are associated with the pellicles of extracellular Toxoplasma 
tachyzoites indicates that ATP production in these organisms is also highly localized. In the 
case of Toxoplasma this would not only markedly improve ATP delivery to active transporter 
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mechanisms in the parasite plasma membrane but also to its motile apparatus in the space 
between the plasma membrane and IMC. As was suggested for glycolysis in erythrocytes, the 
close association of glycolytic enzymes with the Toxoplasma pellicle could also markedly 
improve the overall efficiency of local ATP production by limiting the free diffusion of 
glycolytic reaction intermediates. This impact would be even greater if the glycolytic 
enzymes would physically associate with each other and thus allow for true substrate 
channeling. Although we have not been able to identify such complexes thus far, we do not 
rule out their existence, given that these interactions may well require labile cofactors or 
depend on specific but low-affinity interactions. Further analysis of the various enzymes is 
likely to shed light on this issue. Our experiments also need to be repeated on other members 
of the phylum Apicomplexa to determine if they extend to Cryptosporidium and Plasmodium 
species, causative agents of cryptosporidiosis and malaria. 
Acknowledgements 
The authors would like to thank Drs. Vern Carruthers and Richard Tidwell for the generous 
gift of antisera to MIC2 and atovaquone, respectively. We are indebted to Hal MeKeel for his 
expert assistance with electron microscopy. We would also like to thank Anna Berg and Dr. 
Richard Cheney for their useful criticisms on the manuscript and many helpful discussions 
throughout the study. 
Author Contributions 
Conceived and designed the experiments: SP FCYL CJMB. Performed the experiments: SP 
FCYL CJMB. Analyzed the data: SP FCYL CJMB. Wrote the paper: FCYL CJMB. 
151 
 
Materials and Methods 
Toxoplasma culture 
Toxoplasma gondii tachyzoites of the RH(HX
-
) strain were grown in confluent 
monolayers of human foreskin fibroblasts (HFF) maintained in a minimal essential medium 
(αMEM; Invitrogen,Carlsbad, CA) supplemented with 2% fetal bovine serum (Hyclone, 
Logan, UT), 2mM glutamine, 100 IU/ml penicillin and 100 μg/ml streptomycin at 37°C with 
5% CO2. 
Buffers 
EC buffer: 120 mM NaCl, 1mM CaCl2, 5 mM MgCl2, 25 mM Hepes-NaOH pH 7.2, 
1 mg/ml BSA. IC buffer: 142 mM KCl, 5 mM NaCl, 2 mM EGTA, 5 mM MgCl2, 25 mM 
Hepes-KOH pH 7.2, 1 mg/ml BSA. Where indicated, these buffers were supplemented 25 
mM glucose, 25 mM 2-deoxyglucose, 2 mM KCN, or with 0.5 mM sodium pyruvate, 3 mM 
sodium lactate, 10 mM glutamine, or combinations thereof. IC-SUC buffer:  44.7 mM 
K2SO4, 10 mM MgSO4, 106 mM sucrose, 5 mM glucose, 20 mM Tris-H2SO4 pH 8.2, 1 
mg/ml BSA. 
Production of antisera to Toxoplasma aldolase 
The Toxoplasma aldolase-1 open reading frame was generated by PCR and cloned in 
pCR 2.1 TOPO (Invitrogen). The insert was recovered after digestion of the plasmid with 
BglII and EcoRI and ligated between the BglII and EcoRI sites of pRSET B (Invitrogen). 
Recombinant his6-tagged aldolase-1 was expressed in Escherichia coli BL21(DE3) strain 
(Stratagene, La Jolla, CA) and purified on a HisTrap Chelating HP column (Amersham 
Biosciences, Piscataway, NJ). The recombinant protein was used to immunize a mouse by 
subcutaneous injection (Cocalico Biologicals, Reamstown, PA). Anti-aldolase-1 antibodies 
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were further purified by affinity chromatography on immobilized recombinant Toxoplasma 
aldolase. 
Expression constructs and transfection of Toxoplasma 
The open reading frames of TgGT1, hexokinase (HK), aldolase-1 (ALD1), 
glyceraldehyde-3-phosphate dehydrogenase-1 (GAPDH1), pyruvate kinase-1 (PK1), and the 
tachyzoite lactate dehydrogenase-1 (LDH1) were amplified from Toxoplasma gondii cDNA 
(Thermoscript RTPCR, Invitrogen) using the following primer pairs: TgGT1, 5′-
gacggatccatcATGGCGACGGAGGAGATGCG-3′ and 5′-
atgcctaggAATACCACCTCCGTCCCCTTGG-3′; HK, 5′-
cttagatctaaaATGCAGCCTCGTCAACCAGGC-3′ and 5′-
tggcctaggcacTCAGTTCACATCTGCGATCAG-3′; ALD1, 5′-
acaagatctaccATGTCGGGATACGGTCTTCCC-3′ and 5′-
ctccctaggcgtTTAGTACACGTAGCGTTTCTC-3′; GAPDH1, 5′-
cacagatctaagATGGTGTGCAAGCTGGG-3′ and 5′-
taacctaggagcTTACGCGCCGTCCTGGACG-3′; PK1, 5′-
ctcagatctacaATGGCATCTAAACAACCGC-3′ and 5′-
ctgcctaggagtTTACTCCACAGTAAGAACC-3′; LDH1, 5′-
tagagatctaaaATGGCACCCGCACTTGTGCAG-3′ and 5′-
tttcctaggcgcTTACGCCTGAAGAGCAGCAAC-3′. The Bgl II, Bam HI, and Avr II 
restriction sites are underlined and non-coding sequences are shown in lowercase. 
Isolated PCR products for HK, ALD1, GAPDH1, PK1, and LDH1 were digested with 
BglII and AvrII or BamHI and AvrII (TgGT1) and inserted between the BglII and AvrII sites 
of the vector pTG70, thus creating in-frame fusion between an N-terminal c-myc epitope and 
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the different glycolytic enzymes. The PCR product for TgGT1 was digested with Bam HI 
and AvrII and ligated between Bgl II and Avr II sites of pTG168 thus creating an in-frame 
fusion between TgGT1 and a C-terminal myc epitope. Expression of the fusion proteins in 
both plasmids was driven by the α-tubulin promoter. After confirmation of all constructs by 
sequencing, they were transfected into Toxoplasma tachyzoites [5]. Stable transfectants 
expressing the myc-tagged protein of interest were selected by chloramphenicol as 
previously described [26]. 
Aldolase-1 location after Toxoplasma egress 
Infected HFF cells (24 h) were washed 3 times and mechanically disrupted on ice in 
ice-cold EC or IC buffer containing 25 mM glucose. Parasites were processed for 
immunofluorescence immediately after host cell egress (T0), or after an incubation of 15 
minutes (T15) or 60 minutes (T60) at 37°C. Parasites that were incubated 60 minutes in IC 
buffer with glucose at 37°C were further washed 3 times in EC buffer with glucose, 
incubated 15 minutes (T15) or 60 minutes (T60) at 37°C and processed for 
immunofluorescence as described below. 
Aldolase-1 location during Toxoplasma invasion 
 
Parasites expressing myc-aldolase-1 (5x10
6
 per coverslip) were allowed to invade 
host cell monolayers in complete medium for 2 minutes and subsequently incubated for 30 
minutes, 2 hours, 4 hours, or 24 hours at 37°C. After two washes in PBS, cells were 
incubated for 30 minutes at 4°C with rabbit anti SAG1 antiserum BSA/PBS. After 3 washes 
in PBS, cells were fixed for 15 minutes with methanol at -20°C and processed for 
immunofluorescence as described below. 
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Motility assays 
 
The fraction of motile parasites, as well as the extent and consistency of parasite 
movement was optimal if parasites were released from infected host cells 30–32 hours after 
infection. At this stage, the vast majority (>95%) of parasites were intracellular. Infected 
HFF monolayers were typically scraped into IC buffer at 4°C. Parasites were released from 
cells by serial passage (3–4x) through a 18G needle and (26) through a 25G needle. Parasites 
were recovered by centrifugation for 10 minutes at 600x g and resuspended in the buffer of 
choice. Parasites (5x10
6
) were placed on acid washed coverslips and incubated for 10 
minutes at 25°C to allow for parasites attachment. Motility assays were performed for 15 
minutes at 37°C. In experiments utilizing a nitrogen atmosphere, both the preincubation at 
25°C and the actual motility assay at 37°C were performed in sealed vials flushed with dry 
nitrogen gas. Parasite motility was assessed by monitoring the trails of the cell surface 
antigen SAG1 deposited by moving parasites [27]. After fixation for 15 minutes in methanol 
at -20°C the parasites and deposited trails were visualized using a rabbit anti-SAG1 and 
Alexa594-conjugated goat-anti-rabbit IgG secondary antibodies. Length of individual trails 
was determined using ImageJ software (National Institutes of Health, Bethesda, MD). 
Parasites that had left a trail longer than 2 μM were considered motile, parasites with shorter 
or no trails were considered nonmotile. In the vast majority of cases, trails left by motile 
parasites exceeded 10 microns. 
BAPTA/AM treatment 
 
Host cells that were infected for 24 hours were washed 3 times in either IC buffer or 
IC-SUC buffer containing 25 mM glucose and either DMSO or 20 μM BAPTA/AM. Infected 
host cells were harvested in the same buffers and passed through a 25G needle to release the 
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parasites from the parasitophorous vacuole. After a 30 minute incubation at 37°C, parasites 
were washed 3 times in EC buffer containing 25 mM glucose and either DMSO or 20 μM 
BAPTA/AM, incubated for 30 minutes at 37°C and processed for immunofluorescence. 
Likewise, extracellular parasites were washed 3 times in EC buffer containing 25 mM 
glucose and DMSO or 20 μM BAPTA/AM, and incubated 30 minutes at 37°C. After 3 
washes in IC or IC-SUC buffers containing 25 mM glucose and either DMSO or 20 μM 
BAPTA-AM, parasites were incubated 30 minutes at 37°C and processed for 
immunofluorescence. 
Cytochalasin D and oryzalin treatments 
 
Cytochalasin D treatment was performed by incubating intracellular parasites for 15 
minutes at 37°C with 10 μM drug. Infected host cells were disrupted by passing them 
through a 25G needle. Parasites were washed twice in EC buffer containing 25 mM glucose 
and 10 μM cytochalasin D before performing motility assay as described above but in the 
presence of 10 μM cytochalasin D. Oryzalin treatment was performed in the same manner 
except that drug was used at a concentration of 2.5 μM and intracellular parasites were 
treated for 24 hours. 
Cell fractionation 
 
Parasites pellets (1x10
8
) were resuspended in 25 mM MOPS-KOH pH 7.0 containing 
5 mM MgCl2, protease inhibitors (Sigma), and 25 mM, 150 mM, or 300 mM KCl and 
disrupted by sonication for 2x20 seconds at 4°C using 50% power output and a continuous 
duty cycle (Branson Sonifier 450, Danbury, CT). Homogenates were centrifuged for 10 
minutes at 14,000x g and 4°C. The pellets were resuspended in the same buffers containing 
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1% Triton X-100, incubated on ice for 5 minutes, and subjected to centrifugation as above. 
Samples of the original homogenate, the supernatant, and pellet fractions equivalent to 5x10
6
 
parasites were separated by SDS-PAGE on 10% polyacrylamide gels, transferred to 
nitrocellulose, and probed with the indicated antibodies. Bound antibodies were visualized 
using a Li-Cor Odyssey Infrared Imaging System (Lincoln NE) and the appropriate 
secondary antibodies. 
Immunofluorescence microscopy 
 
Extracellular Toxoplasma tachyzoites were allowed to adhere to acid-washed 
coverslips for 10 minutes at 4°C prior to fixation. Routinely, intracellular and extracellular 
parasites were fixed in cold methanol (-20°C) for 15 minutes at room temperature. Where 
indicated, parasites and parasite-infected cells were fixed instead in 3% formaldehyde and 
0.01% glutaraldehyde in PBS for 15 minutes at 4°C. Coverslips were washed twice in PBS 
and remaining reactive aldehyde groups were neutralized with 1 mM NaBH4 in PBS for 10 
minutes. After three washes in PBS cells were permeabilized for 10 minutes at 4°C with 1% 
TX100 in PBS. After 3 washes in PBS, samples were blocked with 3% BSA in PBS 
(BSA/PBS) for 15 minutes and subsequently incubated for 30 minutes with the indicated 
primary antibodies in BSA/PBS. After three washes in PBS, coverslips were incubated for 30 
minutes with goat-anti-rabbit or goat-anti-mouse IgG conjugated to Alexa 488 or Alexa 594 
(Molecular probes, Eugene, OR) and DAPI (5 ng/ml) in BSA/PBS. Coverslips were washed 
three times in PBS and mounted in MOWIOL. Cells were examined using a Nikon Eclipse 
TE2000-U epifluorescence microscope. Stacks of images were acquired using a Hamamatsu 
digital CCD camera (IEEE1394) directed by Metamorph (version 6.2r5, Sunnyvale, CA) 
software and processed for optical deconvolution by Auto deblur+Auto visualize program 
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(version 9.3.3, Watervliet, NY) using 10 total iterations and low noise level for the algorithm 
settings. 
Immunoelectron microscopy 
 
Extracellular and intracellular parasites (10
8
) were resuspended on ice in 25 mM 
MOPS-KOH pH 7.0 containing 5 mM MgCl2, protease inhibitors (Sigma), and 25 mM or 
300 mM KCl and disrupted by sonication as described above. The pellicle fraction was 
recovered by centrifugation for 10 minutes at 14,000x g and 4°C, resuspended in the same 
buffer and centrifuged again. The pellet fractions were resuspended in 3%BSA in the 
homogenization buffer containing mouse-anti-aldolase-1 or a nonspecific antiserum at 1:50 
dilution for 1 hour on ice followed by incubation with 10 nm gold-conjugated donkey anti-
mouse IgG secondary antibody (Jackson Immuno Research Laboratories Inc., West Grove, 
PA) diluted 1/15 in the same buffer. Samples were washed 3 times in homogenization buffer 
and fixed in 1% glutaraldehyde in the same buffer for 1 hour at 4°C. After one wash in PBS, 
samples were incubated in 1% tannic acid in PBS for 20 minutes at 4°C. After 3 washes in 
0.1 M sodium cacodylate pH 7.3, samples were treated with 1% osmium tetroxide in 0.1 M 
sodium cacodylate pH 7.3 for 20 min. After 3 washes in water, samples were dehydrated in 
increasing concentrations of ethanol and after 2 washes in propylene oxide, embedded in 
Epon. The polymerized blocks were sectioned at 60 nm with a Leica Ultracut UCT 
ultramicrotome (Leica Microsystems). Sections were stained with 2% uranyl acetate and 
Sato‟s lead stain and were viewed on an FEI Tecnai 12 electron microscope (FEI, Hillsboro, 
OR). Images were collected with a Gatan model 794 multiscan digital camera 
(Gatan, Pleasanton, CA). 
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Figures and Legends 
Figure 4-1. Glycolysis is the primary source of energy for Toxoplasma motility 
Toxoplasma tachyzoites were isolated from an infected monolayer 30–32 hours after 
infection as described in Materials and Methods. Parasites were collected by centrifugation 
and resuspended in EC buffer containing no carbon source or in the presence of glucose, 
glucose and KCN, or a mixture of pyruvate, lactate and glutamine. The effect of 10 nM 
atovaquone on Toxoplasma motility was analyzed in separate experiments. Incubations were 
performed in air or under a nitrogen atmosphere for 15 minutes at 37°C. Motility 
experiments were performed in quadruplicate and analyzed as described in Materials and 
Methods. The average fraction of motile parasites (±S.D.) under the different incubation 
conditions is shown. 
 
Figure 4-2. The glucose transporter GT1 is found in the plasma membrane 
of Toxoplasma gondii tachyzoites 
The subcellular location of the myc-tagged glucose transporter GT1 in intracellular and 
extracellular Toxoplasma tachyzoites was determined by immunofluorescence microscopy 
using antibodies to the myc-epitope (green) and to the membrane skeleton protein IMC1 
(red). Overlays of DIC and DAPI fluorescence images are shown on the right. Bars = 2 µm. 
 
Figure 4-3. Endogenous aldolase-1 is cytoplasmic in intracellular Toxoplasma and 
associated with the pellicle of extracellular tachyzoites 
The subcellular locations of (A) endogenous aldolase-1 (ALD1) and (B) the cytoplasmic 
protein kinase CDPK1 were determined in intracellular and extracellular Toxoplasma fixed 
in −20°C methanol and compared to the membrane skeleton protein IMC1. Note that 
whereas aldolase-1 localizes differently in intracellular and extracellular parasites, the 
distribution of CDPK1 does not differ substantially. The nuclei were visualized in both cases 
with DAPI and are shown in overlays with DIC images. Bars = 2 µm. 
 
Figure 4-4. Different fixation conditions do not affect aldolase-1 distribution 
To ensure that the observed redistribution of aldolase-1 is not a fixation artifact, we also 
compared the distribution of aldolase-1 and cytoplasmic YFP in extracellular (EC) and 
intracellular (IC) Toxoplasma fixed in methanol (MeOH) or 3% paraformaldehyde/0.01% 
glutaraldehyde (PFA/GAH). Merged images of the various proteins and the parasite nuclei 
are shown as well as DIC images. Bars = 2 µm. 
 
Figure  4-5. Distribution of aldolase-1 in extracellular, invading, and 
intracellular Toxoplasma 
(A–D) Immunofluorescence microscopy was used to determine the distribution of myc-
tagged aldolase-1 (mALD1, green) in (A, D) extracellular parasites, (B) invading parasites, 
and (C) intracellular parasites immediately after invasion or after 1, 2, 3, and 5 rounds of 
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replication. Panel D demonstrates the distribution of aldolase-1 in extracellular parasites 
caught in the process of endodyogeny. Note the selective association of the enzyme with only 
the IMC of the mother parasite and not that of the immature daughter cells. All panels show 
parasites and parasite-infected cells fixed in −20°C methanol. In panels A and D, parasites 
were counterstained with antibodies to the membrane skeleton protein IMC1 (red). In panel 
B, parasites expressing myc-aldolase-1 were allowed to interact with HFF cells for 2 minutes 
at 37°C, followed by the decoration of extracellular parts of the parasites with anti-SAG1 
antiserum (red), which was in turn followed by cell fixation and permeabilization and 
staining with anti-myc monoclonal antibody (green). Parasite nuclei were visualized using 
DAPI (blue). Bars = 2 µm. 
 
Figure 4-6. Quantitative analysis of aldolase-1 distribution in Toxoplasma 
Freshly egressed parasites expressing myc-aldolase 1 were allowed to attach to HFF 
monolayers for 5 minutes at 37°C in complete medium. Non-attached parasites were washed 
off and the incubation continued in complete medium at 37°C for the indicated times. (A) 
The distribution of aldolase-1 30 minutes and 4 hours after invasion of host cells. Overlays 
are shown of myc-aldolase-1 (mALD1, green), the IMC protein IMC1 (red). Overlay pictures 
of DIC and DAPI blue) are shown on the right. Parasite-infected cells were fixed in −20°C 
methanol. Images of the individual channels are shown in Figure 4- S4. Bars = 2 µm. (B) A 
quantitative analysis of the results is shown. Data represent averages of 32 fields counted 
over 4 samples. Error bars indicate the standard deviation. 
 
Figure 4-7. Aldolase-1 relocation during egress requires a decrease in environmental 
[K
+
] and an increase in [Ca
2+
]c and does not require either F-actin or microtubules 
(A) Intracellular parasites expressing myc-aldolase-1 were harvested 24 hours after infection 
in IC buffer as described in Materials and Methods and subsequently incubated for the 
indicated times in IC buffer at 37°C. After 60 minutes in IC buffer, parasites were recovered 
by centrifugation, resuspended in EC buffer, and incubated at 37°C for the indicated time. 
The fraction of parasites with peripheral aldolase-1 was determined as described above.  
(B) Intracellular parasites expressing myc-aldolase-1 were harvested 24 hours after infection 
in EC buffer as described in Materials and Methods and subsequently incubated for the 
indicated times in EC buffer at 37°C before fixation and processing for immunofluorescence 
microscopy as in Figure 4- 4. The fraction of parasites with peripheral aldolase-1 was 
determined as in panel A.  
(C) Intracellular parasites expressing myc-tagged aldolase-1 were released from host cells in 
IC buffer and subsequently switched to EC buffer. Extracellular parasites expressing myc-
tagged aldolase-1 were resuspended in EC buffer and further switched to IC buffer. Each 
buffer was supplemented by DMSO (control) or BAPTA-AM (20 µM). Parasites were 
incubated in each buffer for 30 min at 37°C and processed for immunofluorescence using 
mouse anti-myc antibody (green) and rabbit anti-IMC1 antiserum (red). Bars = 2 µm.  
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(D) Intracellular parasites expressing myc-tagged aldolase-1 were treated with DMSO or 10 
µM cytochalasin D (CytD) for 15 min at 37°C and subsequently released from host cells by 
passage through a 25G needle. Motility assays were performed in the presence of DMSO or 
cytochalasin D as described in Materials and Methods. Parasites were labeled using anti-myc 
(mALD1, green) and anti-SAG1 (red) antibodies. In the top panel, note the presence of a 
motile (top) and a non-motile (bottom) parasite. No motility was detected after cytochalasin 
D treatment. Overlay pictures of DIC and DAPI are shown on the right. Bars = 2 µm.  
(E) Intracellular parasites were treated for 24 hours with 2.5 µM oryzalin and subsequently 
released from host cells by passage through a 25G needle into EC buffer. After 15 minutes at 
37°C, parasites were fixed and processed for immunofluorescence microscopy using anti-
myc (mALD1, green) and anti-IMC1 (red) antiserum. An overlay of the DIC and DAPI are 
shown on the right. All samples were fixed in −20°C methanol. Bar = 2 µm. 
 
Figure 4-8. Redistribution of other glycolytic enzymes to the pellicle of extracellular 
parasites 
The subcellular location of myc-tagged hexokinase (mHK), glyceraldehyde-3-phosphate 
dehydrogenase-1 (mGAPDH1), pyruvate kinase-1 (mPK1), or lactate dehydrogenase-1 
(mLDH1) was determined in (A) intracellular and (B) extracellularToxoplasma tachyzoites 
by immunofluorescence microscopy after fixation in −20°C methanol. The IMC of the 
parasites was visualized using antibodies to IMC1 (red) and their nuclei using DAPI (blue). 
The separate images are shown in Figure 4- S5. Bars = 2 µm. 
 
Figure 4-9. Pellicle-association of aldolase-1 in extracellular Toxoplasma tachyzoites 
(A) Extracellular parasites were disrupted at 4°C by sonication in 25 mM MOPS pH 7.0 
containing 5 mM MgCl2 and 25 mM, 150 mM, or 300 mM KCl and subsequently 
fractionated into soluble and insoluble fraction by centrifugation. Equal parasite equivalents 
of the starting material, supernatant, and pellet fractions were separated by SDS-PAGE and 
analyzed by immunoblotting with monospecific antisera toToxoplasma aldolase-1 and the 
membrane skeleton protein IMC1.  
(B) Extracellular parasites and intracellular parasites were harvested, homogenized in 25 mM 
MOPS pH 7.0, 5 mM MgCl2 and 25 mM KCl as described above. The homogenate was 
fractionated into soluble and particulate material by centrifugation as above. The particulate 
fraction was subsequently extracted with 1% TX100 in the homogenization buffer and 
separated by centrifugation into detergent-soluble and insoluble fraction as described above. 
Equal parasite equivalents were analyzed by SDS-PAGe and immunoblotting with antisera 
to Toxoplasma aldolase-1, the membrane skeleton protein IMC1, the cytoplasmic protein 
CDPK1 and the plasma membrane protein SAG1. The starting material (TOT), supernatant 
(SN), and pellet (P) fractions were separated by SDS-PAGE and immuno-blotted with 
antisera to the indicated proteins. 
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Figure 4-10. Aldolase-1 is associated with the cytoplasmic face of the IMC in 
extracellular Toxoplasma 
Toxoplasma aldolase-1 is associated with the cytoplasmic face of the IMC. Intracellular (A, 
B) and extracellular (C–F) Toxoplasma tachyzoites were homogenized in 25 mM MOPS pH 
7.0, 5 mM MgCl2 containing either 25 mM (A, C, D, F) or 300 mM KCl (B, E) and 
fractionated as described in Fig. 8A. Isolated pellicle fractions were incubated with antiserum 
to Toxoplasma aldolase-1 (A–E) or non-specific antiserum (F) and gold-conjugated 
secondary antibodies in the same extraction buffer and subsequently processed as described 
in Materials and Methods. Bars = 200 nm. Asterisks indicate the subpellicular microtubules 
on the cytoplasmic face of the IMC. 
 
Supplementary Figure 4-1. Distances between membranes of the Toxoplasma pellicle 
Extracellular Toxoplasma tachyzoites were harvested and processed for electron microscopy 
as described. Sections were analyzed at 70,000× magnification and 4 images of pellicle of 
each of 4 parasites from two separate preparations of parasites were collected. Distances 
between the plasma membrane and the outer and inner membranes of the inner membrane 
complex were determined by plotting the optical density along lines drawn perpendicular to 
the pellicle membranes and determining the distances between the centers of the lipid 
bilayers. Panel A shows a representative image used for this analysis. Two parasites are 
shown lying side-by-side. Panel B shows a diagram of the Toxoplasma pellicle structure. 
Panel C shows the optical density profile of a line scan performed on the image in panel A. 
Panel D shows the results of the analysis (±S.D.). 
 
Supplementary Figure 4-2. Antisera reactivity with Toxoplasma aldolase-1 
(A) Purified rabbit (Rb) aldolase and purified his6-tagged recombinant Toxoplasma (Tg) 
aldolase-1 were separated by SDS-PAGE and transferred to nitrocellulose membranes. The 
same membrane was first stained with Ponceau S to visualize the proteins (left panel) and 
subsequently incubated with commercial goat-anti-rabbit aldolase (Chemicon, right panel). 
The membrane incubated with goat-anti-rabbit aldolase was exposed overnight. Molecular 
weights are in kDa.  
(B) Purified rabbit aldolase (ALD; 100 ng), purified recombinant his6-
tagged Toxoplasma aldolase-1 (100 ng), total protein extracts of RH parasites 
(2×10
6
 parasites) and a RH parasite strain expressing myc-tagged aldolase-1 
(2×10
6
 parasites) were separated in parallel by SDS-PAGE and analyzed by immunoblot 
using either pre-immune serum (left membrane), anti-Toxoplasma aldolase-1 antiserum 
(middle membrane) or anti-myc monoclonal antibodies (right membrane). The slightly 
higher MWapp of the recombinant compared to endogenous Toxoplasmaaldolase-1 is due to 
the presence of the his6 and Xpress™-tags on the former. Molecular weights are indicated in 
kDa. 
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Supplementary Figure 4-3. Localization of aldolase-1 and MIC2 in motile parasites 
Parasites expressing myc-tagged aldolase-1 were used for motility assays and after fixation in 
−20°C methanol analyzed by immunofluorescence microscopy using anti-myc (mALD1, 
green) and anti-MIC2 (red) antibodies. A DIC image is shown on the right. Bars = 2 µm. 
 
Supplementary Figure 4-4. Localization of aldolase-1 in intracellular parasites 
Immunofluorescence of 2, 4, 8 or 32 parasites per parasitophorous vacuole with details of 
green, red, blue channels and DIC corresponding to overlay pictures shown in Figure 4- 4C. 
Parasites expressing myc-tagged aldolase-1 were fixed in −20°C methanol and labeled with 
mouse anti myc (mALD, green), rabbit anti IMC1 (red) and DAPI (blue). Overlay pictures of 
DIC and DAPI are represented on the right. Bars = 2 µm. 
 
Supplementary Figure 4-5. Localization of hexokinase, GAPDH1, pyruvate kinase-1 
and LDH1 in Toxoplasma tachyzoites  
Intracellular and extracellular Toxoplasma tachyzoites expressing myc-tagged versions of 
hexokinase, GAPDH1, pyruvate kinase-1, and LDH1 were fixed in −20°C methanol and 
processed for immunofluorescence microscopy using antibodies to the myc-epitope (green) 
and IMC1 (red). DAPI (blue) was used to label parasite nuclei. Overlay pictures of DIC and 
DAPI images are shown on the right. Bars = 2 µm. 
Freshly egressed parasites expressing myc-aldolase 1 were allowed to attach to HFF 
monolayers for 5 minutes at 37°C in complete medium. Non-attached parasites were washed 
off and the incubation continued in complete medium at 37°C for the indicated times. (A) 
The distribution of aldolase-1 30 minutes and 4 hours after invasion of host cells. Overlays 
are shown of myc-aldolase-1 (mALD1, green), the IMC protein IMC1 (red). Overlay pictures 
of DIC and DAPI blue) are shown on the right. Parasite-infected cells were fixed in −20°C 
methanol. Images of the individual channels are shown in Figure 4- S4. Bars = 2 µm. (B) A 
quantitative analysis of the results is shown. Data represent averages of 32 fields counted 
over 4 samples. Error bars indicate the standard deviation. 
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Figure 4-1. Glycolysis is the primary source of energy for Toxoplasma motility 
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Figure 4-2. The glucose transporter GT1 is found in the plasma membrane 
of Toxoplasma gondii tachyzoites 
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Figure 4-3. Endogenous aldolase-1 is cytoplasmic in intracellular Toxoplasma and 
associated with the pellicle of extracellular tachyzoites 
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Figure 4-4. Different fixation conditions do not affect aldolase-1 distribution 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
167 
 
Figure  4-5. Distribution of aldolase-1 in extracellular, invading, and 
intracellular Toxoplasma 
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Figure 4-6. Quantitative analysis of aldolase-1 distribution in Toxoplasma 
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Figure 4-7. Aldolase-1 relocation during egress requires a decrease in environmental 
[K
+
] and an increase in [Ca
2+
]c and does not require either F-actin or 
microtubules 
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Figure 4-8. Redistribution of other glycolytic enzymes to the pellicle of extracellular 
parasites 
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Figure 4-9. Pellicle-association of aldolase-1 in extracellular Toxoplasma tachyzoites 
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Figure 4-10.  Aldolase-1 is associated with the cytoplasmic face of the IMC in 
extracellular Toxoplasma 
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Supplementary Figure 4-1.                 
Distances between membranes of the Toxoplasma pellicle 
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Supplementary Figure 4-2.                              
Antisera reactivity with Toxoplasma aldolase-1 
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Supplementary Figure 4-3.                           
Localization of aldolase-1 and MIC2 in motile parasites 
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Supplementary Figure 4-4.                     
Localization of aldolase-1 in intracellular parasites 
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Significance 
Post-translational modification involves the covalent attachment of carbohydrates, 
fatty acids, phosphates, and sulfates to protein backbones.  This modification is important in 
regulating protein stability, folding, localization, and proteolysis.  Subsequently, post 
translationally modified proteins play essential roles in cellular processes such as protein-
protein interactions, signal transduction, and membrane association. In addition to the 
processes mentioned above, these modifications also mediate parasite specific processes such 
as motility, invasion, egress, replication, and evasion of host cell immune response in 
Toxoplasma gondii.  This body of work explored the contribution of two key post-
translational modifications, glycosylation and protein palmitoylation, on Toxoplasma 
biology.  The modifications were detected in essential proteins of the myosin XIV motor 
complex, and may play an important role in mediating cellular process essential for parasite 
survival.   
 
Summary 
 
Chapter 2: N-linked glycosylation of proteins in the protozoan parasite Toxoplasma  
Gondii- Summary of findings 
 
1.  N-glycosylation is a common post-translation modification in Toxoplasma 
 
2. Glycosylation is important for parasite motility.  Inhibition of N-glycosylation with 
tunicamycin does not affect parasite growth or replication but impairs motility and re-
invasion after their egress.   
 
3. Toxoplasma N-glycans are structurally distinct from other eukaryotes.   
 
In Chapter 2, we described the analysis of protein glycosylation in Toxoplasma.  We began 
with the detection of multiple Toxoplasma proteins modified by N-glycosylation, and 
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proceeded to characterize the structure of N-linked glycans and the role of N-glycosylation in 
parasite survival.   Despite the presence of genes encoding the general enzymatic machinery 
to synthesis N-linked oligosaccharides in the genome, very little was known about protein 
glycosylation at the time and only two proteins were experimentally identified as N-
glycosylated.  Subsequent proteomic and glycomic studies of Toxoplasma glycoproteins 
[Fauquenoy, 2008] confirmed our finding that N-glycans are structurally different from other 
eukaryotes and proteins essential for host cell attachment and motility are glycosylated.  
Given the structural differences between Toxoplasma N-linked glycans and other eukaryotes, 
N-linked glycans would serve as novel diagnostic and therapeutic strategies.   
 
 
Chapter 3:   Global analysis of Toxoplasma palmitoyl proteome- Summary of findings 
 
1. 400 candidate palmitoyl proteins were identified from total cellular membrane lysates 
of Toxoplasma.  Candidates included both cytoplasmic and transmembrane proteins.  
And candidates were either singly palmitoylated or dually acylated with myristate or 
additional palmitates on neighboring glycine or cysteine residues, respectively.     
 
2. 38 proteins were designated for primary analysis based on relative protein abundance 
or spectral count values of known palmitoylated proteins, GAP45, MLC1, and 
Myosin-A.  
 
3.  4 (MORN2, Hsp20, hypothetical protein 50.m03599 and 59.m03599) of the 5 
candidate palmitoyl proteins selected for validation were indeed palmitoylated as 
shown by small scale acyl-biotin exchange and [3H]palmitate incorporation. 
Palmitoylation is necessary for MORN2 and Hsp20 pellicle association.  However, 
the significance of hypothetical protein 50.m03599 and 59.m03599 palmitoylation 
remains unknown.   
 
4. A small heat shock protein 20kDa that displayed a unique localization pattern to 
filamentous like structures in Toxoplasma. 
 
In Chapter 3, we identified and characterized the Toxoplasma palmitoyl proteome after the 
initial finding that key members of the myosin XIV motor complex are palmitoylated, with 
the exception of GAP50.  This represented the first analysis of Toxoplasma palmitoyl 
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proteome. Many proteins in Toxoplasma were previously predicted to be palmitoylated either 
by sequence analysis (looking for clusters of cysteine residues or adjacent acylation sites) or 
by mutational analysis with loss of membrane association as a positive read out.  The 
palmitoyl proteome of one other apicomplexa, Trypanosomes, has been identified.  Emmer et 
al showed that parasite specific palmitoyl proteins along with protein palmitoyl transferases 
were essential for targeting to flagellar membrane [Emmer, 2011].  Given that such a large 
number of proteins were identified, protein palmitoylation is a common post-translational 
modification of many Toxoplasma proteins.  This analysis will help us elucidate the function 
of many hypothetical proteins that have not been previously identified or characterized as we 
study additional candidates. Although protein palmitoyl transferases were considered false 
positives in our analysis, PPTs must play an important role in regulating protein 
palmitoylation in Toxoplasma.  We have identified 17 proteins with the characteristic 
DHHC-CRD domain of PPTs, and many were localized throughout the secretory pathway in 
our initial analysis.  The identification of PPT/substrate pairs would be important in 
identifying the PPTs that regulate the function of essential palmitoyl proteins such as GAP45 
and MLC1. As we proceed with the characterization of additional candidates, we will surely 
find that the significance of palmitoylation will extend beyond mere membrane association, 
and play a key role in regulating essential parasitic processes such as motility.   
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